

**Application  
for  
United States Letters Patent**

**To all whom it may concern:**

**Be it known that we,**

**Elena Feinstein, Igor Mett, Sylvia G. Kachalsky and Svetlana Gorodin  
have invented certain new and useful improvements in**

**GENES INVOLVED IN STROKE RESPONSE AND/OR REGULATED BY FK506, PROTEINS ENCODED  
THEREBY, AND METHODS OF USE**

**of which the following is a full, clear and exact description.**

POLYNUCLEOTIDES INVOLVED IN NEUROTOXICITY AND NEUROPROTECTION,  
AND/OR REGULATED BY FK506, PROTEINS ENCODED THEREBY,  
ANTIBODIES AND METHODS OF USE

5

FIELD OF THE INVENTION

10 The present invention relates to genes and the  
proteins encoded thereby which are involved in neurotoxicity  
and/or are regulated by FK506. Polynucleotides were  
discovered using in vivo or in vitro models by determining  
which genes were differentially upregulated or downregulated  
when subjected to various stresses, such as hypoxia, and/or  
upon treatment of the model with FK506. Polynucleotides were  
also found by a functional selection (assay) of cDNA fragments  
15 specifically selected for their ability to confer cell  
resistance to various stresses which can result in  
neurotoxicity, such as hypoxia, glutamate or dopamine  
treatment. The invention includes such polynucleotides,  
corresponding genes, and proteins encoded thereby, as well as  
20 naturally-occurring variants of such polynucleotides, analogs,  
salts and functional derivatives of such proteins, DNA  
encoding such analogs, antibodies, antisense molecules and  
methods of use. Such methods of use include methods for  
protecting cells from neurotoxicity and ameliorating the  
25 effects of stroke, hypoxia and/or ischemia by regulating such  
genes or proteins.

## BACKGROUND OF THE INVENTION

Brain injury such as trauma and stroke are among the leading causes of mortality and disability in the modern world.

5 Traumatic brain injury (TBI) is one of the most serious reasons for hospital admission and disability in modern society. Clinical experience suggests that TBI may be classified into primary damage occurring immediately after injury, and secondary damage, which occurs during several days  
10 post injury. Current therapy of TBI is either surgical or else mainly symptomatic. Stroke is the third leading cause of death and disability in developed countries, affecting more than half a million Americans each year. Stroke is an acute neurologic injury occurring as a result of an insult to the  
15 brain, thus interrupting its blood supply. Stroke induces neuronal cell death, which leads to the clinical outcomes of patients' death or disability ranging from total paralysis to milder dysfunction. Cerebral ischemia is the most common type of stroke, which may lead to irreversible neuronal damage at  
20 the core of the ischemic focus, whereas neuronal dysfunction in the penumbra may be reversible. Cells in the penumbra have an estimated time window for survival of up to 6 hours. The ability to intervene as soon as the patient is identified is essential for recovery. It is well established that ischemic  
25 tissue damage is multifactorial and involves at least excitotoxicity, reactive oxygen species, and inflammation - all leading to neuronal cell death.

Treatment strategies for stroke are aimed to induce rapid reperfusion and rescue of neurons in the penumbral area.  
30 Neuroprotective drugs are constantly being developed in an

effort to rescue neurons in the penumbra from dying. However, potential cerebroprotective agents need to counteract all the above-mentioned destructive mechanisms. Therefore, current therapy in stroke focuses primarily on prevention, minimizing subsequent worsening of the infarction, and decreasing edema.

FK506 (tacrolimus) is a known immunosuppressive agent produced by *Streptomyces tsukubaensis*, a species discovered by the Fujisawa Pharmaceuticals' scientists in a soil sample from Tsukuba, Japan. See Kino et al, 1987, and U.S. patent 5,338,684. FK506 possesses neuroprotective activity by delaying or preventing hypoxia-induced death of neuronal cells. In addition, it can cause regrowth of damaged nerve cells. The specific molecular mechanism underlying the neuroprotective activity of FK506 is largely unknown although there are indications for suppression of activities of calcineurin and nitric oxide synthase as well as prevention of stroke induced generation of ceramide and Fas signaling. An additional model has been proposed involving steroid receptor complexes in context of FK506 neurotrophic actions. As a first step to novel drug discovery, these mechanisms should be delineated and key genes involved in these processes should be identified.

#### SUMMARY OF THE INVENTION

The polynucleotides of the present invention have been discovered by merging two technologies:

- (1) microarray-based differential gene expression, evaluated in both *in vivo* and *in vitro* models, and
- (2) direct functional selection of genes with pro- or anti-apoptotic activities, performed in cell



systems subjected to neurotoxic stress, such as hypoxia, glutamate or dopamine.

Differential profiling of gene expression was performed both in an *in vivo* model of permanent ischemia in rats either treated or untreated with FK506, performed by electrocoagulation of middle cerebral artery (MCA), and in an *in vitro* model of primary rat cerebellar neuron cultures exposed to hypoxia, with or without FK506 treatment. Polynucleotides were identified which were either upregulated or downregulated by either ischemia/hypoxia or the FK506 treatment or influenced by the combination of both treatments. Two proprietary cDNA microarrays, the "Apoptosis" and "Stroke" chips, were used in this study.

In addition, a direct functional selection of genes exhibiting pro-or anti-apoptotic activities induced by hypoxia, glutamate or dopamine was done on BE2C, an established human neuroblastoma cell line, upon introduction of expression cDNA library cloned into retroviral vector.

Accordingly, the present invention is directed to either novel polynucleotides whose expression (or function) in cells, in particular neural cells is modulated when cells are subjected to neurotoxic stress or whose activity is important for transduction of neurotoxic signals.

A total of 131 fragments, SEQ ID Nos: 1-131, were characterized as polynucleotides located in genes whose expression in neural cells is modulated when cells are subjected to neurotoxic stress or whose activity is important for neurotoxic signal transduction. Of these, 14 fragments which are incorporated in cDNA clones (all being KIAA clones) have been identified in our selection procedures as

particularly preferred. This includes all of the polynucleotides of SEQ ID NOs:49, 50, 51, 65, 67, 85, 87 and 94-100, as well as the naturally-occurring full-length RNAs and corresponding full-length cDNAs and genes and natural antisense polynucleotides which include any one of these sequences, and corresponding polypeptides and proteins encoded by them.

Currently most preferred according to the present invention are the polynucleotides identified as SEQ ID NO:94, which is a fragment of KIAA 0538 and SEQ ID NO:65 which is a fragment of KIAA 0284 . The former of these has been further identified as encoding a Ca<sup>2+</sup>-dependent Ras-GTPase Activator Protein. Elevated expression of Ras-GAP results in increased Ras inactivation and may contribute to cell death, in particular neuronal cell death.

The invention is further directed to naturally-occurring polynucleotides having at least 70% identity with any of the polynucleotides which include any one of SEQ ID Nos: 1-131, preferably SEQ ID Nos: 49, 50, 51, 65, 67, 85, 87 and 94-100, or which are capable of hybridizing under moderately stringent conditions to any of such polynucleotides, and whose expression or activity in naturally-occurring neural cells is modulated when the cells are subjected to neurotoxic stress.

The present invention is also directed to the polynucleotide comprising the sequence of any one of SEQ ID Nos: 1-48, 52-64, 66, 68-84, 86, 88-93, 101-131, which are novel polynucleotides and genes. The expression or activity of these polynucleotides

in naturally-occurring neural cells is modulated when the cells are subjected to neurotoxic stress.

The present invention is also directed to fragments  
5 having at least 20 nucleotides of any of the polynucleotides of the present invention and to polynucleotide sequences complementary to any of such polynucleotides or fragment and to polypeptides encoded by any of the polynucleotides of the present invention .

10 In a more preferred embodiment, the isolated polynucleotide is a strand of a full-length cDNA.

According to one currently more preferred embodiment, the invention particularly encompasses methods for screening drugs which upregulate or downregulate a gene which  
15 is transcribed to an RNA containing a sequence of any of SEQ ID Nos: 1-131 , preferably SEQ ID NOs: 49, 50, 51, 65, 67, 85, 87 and 94-100-.

According to another more preferred embodiment, the present invention provides methods for screening a compound  
20 which induces or inhibits apoptosis after exposure of neural cells or other cells such as glia, lymphocytes, macrophages to a neurotoxic insult.

According to yet another more preferred embodiment, the present invention provides methods of screening for a  
25 compound capable of exerting a neuroprotective effect that ameliorates or diminishes the damage induced by a neurotoxic insult.

The present invention is further directed to isolated proteins or polypeptides encoded by any such full-  
30 length cDNA, as well as variants which have an amino acid

sequence having at least 70% identity to such an isolated protein and retain the biological activity thereof, or biologically active fragments of such protein or variant, as well as to salts or functional derivatives of any such protein, variant or biologically active fragment. The expression or activity of these polypeptides in naturally-occurring neural cells is modulated when the cells are subjected to neurotoxic stress. The present invention is preferably directed to the polypeptides encoded by polynucleotides comprising the sequence of any one of SEQ ID Nos: 1-48, 52-64, 66, 68-84, 86, 88-93, 101-131.

The present invention is also directed to antibodies specific to any of the proteins, variants or fragments of the present invention and to any molecule comprising the antigen-binding portion of any such antibody, in particular to the antibodies. The present invention is particularly directed to antibodies specific to the polypeptides encoded by polynucleotides comprising the sequence of any one of SEQ ID Nos: 1-48, 52-64, 66, 68-84, 86, 88-93, 101-131, which are novel polypeptides. The present invention is also directed to a molecule which comprises the antigen-binding portion of an antibody specific for a protein, variant or fragment.

25

The present invention also comprehends antisense DNA/RNA of a length sufficient to prevent transcription and/or translation of any gene identified in accordance with the present invention, preferably comprising a sequence which is complementary to a portion of a gene of which a sequence of

SEQ ID NO:94 is a part or complementary to a portion of a gene of the KIAA0538 gene family. The present invention also comprehends ribozymes which specifically bind and cleave mRNA sequences identified in accordance with the present invention.

5

The present invention further comprehends methods of treating the effects of stroke, hypoxia and/or ischemia, and neurotoxicity as well as for diagnosing cells which have been subjected to hypoxia and/or ischemia, using the  
10 polynucleotides, polypeptides /proteins, antibodies, or ribozymes of the present invention.

The present invention further comprehends methods of treating the effects of neurotoxicity, stroke, hypoxia, or  
15 ischemia, comprising regulating in the cells to be treated the level of expression of any of the polynucleotides of the present invention, preferably polynucleotides comprising SEQ ID Nos: 49, 50, 51, 65, 67, 85, 87, 94-100, most preferably polynucleotides comprising SEQ ID No: 94 (corresponding to  
20 KIAA0538).

The present invention further comprehends methods of treating the effects of neurotoxicity, stroke, hypoxia, or ischemia, comprising bringing into the vicinity of the cells to be treated any of the polypeptides of the invention,  
25 preferably a polypeptide encoded by a cDNA comprising a polynucleotide having a sequence SEQ ID NO:65 (corresponding to KIAA0284), a variant which has an amino acid sequence having at least 70% identity to said polypeptide and retains the biological activity thereof, or a fragment of said  
30 polypeptide or variant which retains the biological activity

thereof, or a functional derivative or salt of said protein, variant or fragment.

The present invention further comprehends methods of treating the effects of neurotoxicity, stroke, hypoxia, and/or ischemia, comprising bringing into the vicinity of the cells to be treated an agent for inhibiting the polypeptide a protein encoded by a cDNA selected from SEQ ID No:94 or KIAA0538, a variant which has an amino acid sequence having at least 70% identity to said protein and retains the biological activity thereof, or a fragment of said protein or variant which retains the biological activity thereof, or a functional derivative or salt of said protein, variant or fragment.

The present invention further comprehends methods for the treatment of a subject in need of treatment for the effects of neurotoxicity, stroke, hypoxia, or ischemia, comprising regulating in said subject the level of expression of any of the polynucleotides of the invention, so as to thereby treat the subject, preferably preferably polynucleotides comprising SEQ ID Nos: 49, 50, 51, 65, 67, 85, 87, 94-100, most preferably polynucleotides comprising SEQ ID No: 94 (corresponding to KIAA0538).

The present invention further comprehends methods for the treatment of a subject in need of treatment for the effects of neurotoxicity, stroke, hypoxia, or ischemia, comprising administering to said subject a polypeptide encoded by a cDNA selected from SEQ ID NO:65 or KIAA0284, a variant which has an amino acid sequence having at least 70% identity to said protein and retains the biological activity thereof, or a

fragment of said protein or variant which retains the biological activity thereof, or a functional derivative or salt of said protein, variant or fragment.

The present invention further comprehends, as a preferred  
5 embodiment, the treatment of a subject in need of treatment for the effects of neurotoxicity, stroke, hypoxia, or ischemia, comprising administering to said subject a compound for inhibiting a polypeptide comprising a protein encoded by a cDNA selected from SEQ ID No:94 or KIAA0538, a  
10 variant which has an amino acid sequence having at least 70% identity to said protein and retains the biological activity thereof, or a fragment of said protein or variant which retains the biological activity thereof, or a functional derivative or salt of said protein, variant or fragment.

15

The present invention further comprehends methods for diagnosing cells which have been subjected to a neurotoxic insult, hypoxia and/or ischemia, comprising assaying for RNA  
20 comprising a sequence of any one of SEQ 1-131, preferably RNA comprising a sequence of any one of SEQ ID NOs:49, 50, 51, 65, 67, 85, 87, 94-100, most preferably RNA comprising a sequence of any one of SEQ ID NOs: 65, or 94, or for the expression product of a gene in which one of said sequences is a part,  
25 the change in amount of said RNA or expression product as compared to a control indicating the likelihood that such cells have been subjected to hypoxia or ischemia.

The present invention further comprehends methods of  
30 screening for a neuroprotective compound comprising testing the ability of the compound to upregulate or downregulate a

gene which is transcribed to an RNA containing a sequence of  
any of SEQ ID NOs: 1-131, preferably any of SEQ ID NOs: 49,  
50, 51, 65, 67, 85, 87 and 94-100, most preferably  
downregulate the transcription of SEQ ID No:94 or KIAA0538 or  
5 upregulate the transcription of SEQ ID No65 or KIAA 0284.

The present invention further comprehends methods of  
identifying a neuroprotective compound or screening for a  
neuroprotective compound comprising testing the ability of the  
10 compound to inhibit or enhance the activity of a polypeptide  
which is encoded by a polynucleotide of any of SEQ ID NOs: 1-  
131, as compared to a control, preferably SEQ ID NOs: 49,  
50, 51, 65, 67, 85, 87 and 94-100, most preferably to inhibit  
SEQ ID NO 94, even more preferably wherein the compound is  
15 screened for the ability to inhibit a  $Ca^{2+}$  promoted Ras  
inactivator encoded by a member of the KIAA0538 gene family;  
another preferred embodiment is wherein the compound is  
screened for the ability to activate or enhance the activity  
of a polypeptide encoded by KIAA0284.

20

The present invention further comprehends methods for  
screening for a compound or identifying a compound which  
induces or inhibits apoptosis after exposure of mammalian  
cells, preferably neural cells, to a neurotoxic insult,  
25 comprising the step of exposing the cells to the test compound  
and testing the change in expression, as compared to a  
control, of any one of the polynucleotides of the invention,  
preferably the change in expression of any member of the  
KIAA0538 gene family or the expression of KIAA0284.

30



The present invention further comprehends methods for screening for a compound or identifying a compound which induces or inhibits apoptosis after exposure of mammalian cells, preferably neural cells, to a neurotoxic insult,  
5 comprising the step of exposing the cells to the test compound and testing the change in activity of any one of the polypeptides of the invention, as compared to a control, preferably where the compound is screened for the ability to inhibit a  $\text{Ca}^{2+}$  promoted Ras inactivator encoded by a member of  
10 the KIAA0538 gene family.

The present invention further comprehends methods for screening for a compound or identifying a compound capable of exerting a neuroprotective effect that ameliorates or  
15 diminishes the damage induced by a neurotoxic insult, comprising the step of screening for the ability of the compound to alter the level of expression of any of the polynucleotides of the invention, compared to a control, testing the compound for its ability to inhibit the expression  
20 of any polynucleotide of the KIAA0538 gene family.

The present invention further comprehends methods for screening for a compound or identifying a compound capable of exerting a neuroprotective effect that ameliorates or  
25 diminishes the damage induced by a neurotoxic insult, comprising the step of screening for the ability of the compound to alter the activity by enhancement or inhibition of any one of the polypeptides of the invention, preferably wherein the compound is screened for its ability to inhibit

the activity of a Ca<sup>2+</sup> promoted Ras inactivator encoded by a member of the KIAA0538 gene family.

The present invention further comprehends methods for  
5 screening for a compound or identifying a compound which up-regulate or downregulate a gene, the improvement wherein said gene is a gene which is transcribed to an RNA complementary to any of the polynucleotides of the invention.

10 The present invention further comprehends methods for screening for or identifying a neuroprotective compound which specifically inhibits the polypeptide product of KIAA0538 gene which comprises:

(a) contacting cells expressing DNA encoding the KIAA0538  
15 gene under conditions permitting expression of the DNA; and

(b) determining if the compound inhibits the polypeptide as compared to a control; preferably the cells in this method are either transfected with the KIAA0538 gene or endogenously express the KIAA0538 gene, most preferably the cells are  
20 neuronal cells.

The present invention further comprehends a method of preparing a pharmaceutical composition which comprises the steps of:

(a) obtaining a compound which specifically inhibits the  
25 activity of the polypeptide product of the KIAA0538 gene; and

(b) admixing said compound with a pharmaceutically acceptable carrier. The inhibitory compound may be obtained by using one of the screening assay methods disclosed herein for identifying such compounds.

30

40031939-12494  
The compositions and methods of invention can be used to treat the adverse consequences of central nervous system injuries that result from any of a variety of conditions. Thrombus, embolus, and systemic hypotension are among the most common causes of cerebral ischemic episodes. Other injuries may be caused by hypertension, hypertensive cerebral vascular disease, rupture of an aneurysm, an angioma, blood dyscrasias, cardiac failure, cardiac arrest, cardiogenic shock, septic shock, head trauma, spinal cord trauma, seizure, bleeding from tumor, or other blood loss. Where the ischemia is associated with stroke, it can be either global or focal ischemia, as defined below.

The present invention is additionally directed to pharmaceutical compositions which include the nucleic acids, proteins or polypeptides in accordance with the present invention, along with pharmaceutically acceptable carriers or excipients.

In addition, the present invention is directed to knockout or transgenic non-human animals, in which a gene identified by the present invention has been introduced or knocked out.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a graph showing the effect of FK506 on primary neurons undergoing 16h hypoxia treatment. An optimal neuroprotective effect is achieved after 16h hypoxia in the presence of 100 ng/mL of FK506.

Figures 2A and 2B are microphotographs showing glutamate-induced killing of BE2C cells infected with an empty pLXSN vector (Fig. 2A) or the expression cDNA sub-library, following 2 rounds of selection (Fig. 2B) aimed for isolation

of library clones resistant to glutamate toxicity by virtue of library-derived cDNA expression. A comparison of Fig. 2B with Fig. 2A shows that a significant portion of the cells infected with the enriched sublibrary was protected from the toxic effects of glutamate.

Figures 3A and 3B show agarose gel electrophoresis of elements from libraries after 1 (Fig. 3A) and 4 (Fig 3B) rounds of selection. Discrete bands can be seen in Fig. 3B in enrichment of certain protective cDNA fragments in the course of functional selection

Figure 4 shows the protection of infected BE2C cells(human neuroblastoma cells) expressing SEQ ID No 94 [i.e. library-derived antisense (a.s.) cDNA fragment of KIAA 0538] 24 hours after exposure to high dopamine concentrations, compared to control vector-transfected cells( PLXSN).Neutral red staining.

Figure 5 shows the protection of transiently transfected BE2C cells expressing SEQ ID No 94 [i.e. library-derived antisense (a.s.) cDNA fragment of KIAA 0538] 24 hours after exposure to high dopamine concentrations, compared to control vector-transfected cells( PLXSN).Neutral red staining.

Figure 6 shows the cytotoxic effect exerted by full length cDNA clone of KIAA 0538 in a colony formation assay (in P19 mouse embryonic stem cells) performed either in normoxic or hypoxic/low glucose(ischemic) conditions. This shows that the full length cDNA clone of KIAA 0538 sensitizes P19 cells in ischemic conditions, since there are very few colonies

remaining, compared to the control (empty vector). Figure 6B is a graphical representation of Figure 6A.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

##### **I. Definitions**

5           The following definitions apply to the terms used in the present specification and claims:

          The term "gene" refers to the genomic nucleotide sequence which is transcribed to a full-length RNA. Such RNA molecules may be converted into corresponding cDNA molecules  
10 by techniques well known to the art of recombinant DNA technology. The term "gene" classically refers to the genomic sequence, which, upon processing, can produce different RNAs, e.g., by splicing events. However, for ease of reading, any full-length counterpart RNA sequence will also be referred to  
15 by shorthand herein as a "gene".

          The term "neurotoxic stress" as used herein is intended to comprehend any stress that is toxic to normal neural cells. Such stress may be hypoxia or hyperoxia or ischemia or trauma, or it may involve subjecting the cells to  
20 a substance that is toxic to the cells *in vivo*, such as glutamate or dopamine or the A protein. The neurotoxic substance may be endogenous or exogenous and the term neurotoxic is also intended to comprehend exposure to various known neurotoxins including organophosphorous poisoning, or  
25 any other insult of this type.

          By "ischemic episode" is meant any circumstance that results in a deficient supply of blood to a tissue. Cerebral ischemic episodes result from a deficiency in the blood supply to the brain. The spinal cord, which is also part  
30 of the central nervous system, is equally susceptible to

ischemia resulting from diminished blood flow. An ischemic episode may be caused by a constriction or obstruction of a blood vessel, as occurs in the case of a thrombus or embolus. Alternatively, the ischemic episode can result from any form of compromised cardiac function, including cardiac arrest. It is expected that the invention will also be useful for treating injuries to the central nervous system that are caused by mechanical forces, such as a blow to the head or spine. Trauma can involve a tissue insult such as an abrasion, incision, contusion, puncture, puncture, compression, etc., such as can arise from traumatic contact of a foreign object with any locus of or appurtenant to the head, neck, or vertebral column. Other forms of traumatic injury can arise from constriction or compression of CNS tissue by an inappropriate accumulation of fluid (for example, a blockade or dysfunction of normal cerebrospinal fluid or vitreous humor fluid production, turnover, or volume regulation, or a subdural or intracranial hematoma or edema). Similarly, traumatic constriction or compression can arise from the presence of a mass of abnormal tissue, such as a metastatic or primary tumor.

By "focal ischemia" as used herein in reference to the central nervous system, is meant the condition that results from the blockage of a single artery that supply blood to the brain or spinal cord, resulting in the death of all cellular elements (pan-necrosis) in the territory supplied by that artery.

By "global ischemia" as used herein in reference to the central nervous system, is meant the condition that results from general diminution of blood flow to the entire

brain, forebrain, or spinal cord, which causes the death of neurons in selectively vulnerable regions throughout these tissues. The pathology in each of these cases is quite different, as are the clinical correlates. Models of focal ischemia apply to patients with focal cerebral infarction, while models of global ischemia are analogous to cardiac arrest, and other causes of systemic hypotension

The term "Expressed Sequence Tag" or "EST" refers to a partial cDNA sequence of about 150 to 500, more preferably about 300, sequential nucleotides of a longer sequence obtained from a cDNA library prepared from a selected cell, cell type, tissue type, organ or organism which longer sequence corresponds to an mRNA (or other full-length RNA) transcribed in the above mentioned library sources. . One or more libraries made from a single tissue type typically provide many different (i.e., unique) ESTs and potentially the full complement of all possible ESTs representing all cDNAs, e.g., 50,000-100,000 in an animal such as a human. Further background and information on the construction of ESTs is described in Adams et al (1991) and International Application Number PCT/US92/05222 (January 7, 1993).

The term "apoptosis" is particularly defined as execution of built-in cell death program resulting in chromatin fragmentation into membrane-bound particles, changes in cell cytoskeleton and membrane structure and subsequent phagocytosis of apoptotic cell by other cells. , However, as used herein, it should be understood that this term should be construed more broadly as encompassing neuronal cell death, whether or not that cell death is strictly by means the apoptotic process described above.

Two proteins are "cognate" if they are produced in different species, but are sufficiently similar in structure and biological activity to be considered the equivalent proteins for those species. Two proteins may also be  
5 considered cognate if they have at least 50% amino acid sequence identity (when globally aligned with a pam250 scoring matrix with a gap penalty of the form  $q+r(k-1)$  where  $k$  is the length of the gap,  $q=-12$  and  $r=-4$ ; percent identity=number of identities as percentage of length of shorter sequence) and at  
10 least one biological activity in common. Similarly, two genes are cognate if they are expressed in different species and encode cognate proteins.

Whenever used in this invention "KIAA0538" (also referred to as "CAPRI") is defined as: any member of the  
15 KIAA0538 gene family, either full-length, mutant, splice variant, as a chimera with other proteins, or a polypeptide or biologically active fragment or domain of KIAA0538, or of any member of the KIAA0538 gene family having similar biological activity. KIAA0538 or KIAA0538 gene family member may be  
20 present in different forms, including: soluble protein; membrane-bound; bead-bound; or any other form of presenting KIAA0538 protein or fragments and polypeptides derived therefrom.

## II. Gene Discovery Techniques

25 Two different techniques were used to identify genes that are involved in stroke response and/or regulated by FK506. The first technique is known as microarray hybridization (differential profiling). It was performed using two different types of microarrays: the rat "Stroke Chip"  
30 human "Apoptosis Chip" or "HAP Chip". The second technique is



direct functional selection of genes which confer protection of neuron-like cells from genotoxic stress as full-length cDNAs or as their fragments expressed either in sense or antisense orientation (functional profiling)..

5           In the chip techniques, cDNA clones are arranged in a microarray on a chip substrate. The peculiarity of the HAP chip is that printed cDNA clones are selected by above-mentioned functional profiling. Thus, in the HAP Chip, the cDNA fragments are those that correspond to genes with pro- or  
10 anti-apoptotic activity.

In the Stroke Chip, the cDNA fragments are those that correspond to genes that are believed to be stroke specific. They are obtained from brain tissue of rats subjected to MCAO  
15 and from primary neurons cultured in vitro under hypoxic conditions.

The cDNA libraries that served as a source for the clones printed on the "Stroke chip" were prepared by two different techniques. First, by subtractive hybridization (by  
20 SSH) to enrich for clones differentially expressed in ischemic rat brains and hypoxic neurons and sequence-dependent gene identification (SDGI) to ensure maximal library complexity and minimal redundancy. The clones originating from these two cDNA libraries are combined on the same stroke chip.

25

The expression libraries for functional profiling are made by cloning total cellular cDNA into retroviral expression vectors. The clones of such library may contain either full-length cDNA either in sense or in the antisense  
30 orientation or cDNA fragments also expressed either as an

“antisense RNA” or it can make a short protein that can act as a dominant negative peptide. When the cDNA is expressed in the antisense orientation or as short peptide, the result will be inhibition of the expression or activity of the matching endogenous gene. A plasmid DNA pool is prepared from the bacteria and used for the introduction of the library into mammalian mammalian retroviral packaging cells of choice. The rescued recombinant retrovirus mixture is further used for transduction of the target cells. The cDNA fragment that is expressed by such mammalian cells can potentially inhibit or stimulate the expression of a specific endogenous gene or the function of the protein expressed by such a gene. The pool of mammalian cells is subjected to a certain selection process in which the activity of a number of genes is necessary for the cells to show a specific phenotype, after a specific induction, that can be followed experimentally. Thus, if the expression of a key gene is inhibited, the phenotype does not show for that cell. The selection process allows the selection of exactly these types of cells. This is followed by identification of the cDNA fragment that was present in the expression vector that was found in the cell. The identity of this cDNA fragment is indicative of the identity of the inhibited gene, thus identifying it as a key gene required for the change in phenotype. In the direct functional profiling method, these identified fragments are used as the candidates for further analysis.

Alternatively, the rescued cDNA clones are used for the printing of HAP chip. Further implication of such a chip in differential profiling enables a direct identification of “functional” genes differentially expressed in pathological

conditions. The chips may be used for differential hybridization experiments. Thus, cells, either in vivo or in vitro, may be subjected to a developmental, physiological, pharmacological or other cued event that will cause genes to be activated or repressed in response thereto. Such a cued event may be mechanical, chemical, toxic, pharmaceutical or other stress, hormones, physiological disorders or disease. A library of clones is made from the cDNA expressed by the cells subjected to such a cued event. These clones may then be labeled and used as a first probe. A control probe is made from the cDNA of cells that have not been subjected to the cued event. The two probes are labeled with first and second different fluorescent reporters. A mixture of the labeled cDNAs from the two cell types is added to the array of polynucleotides on the chip, under conditions that result in hybridization of the cDNAs to the complementary-sequence polynucleotides in the array. The array is then examined by fluorescence under fluorescence excitation conditions in which (i) polynucleotides in the array that are hybridized predominantly to cDNAs derived from one of the first or second cell types give a distinct first or second fluorescence emission color, respectively, and (ii) polynucleotides in the array that are hybridized to substantially equal numbers of cDNAs derived from the first and second cell types give a distinct combined fluorescence emission color, respectively. The relative expression of each polynucleotide in the array on the chip can then be determined by the observed fluorescence emission color of each spot. Thus, one can rapidly determine which genes are differentially expressed between the control cells and the cells which have been subjected to the cued

event and one can readily determine if the gene has been upregulated or downregulated. This gene expression array technology is disclosed, for example in U.S. patent 5,807,522, the entire contents of which are hereby incorporated herein by  
5 reference.

In the production of the Stroke Chip, the cDNA microarray was constructed by combining various types of libraries. An ischemia (stroke) model was created in SD and SHR rats by permanent middle cerebral artery occlusion (MCAO).  
10 Control rats of the same strain were subjected to a sham operation (Sham). Half of the rats of each group were given FK506 treatment at 0 hour. Subtraction libraries comprised: genes expressed in the MCAO rats but not in the sham operated rats (MCAO - Sham); and those genes expressed in the MCAO rats  
15 treated with FK506 (taken at 3 hours and 6 hours after FK506 treatment) but not in the MCAO treated rats which had not been exposed to FK506 treatment ([MCAO+FK506] - [MCAO]).

Another library included in the Stroke Chip was derived from in vitro treatment of primary neurons from the cerebellum of 7 day rat pups. The cells were subjected to  
20 hypoxia (0.5% O<sub>2</sub>) for 16 hours. The cells under hypoxia and control cells under normal oxygen concentration (normoxia) were treated with FK506 (100 ng/ml) at 0 hour and the cDNA extracted after 16 hours. A subtraction library was made from  
25 the cDNA fragments expressed in the FK506 treated cells under hypoxia but not in the FK506 treated cells under normoxia ([Hypoxia + FK506] - [Normoxia + FK506]).

Additional libraries were generated by sequence-dependent gene identification (SDGI). This technique is  
30 described in U.S. application no. 09/538,709, now PCT

publication No. WO 01/75180, the entire contents of which are hereby incorporated herein by reference. SDGI libraries were prepared from brain tissues of rats subjected to MCAO, MCAO rats three and six hours after treatment with FK506, and sham operated rats three and six hours after treatment with FK506. SDGI libraries were prepared from primary neurons that were subjected to hypoxia for 16 hours in the *in vitro* experiments and from primary neurons, pretreated with FK506 and subjected to hypoxia for 16 hours.

Polynucleotides from each of these libraries were combined onto the Stroke Chip, which contained about 10,000 clones.

In the HAP Chip, the clones were selected from among seven different libraries prepared using different functional profiles obtained by functional selection. A library of human BE2C neuroblastoma cells was prepared having inserted therein expression vectors with cDNA derived from human A172 or T98G glioma cells. The cells were subjected either to dopamine, glutamate or hypoxia. In all cases, the treatment in the selection type normally causes cell death. Cells that survived the selection by virtue of the library clone expression were selected and the cDNA fragments found in the expression vectors were recovered as a pool. This cDNA pool is highly enriched for cDNA fragments of genes required for cell death caused by the treatments mentioned in the selection type or by full-length cDNA required for cell survival under the conditions applied. Each cDNA pool was cloned to make a small library from which clones were taken for printing on the HAP chip.

Similarly, human HeLa cells were transformed with the TKO expression libraries ( coassigned U.S. patent No. 6,057,111 ;Deiss and Kimchi, 1991, Science, 252, 117-120) with antisense cDNA derived from HeLa cells therein. The library-  
5 transfected cells were subjected either to either irradiation, or taxol, or serum starvation, or serum starvation in conjunction with FAS antibody treatment. Again, the selection type normally causes cell death. Cells that survived the selection were selected and the cDNA fragments found in the  
10 expression vectors were recovered as a pool. Clones from these pools were also taken for printing on the HAP Chip.

### III. Novel Polynucleotide Sequences

Once candidate sequences are identified by one or  
15 more of the three selection processes, they were subjected to a bioinformatics analysis to annotate them and to identify if they are part of any known genes or ESTs or to determine whether they may be part of novel genes.

Polynucleotides that are selected on the basis of  
20 the stroke chip model discussed above originated as rat cDNA. Thus, when the positively identified polynucleotides from the array are sequenced, they will correspond to at least a fragment of a rat cDNA whose expression in neural cells is modulated when those cells are subjected to neurotoxic stress.  
25 Polynucleotides that are selected on the basis of the HAP chip model or the direct functional profiling originated as human cDNA. Thus, when the positively identified polynucleotides from the HAP chip array or directly identified from the functional profiling are sequenced, they will correspond to at  
30 least a fragment of a human cDNA whose expression in neural

cells is modulated when those cells are subjected to neurotoxic stress.

The polynucleotides determined in these assays fall within two categories. The first have novel sequences which are not found in any sequence databank or not substantially homologous to any sequence found in any sequence databank, or at least are not homologous to any sequence which is identified as being part of a known gene or having any known function. Some of the polynucleotides discussed in the present specification have such novel sequences, SEQ ID Nos: 1-48, 52-64, 66, 68-84, 86, 88-93, 101-131. The second is sequences that turn out to be a part of a known gene or are substantially homologous to a part of a known gene in another species, e.g. KIAA sequences, but were not previously known to have a connection to hypoxia or stroke. Some of the polynucleotides discussed in the present specification have such known sequences. Such polynucleotides have SEQ ID Nos: 49-51, 65, 67, 85, 87, 94-100 .

To the extent that the sequence is positively identified , the present invention comprehends that sequence, as well as any naturally-occurring polynucleotide that includes that sequence as a part thereof. The sequence *per se* has utility based on the fact that it has been identified on the basis of differential expression in cells subjected to neurotoxic stress. It can be used in diagnostic processes and kits for determining whether any given neurological cells have been subjected to neurotoxic stress or whether neurons *in vivo* have been protected from neurotoxicity by some means. Even when such sequences are rat sequences, there is real-world utility for the purpose of medical research for determining in



a rat model which cells have been subjected to neurotoxic stress and which cells may have been protected from neurotoxic stress when subjected to a treatment protocol in a rat model. By using the novel sequence as a probe, or a portion thereof as a oligonucleotide probe, one can identify the places in the brain (whether the brain is a rat brain when the sequence is a rat sequence or a human brain when the sequence is a human sequence) where the cDNA including the sequence is expressed and whether or not, or in what degree, it is expressed when subjected to various treatment protocols.

Human genes may be directly discovered using the HAP chip or functional profiling or indirectly discovered by determining the human gene which corresponds to the rat gene discovered using the stroke chip. Such human genes are also  
15 useful for determining whether human neural cells have been subjected to neurotoxic stress, for example in diagnosing whether or not a patient has suffered a stroke. As will be discussed in greater detail below, it is a procedurally routine matter to determine a cognate human gene based on the  
20 sequence of a rat gene. Thus, regardless of whether or not one knows the actual sequence of the corresponding human gene, the rat gene has utility as a probe for seeking and identifying the corresponding human gene which, when identified, will have its own utility.

25           The positively identified polynucleotide sequences  
are ESTs. The location of an EST in a full-length cDNA is  
determined by analyzing the EST for the presence of coding  
sequence. A conventional computer program is used to predict  
the extent and orientation of the coding region of a sequence  
30 (using all six reading frames). Based on this information, it



is possible to infer the presence of start or stop codons within a sequence and whether the sequence is completely coding or completely non-coding or a combination of the two. If start or stop codons are present, then the EST can cover  
 5 both part of the 5'-untranslated or 3'-untranslated part of the mRNA (respectively) as well as part of the coding sequence. If no coding sequence is present, it is likely that the EST is derived from the 3' untranslated sequence due to its longer length and the fact that most cDNA library  
 10 construction methods are biased toward the 3' end of the mRNA. It should be understood that both coding and non-coding regions may provide ESTs equally useful in the described invention.

Methods for obtaining complete gene sequences from  
 15 ESTs are well-known to those of skill in the art. See, generally, Sambrook et al, (1989) and Ausubel et al (1994-2000). Briefly, one suitable method involves purifying the DNA from the clone that was sequenced to give the EST and labeling the isolated insert DNA. Suitable labeling systems  
 20 are well known to those of skill in the art. See, e.g., Davis et al (1986). The labeled EST insert is then used as a probe to screen a lambda phage cDNA library or a plasmid cDNA library, identifying colonies containing clones related to the probe cDNA that can be purified by known methods. The ends of  
 25 the newly purified clones are then sequenced to identify full-length sequences and complete sequencing of full-length clones is performed by enzymatic digestion or primer walking. A similar screening and clone selection approach can be applied to clones from a genomic DNA library. The entire naturally-  
 30 occurring cDNA or gene sequence, including any allelic



$$T_m = 81.5^{\circ}\text{C} + 16.6 (\log M) + 0.41 (\%GC) - 0.61 (\% \text{ form}) - 500/L$$

and for DNA:RNA hybrids, as

5

$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log M) + 0.58 (\%GC) - 11.8 (\%GC)^2 - 0.56(\% \text{ form}) - 820/L$$

where

M, molarity of monovalent cations, 0.01-0.4 M NaCl,  
 10 %GC, percentage of G and C nucleotides in DNA, 30%-75%,  
 % form, percentage formamide in hybridization solution, and  
 L, length hybrid in base pairs.

15 T<sub>m</sub> is reduced by 0.5-1.5°C (an average of 1°C can be used for ease of calculation) for each 1% mismatching.

The T<sub>m</sub> may also be determined experimentally. As increasing length of the hybrid (L) in the above equations increases the T<sub>m</sub> and enhances stability, the full-length rat  
 20 gene sequence can be used as the probe.

Filter hybridization is typically carried out at 68°C, and at high ionic strength (e.g., 5 - 6 X SSC), which is non-stringent, and followed by one or more washes of increasing stringency, the last one being of the ultimately  
 25 desired stringency. The equations for T<sub>m</sub> can be used to estimate the appropriate T<sub>i</sub> for the final wash, or the T<sub>m</sub> of the perfect duplex can be determined experimentally and T<sub>i</sub> then adjusted accordingly.

Hybridization conditions should be chosen so as to  
 30 permit allelic variations, but avoid hybridizing to other

genes. In general, stringent conditions are considered to be a  $T_i$  of 5°C below the  $T_m$  of a perfect duplex, and a 1% divergence corresponds to a 0.5-1.5°C reduction in  $T_m$ . Typically, rat clones were 95-100% identical to database rat sequences, and the observed sequence divergence may be artifactual (sequencing error) or real (allelic variation). Hence, use of a  $T_i$  of 5-15°C below, more preferably 5-10°C below, the  $T_m$  of the double stranded form of the probe is recommended for probing a rat cDNA library with rat EST probes. However, when probing for a human gene cognate, more moderate stringency hybridization conditions should be used.

As used herein, highly stringent conditions are those which are tolerant of up to about 15% sequence divergence, while moderately stringent conditions are those which are tolerant of up to about 30-35% sequence divergence. Without limitation, examples of highly stringent (5-15°C below the calculated  $T_m$  of the hybrid) and moderately stringent (15-20°C below the calculated  $T_m$  of the hybrid) conditions use a wash solution of 0.1 X SSC (standard saline citrate) and 0.5% SDS at the appropriate  $T_i$  below the calculated  $T_m$  of the hybrid. The ultimate stringency of the conditions is primarily due to the washing conditions, particularly if the hybridization conditions used are those which allow less stable hybrids to form along with stable hybrids. The wash conditions at higher stringency then remove the less stable hybrids. A common hybridization condition that can be used with the highly stringent to moderately stringent wash conditions described above is hybridization in a solution of 6 X SSC (or 6 X SSPE), 5 X Denhardt's reagent, 0.5% SDS, 100

μg/ml denatured, fragmented salmon sperm DNA at an appropriate incubation temperature T<sub>i</sub>.

Once any such naturally-occurring DNA is identified, it can be tested by means of routine experimentation to determine whether it is differentially expressed in the neuronal cells in which it naturally occurs when subjected to neurotoxic stress. The present invention is intended to comprehend any such naturally-occurring DNA which binds to an EST of the present invention or any oligonucleotide fragment thereof, preferably having at least 20, more preferably at least 50, contiguous nucleic acids, under highly stringent conditions or under moderately stringent conditions, which identified DNA molecules are determined to be differentially expressed in the neural cells in which they naturally occur when such neural cells are subjected to neurotoxic stress. Any such identified DNA molecules would have the same utility as discussed above for the identified polynucleotide.

If the full-length sequence identified is a rat gene sequence or a sequence of any mammalian gene other than human, the cognate human gene sequence can be readily obtained, as would be readily appreciated by those of skill in the art. Comparison of known cognate protein and gene sequences between rat and human shows a high level of sequence identity, mostly on the order of 70% or higher. The cognate human gene sequence is quite readily identified and determined as long as there is a high level of sequence identity to the rat gene sequence.

While a rat EST sequence would be used to probe a rat cDNA library for a full-length cDNA sequence, and could even be used to probe human cDNA libraries, it would be

expected that there would be some sequence divergence, especially at the EST sequence level, between cognate rat and human DNAs, which sequence divergence may be possibly as much as 25-50%. Preferably, the rat sequence used as a probe is  
5 from the coding region of the rat cDNA, as 5'- or 3'-uncoded region often lack significant homology among different mammalian species.

If a partial human cDNA is obtained, it may be used to isolate a larger human cDNA, and the process repeated as  
10 needed until the complete human cDNA is obtained.

For cross-species hybridization, such as to obtain the cognate human gene sequence from the rat gene sequence, the  $T_i$  should be reduced further, by about 0.5-1.5°C, e.g., 1°C, for each expected 1% divergence in sequence. The degree  
15 of divergence may be estimated from the known divergence of the most closely related pairs of known genes from the two species.

If the desired degree of mismatching results in a wash temperature less than 45°C, it is desirable to increase  
20 the salt concentration so a higher temperature can be used. Doubling the SSC concentration results in about a 17°C increase in  $T_m$ , so washes at 45°C in 0.1 X SSC and 62°C in 0.2 X SSC are equivalent (1 X SSC = 0.15 M NaCl, 0.015M trisodium citrate, pH 7.0).

25 The person skilled in the art can readily determine suitable combinations of temperature and salt concentration to achieve these degrees of stringency.

Examples of successful cross-species-hybridization experiments include Braun et al (1989) (mouse v. human),  
30 Imamura et al (1991) (human v. rat), Oro et al (1988) (human

v. Drosophila), Higuti et al (1991) (rat v. human), Jeung et al (1992) (rat, bovine v. human), Iwata et al (1992) (human v. mouse), Libert et al (1992) (dog v. human), Wang et al (1993) (human v. mouse), Jakubiczka et al (1993) (human v. bovine),  
5 Nahmias et al (1991) (human v. mouse), Potier et al (1992) (rat v. human), Chan et al (1989) (human v. mouse), Hsieh et al (1989) (human, mouse v. bovine), Sumimoto et al (1989) (human v. mouse), Boutin et al (1989) (rat v. human), He et al (1990) (human, rat v. dog, guinea pig, frog, mouse), Galizzi  
10 et al (1990) (mouse v. human). See also Gould et al (1989).

In general, for cross-species hybridization,  $T_i$  = 25-35°C below  $T_m$ . Wash temperatures and ionic strengths may be adjusted empirically until background is low enough.

Any non-rat mammalian sequences obtained from such  
15 hybridization experiments, which sequences test positive for the ability to be differentially expressed when the neuronal cells in which they naturally occur are subjected to neurotoxic stress, are also encompassed by the present invention.

20 Fragments of any such naturally-occurring sequences also have utility and are intended to be encompassed by the present invention. Fragments of preferably at least 20, more preferably at least 50, nucleotides in length can be used as probes for the diagnostic assays described above.

25 Polynucleotide sequences that are complementary to any of the sequences or fragments encompassed by the present invention discussed above are also considered to be part of the present invention. Whenever any of the sequences discussed above are produced in a cell, the complementary  
30 sequence is concomitantly produced and, thus, the

complementary sequence can also be used as a probe for the same diagnostic purposes.

#### IV. Novel Proteins Encoded by Genes of Section III

Once the sequence of any full-length cDNA is  
5 obtained, the protein encompassed thereby is readily  
determinable by analysis of the sequence to find the start and  
stop codons and then decoding the amino acid sequence encoded  
by the cDNA. Thus, the present invention also encompasses any  
protein encoded by a full-length cDNA encompassed by the  
10 present invention as discussed above. Such proteins can be  
used for the same diagnostic utility, as discussed above for  
the polynucleotides, as they will be differentially expressed  
to the same degree that the corresponding cDNA is  
differentially expressed. They can be used to make a  
15 diagnostic tool which can be used to determine their presence  
in a cell. Thus, for example, they can be used to raise  
antibodies that could be used in such a diagnostic assay for  
the presence of such a protein. Such an assay would be useful  
to determine whether any given cell had been subjected to  
20 neurotoxic stress. Such proteins can also be used for any of  
the utilities discussed hereinbelow in the section related to  
methods of use.

Analogous of a protein or polypeptide encoded by the  
DNA sequences discovered in the assays described herein is  
25 also comprehended by the present invention. Preferably, the  
analog is a variant of the native sequence which has an amino  
acid sequence having at least 70% identity to the native amino  
acid sequence and retains the biological activity thereof.  
More preferably, such a sequence has at least 85% identity, at



least 90% identity, or most preferably at least 95% identity to the native sequence.

The term "sequence identity" as used herein means that the sequences are compared as follows. The sequences are aligned using Version 9 of the Genetic Computing Group's GAP (global alignment program), using the default (BLOSUM62) matrix (values -4 to +11) with a gap open penalty of -12 (for the first null of a gap) and a gap extension penalty of -4 (per each additional consecutive null in the gap). After alignment, percentage identity is calculated by expressing the number of matches as a percentage of the number of amino acids in the claimed sequence.

Analogous in accordance with the present invention may also be determined in accordance with the following procedure. Polypeptides encoded by any nucleic acid, such as DNA or RNA, which hybridize to the complement of the native DNA or RNA under highly stringent or moderately stringent conditions, as long as that polypeptide maintains the biological activity of the native sequence are also considered to be within the scope of the present invention. Preferably, such nucleic acids hybridizing to the complement of the polynucleotides of the present invention under the specified conditions are naturally occurring nucleic acids, which may or may not be produced in cells of the same species as the original polynucleotides. As with any other analog, such polypeptide must retain the biological activity of the original polypeptide.

The term "active fragments" is intended to cover any fragment of the proteins identified by means of the present invention that retain the biological activity of the full protein. For example, fragments can be readily generated from

the full protein where successive residues can be removed from either or both the N-terminus or C-terminus of the protein, or from biologically active peptides obtained therefrom by enzymatic or chemical cleavage of the polypeptide. Thus, multiple substitutions are not involved in screening for active fragments. If the removal of one or more amino acids from one end or the other does not affect the biological activity after testing in the standard tests, discussed herein, such truncated polypeptides are considered to be within the scope of the present invention. Further truncations can then be carried out until it is found where the removal of another residue destroys the biological activity.

"Functional derivatives" as used herein covers chemical derivatives which may be prepared from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, i.e., they do not destroy the biological activity of the corresponding protein as described herein and do not confer toxic properties on compositions containing it. Derivatives may have chemical moieties, such as carbohydrate or phosphate residues, provided such a fraction has the same biological activity and remains pharmaceutically acceptable.

Suitable derivatives may include aliphatic esters of the carboxyl of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives or free amino groups of the amino acid residues formed with acyl moieties (e.g., alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of free

1002493B-1204

hydroxyl group (e.g., that of seryl or threonyl residues) formed with acyl moieties. Such derivatives may also include for example, polyethylene glycol side-chains which may mask antigenic sites and extend the residence of the complex or the portions thereof in body fluids.

Non-limiting examples of such derivatives are described below.

Cysteiny l residues most commonly are reacted with alpha-haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteiny l residues also are derivatized by reaction with bromotrifluoroacetone, alpha-bromo- beta-(5-imidazolyl)propionic acid, chloroacetyl phosphate, B alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl-2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4- nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

Histidyl residues are derivatized by reaction with diethylprocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Parabromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.

Lysiny l and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysiny l residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimide; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2, 4-

pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclodexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high  $pK_a$  of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

The specific modification of tyrosyl residues *per se* has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides ( $R'-N-C-N-R'$ ) such as 1-cyclohexyl-3-[2-morpholinyl-(4-ethyl)]carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

The term "derivatives" is intended to include only those derivatives that do not change one amino acid to another of the twenty commonly-occurring natural amino acids.

The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the complex of the invention or analogs thereof. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids, such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids, such as, for example, acetic acid or oxalic acid. Of course, any such salts must have substantially similar biological activity to the complex of the invention or its analogs.

#### **V. Known Polynucleotides and Protein Sequences**

After the polynucleotide sequences are identified following the gene discovery techniques discussed above, and these discovered sequences are subjected to bioinformatics review, it has been determined that many of these sequences appear in the sequence databanks and some are part of identified known genes with known function and encode known proteins. Once it is determined that an EST found by the gene discovery techniques of the present invention are part of a known gene, it is not necessary to go through the hybridization steps in order to find the full-length cDNA for such ESTs. Furthermore, in most cases, it will not be necessary to find the cognate human gene experimentally. If

the rat EST is part of a known rat gene, it is likely that the cognate human gene is also known. If not, it may be determined by the techniques discussed hereinabove with respect to novel rat gene sequences.

5 As the protein encoded by the known gene is also known, it is not necessary to use the techniques discussed hereinabove for determining the sequence encoded by a polynucleotide sequence. However, to the extent that the protein is not known, the techniques discussed hereinabove  
10 with respect to novel polynucleotide sequences may also be used.

Any known allelic variants of the known gene would also be expected to have the properties discovered by the gene discovery techniques discussed herein and, therefore, are also  
15 considered to be part of the present invention. The existence of other naturally-occurring variants having the property of having its sequence modulated when subjected to neurotoxic stress may also be determined using hybridization experiments under highly stringent conditions or moderately stringent  
20 conditions, all as discussed in detail hereinabove with respect to the novel polynucleotide sequences.

Analogous, active fragments, functional derivatives and salts of the known proteins which retain the property of that protein for the purposes of the present invention  
25 (although not necessarily for the properties previously known for that protein) are comprehended by the present invention, if novel, and their use is considered to be part of the present invention.

## VI. Utility of Good Genes and Bad Genes

The genes found in the *in vivo* experiment on the two chips which were upregulated by MCAO without FK506 treatment (vs. sham), but downregulated when treated with FK506 (vs MCAO without FK506), illustrate genes which contribute to the effects of stroke and which it would be desirable to downregulate in the treatment of stroke, or otherwise decrease the titer of the expression product of such genes or inactivate it at the site of the stroke. These genes will be referred to as "bad genes" herein. The utility of such bad genes and methods of use thereof will be discussed below

The genes found in the *in vivo* experiment on the two chips that were downregulated by MCAO vs. sham but upregulated when the MCAO rats are treated with FK506, illustrate genes which contribute to the alleviation of the detrimental effects of stroke and which it would be desirable to upregulate or otherwise increase the titer of the expression product of such genes at the site of the stroke. These genes will be referred to as "good genes" herein. The utility of such good genes and methods of use thereof will be discussed below.

The genes found in the *in vitro* experiment on the Stroke chip that were upregulated in hypoxia cells sixteen hours after FK506 treatment are genes that contribute to the alleviation of the detrimental effects of stroke and therefore would fall into the category of good genes. Those that were downregulated after FK506 treatment contribute to the effects of stroke, although they are beneficially downregulated by FK506, and fall into the category of bad genes.

In the direct functional profiling assays, the inserted DNA fragments that protected the cells from death were functional either in effectively knocking out a gene that



would otherwise have contributed to the cell death or being a complete cDNA of a protective gene by itself. If the original orientation of the sequence is antisense, its activity will be antisense, blocking expression from the sense sequence of the corresponding gene. Such genes fall into the category of bad genes. If the original orientation is sense, it may encode either a peptide having a dominant negative effect or the complete functional protein. If cDNAs codes for a protective dominant negative peptide that counteract with the normal function of the corresponding endogenous gene, the latter gene also falls in the category of bad genes. However, in some cases, short sense cDNA fragments may express a minimal active protein segment, thus falling in the category of good genes. cDNAs expressing full-length open reading frames in sense orientation also fall into the category of good genes. As indicated above, it is not always possible to determine directly from the results of the functional profiling tests whether the DNA fragments found are part of a good gene or a bad gene. Even more frequently, it may not be possible to directly determine whether DNA fragments identified in differential profiling are part of good genes or bad genes. It is reasonably certain, however, that the fragments so identified are one or the other as their expression has been significantly modulated based on the neurotoxic stress conditions to which the cells have been subjected, with or without FK506. Even a sham operation places neurotoxic stress on brain cells. However, by means of further experimentation, which experimentation would not be considered to be undue experimentation, one can determine whether the fragments are part of good genes or bad genes. Oneway to test whether the



fragments are part of good genes or bad genes would be to knock out the gene of interest, either in a animal or by knocking out the gene by alternative method in the cell line being tested. In a cell line, the cells can then be tested  
5 with neurotoxic stress to determine whether the absence of that gene has a protective effect or enhances cell death. In a knockout mouse, similar tests can be conducted to see whether the absence of that gene has a protective or detrimental effect on the mouse when subjected to neurotoxic  
10 stress.

A gene can be knocked out in a cell line by means of homologous recombination or by transfecting the cell line with an antisense sequence which prevents the expression of that gene, or by expression of rationally designed dominant-  
15 negative mutant protein or by introduction of RNAi, all as is well known to those of ordinary skill in this art. A gene can be knocked out in an animal such as a mouse, by the techniques discussed below in Section XVII.

Another way is to overexpress the corresponding full-length  
20 cDNA either in animals (transgenic mice) or in cell line (transfection, transduction) and to test the effect of the overexpression of the gene, as regards protection from cell death or augmentation of cell death, under normal or stressful conditions.

25 Accordingly, even if it cannot be directly determined whether any of the DNA fragments of the present invention are parts of good genes or parts of bad genes, it is reasonably expected that they are parts of either one or the other, and, in either event, they have utility for the reasons  
30 discussed below. It can be determined whether they are good

genes or bad genes without resorting to undue experimentation. Accordingly, such genes have utility and industrial applicability.

Good genes are useful as the protein encoded by such  
5 genes can be used to protect neural cells from neurotoxicity, to ameliorate the effects of hypoxia, ischemia, or other neurotoxic stressors, and ultimately in the therapeutic treatment of stroke, hypoxia and/or ischemia. Thus the genes, and the DNA encoding such a protein or active fragment or  
10 analog thereof, are useful in the recombinant production of such proteins or polypeptides. They are also useful as a target for assays for the discovery of drugs which selectively upregulate such genes or activate their protein products. The proteins encoded by such novel good genes, as well as active  
15 fragments thereof, analogs and functional derivatives thereof, are also part of the present invention and have utility to protect neural cells from neurotoxicity, to ameliorate the effects of hypoxia, ischemia, or other neurotoxic stressors, and ultimately in the therapeutic treatment of stroke, hypoxia  
20 and/or ischemia.

Good genes, whether novel or known, but whose relationship to neurotoxicity reported herein was previously unknown, may be used in novel processes which take advantage of these newly discovered properties. Thus, for example, the  
25 expression product of such genes, as well as active fragments, analogs and functional derivatives thereof, may be used to protect neural cells from neurotoxicity, to ameliorate the effects of hypoxia, ischemia, or other neurotoxic stressors, and ultimately for the treatment of the effects of stroke,  
30 hypoxia and/or ischemia by the therapeutic administration

thereof in a manner which causes such product to be brought into the vicinity of the cells to be treated.

Bad genes, if their protein products are secreted into serum, are useful in that they can be used in diagnostic  
5 assays for cells that have been subjected to hypoxia, ischemia, and/or other neurotoxic stresses. If mRNA corresponding to such genes, or the translation product thereof, is found in the cells being assayed it is likely that they have been subjected to hypoxia, ischemia, and/or other  
10 neurotoxic stresses. If diagnosed pre-stroke, this may be predictive of incipient stroke. They are also useful as a target for assays for the discovery of drugs which selectively downregulate such genes or are otherwise dominant negative with respect to the expression of the gene product of such  
15 genes. Antisense RNA that prevents the expression of such gene is also part of the present invention and is useful to protect neural cells from neurotoxicity, to ameliorate the effects of hypoxia, ischemia, or other neurotoxic stressors, and ultimately for the treatment of the effects of stroke,  
20 hypoxia and/or ischemia.

Bad genes, whether novel or known but whose relationship to neurotoxic stresses including ischemic episodes as exemplified by, but not limited to the model of stroke reported herein, was previously unknown, may be used in  
25 novel processes which take advantage of these newly discovered properties. Antisense RNA having a sequence complementary to a portion of such a gene and that prevents the expression of such a gene may be produced and used therapeutically by administering same in a manner by which it enters cells which  
30 have been subjected to stroke, hypoxia, ischemia, and/or other

neurotoxic stress in order to ameliorate the effects of such conditions. They may also be used in methods for assaying for drugs which downregulate such genes. To the extent that such proteins/polypeptides are enzymes, or ion channels, or transporters or other "druggable" entities, the present invention comprehends the protection of neural cells from neurotoxicity, the amelioration of the effects of hypoxia, ischemia, or other neurotoxic stress, and ultimately the therapeutic treatment of the effects of stroke, hypoxia, ischemia, and/or other neurotoxic stress by administering an inhibitor of such enzyme (or other druggable proteins, e.g. ion channel, or transporter, etc) in a manner that brings such inhibitor to the vicinity of the cells in which such enzyme has been upregulated.

It is known in the art, that in certain neurological diseases, for example, brain ischemia or stroke, the blood brain barrier (BBB) is relatively open compared to that of a normal subject, thus enabling penetration of even large molecules such as macromolecules, including antibodies into the brain, and subsequently allowing interaction of the latter with the target moieties. In this connection, the use of neutralizing therapeutic antibodies against the secreted protein products of bad genes is also contemplated by this invention

Nevertheless, it will be appreciated by the skilled artisan that the use of small molecules in general, and particularly small molecules capable of penetration into the central nervous system is advantageous for treatment of the ischemic damage, neurotoxicity, and traumatic insults by

inhibiting the genes or gene products of the present invention.

## VII. Diagnostic Methods

Methods of detecting tissue hypoxia in mammalian tissue, or the fact that tissue has been subjected to another neurotoxic stress, are based on the use of the potentially secreted protein products of the bad genes as a diagnostic marker(s) for cells that have been subjected to hypoxia, ischemia, and/or other neurotoxic stresses. It is possible to determine the level of protein translation products corresponding to these bad genes, in normal tissue fluids as compared to hypoxic tissue fluids and, thus, determine the reference values of these bad genes protein products which are indicative of tissue hypoxia.

Furthermore, regardless of whether or not the gene or gene product has been designated as good or bad, that gene (or EST) can be used in the diagnostic methods of the present invention if it was found in the chip or functional experimentation reported herein to be modulated significantly upward after the cells have been subjected to neurotoxic stress, and particularly hypoxia. Any such gene may be considered to be a gene of interest for the purpose of the diagnostic assays reported herein.

The use of antibodies as diagnostics against the secreted protein products of bad genes is also contemplated by this invention.

**Samples.** The sample for use in the detection methods may be of any biological fluid or tissue which is reasonably expected to contain the the protein expressed from

one of the above mentioned bad genes. . Preferably, the sample is body fluids of the subject being tested. **Analyte**

**Binding Reagents.** The assay target or analyte as a diagnostic marker is a secreted protein translation product of the gene  
5 of interest. When the assay target is a protein, the preferred binding reagent is an antibody, the specifically binding fragment of an antibody, or a molecule that has the antigen-binding portion of an antibody. The antibody may be monoclonal or polyclonal. It can be obtained by first  
10 immunizing a mammal with the protein target, and recovering either polyclonal antiserum, or immunocytes for later fusion to obtain hybridomas, or by constructing an antibody phage library and screening the antibodies for binding to the target. The binding reagent may also be a binding molecule  
15 other than an antibody, such as a receptor fragment, an oligopeptide, or a nucleic acid. A suitable oligopeptide or nucleic acid may be identified by screening a suitable random library.

**Signal Producing System (SPS).** In order to detect  
20 the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the amount of the analyte). The  
25 detectable signal may be one which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an  
30 assay component or product, and precipitation or agglutination

of a component or product. The term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value. The signal may be monitored  
5 manually or automatically.

**Labels.** The component of the signal producing system which is most intimately associated with the diagnostic reagent for the analyte is called the "label". A label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-  
10 enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle, etc.

The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful  
15 for the purpose of the present invention are  $^3\text{H}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$ , and  $^{14}\text{C}$ .

The label may also be a fluorophore. When the fluorescently labeled reagent is exposed to light of the proper wavelength, its presence can then be detected due to  
20 fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde and fluorescamine.

25 Alternatively, fluorescence-emitting metals such as  $^{125}\text{Eu}$ , or others of the lanthanide series, may be incorporated into a diagnostic reagent using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediamine-tetraacetic acid (EDTA).



The label may also be a chemiluminescent compound. The presence of the chemiluminescently labeled reagent is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used for labeling. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Enzyme labels, such as horseradish peroxidase and alkaline phosphatase, can also be used. When an enzyme label is used, the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.

**Conjugation Methods.** A label may be conjugated, directly or indirectly (e.g., through a labeled anti-analyte binding reagent antibody), covalently (e.g., with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP)) or non-covalently, to the analyte binding reagent, to produce a diagnostic reagent.



Similarly, the analyte binding reagent may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.

Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.

The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target. Thus the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.

**Binding Assay Formats.** Binding assays may be divided into two basic types, heterogeneous and homogeneous. In heterogeneous assays, the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label. In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.

In one embodiment, the analyte binding reagent is insolubilized by coupling it to a macromolecular support, and analyte in the sample is allowed to compete with a known quantity of a labeled or specifically labelable analyte analogue. The "analyte analogue" is a molecule capable of

competing with analyte for binding to the analyte binding reagent, and the term is intended to include analyte itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the analyte analogue from analyte. The solid and liquid phases are separated, and the labeled analyte analogue in one phase is quantified. The higher the level of analyte analogue in the solid phase, i.e., sticking to the analyte binding reagent, the lower the level of analyte in the sample.

10 In a "sandwich assay", both an insolubilized analyte binding reagent, and a labeled analyte binding reagent are employed. The analyte is captured by the insolubilized analyte binding reagent and is tagged by the labeled analyte binding reagent, forming a ternary complex. The reagents may be added to the sample in either order, or simultaneously. The analyte binding reagents may be the same or different. The amount of labeled analyte binding reagent in the ternary complex is directly proportional to the amount of analyte in the sample.

20 The two embodiments described above are both heterogeneous assays. However, homogeneous assays are conceivable. The key is that the label be affected by whether or not the complex is formed.

#### **Detection of Protein Products of Genes of Interest.**

25 Techniques for detecting a protein translation product of interest include, but are not limited to, immunoblotting or Western blotting, ELISA, sandwich assays, fluorescence, or biotin or enzymatic labeling with or without secondary antibodies.

Western blot analysis can be done on the tissue biopsies or tissue aspirates. This would involve resolving the proteins on an electrophoretic gel, such as an SDS PAGE gel, and transferring the resolved proteins onto a nitrocellulose or other suitable membrane. The proteins are

5 incubated with a target binding molecule, such as an antibody. This binding reagent may be labeled or not. If it is unlabeled, then one would also employ a secondary, labeled molecule which binds to the binding reagent. One approach

10 involves avidinating one molecule and biotinylating the other. Another is for the secondary molecule to be a secondary antibody which binds the original binding reagent.

To improve detection of the specific protein, immunoprecipitation can be conducted. This typically will

15 involve addition of a monoclonal antibody against the protein of interest to samples, then allowing the Ig-protein complex to precipitate after the addition of an affinity bead (ie antihuman Ig Sepharose bead). The immunoprecipitates will undergo several washings prior to transfer onto a

20 nitrocellulose membrane. The Western blot analysis can be performed using another antibody against the primary antibody used.

There are a number of different methods of delivering the radiolabeled analyte binding reagent to the

25 end-user in an amount sufficient to permit subsequent dynamic and/or static imaging using suitable radiodetecting devices. It may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal. Because proteins and nucleic acids are subject to

30 being digested when administered orally, parenteral

administration, i.e., intravenous, subcutaneous, or intramuscular, would ordinarily be used to optimize absorption of an analyte binding reagent, such as an antibody, which is a protein.

5           The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radioimaging agents as a guide.

10           Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The amount of radiolabeled analyte binding reagent accumulated at a given point in time in relevant target organs can then be quantified.

15           A particularly suitable radiodetecting device is a scintillation camera, such as a gamma camera. A scintillation camera is a stationary device that can be used to image distribution of radiolabeled analyte binding reagent. The detection device in the camera senses the radioactive decay, 20 the distribution of which can be recorded. Data produced by the imaging system can be digitized. The digitized information can be analyzed over time discontinuously or continuously. The digitized data can be processed to produce images, called frames, of the pattern of uptake of the 25 radiolabeled analyte binding reagent in the target tissue/organ at a discrete point in time. In most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in the target tissue/organ over time. In other words, a time-activity 30 analysis of the data will illustrate uptake through clearance

administration, i.e., intravenous, subcutaneous, or intramuscular, would ordinarily be used to optimize absorption of an analyte binding reagent, such as an antibody, which is a protein.

5           The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radioimaging agents as a guide.

10           Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The amount of radiolabeled analyte binding reagent accumulated at a given point in time in relevant target organs can then be quantified.

15           A particularly suitable radiodetecting device is a scintillation camera, such as a gamma camera. A scintillation camera is a stationary device that can be used to image distribution of radiolabeled analyte binding reagent. The detection device in the camera senses the radioactive decay, 20 the distribution of which can be recorded. Data produced by the imaging system can be digitized. The digitized information can be analyzed over time discontinuously or continuously. The digitized data can be processed to produce images, called frames, of the pattern of uptake of the 25 radiolabeled analyte binding reagent in the target tissue/organ at a discrete point in time. In most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in the target tissue/organ over time. In other words, a time-activity 30 analysis of the data will illustrate uptake through clearance

of the radiolabeled binding protein by the target organs with time.

Various factors should be taken into consideration in selecting an appropriate radioisotope. The radioisotope must be selected with a view to obtaining good quality resolution upon imaging, should be safe for diagnostic use in humans and animals (except for animal models which will be sacrificed thereafter and will be maintained anaesthetized until then), and should preferably have a short physical half-life so as to decrease the amount of radiation received by the body (with the same exceptions). The radioisotope used should preferably be pharmacologically inert, and, in the quantities administered, should not have any substantial physiological effect.

The analyte binding reagent may be radiolabeled with different isotopes of iodine, for example  $^{123}\text{I}$ ,  $^{125}\text{I}$ , or  $^{131}\text{I}$  (see for example, U.S. Patent 4,609,725). The extent of radiolabeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e., a diiodinated analyte binding reagent will result in twice the radiation count of a similar monoiodinated analyte binding reagent over the same time frame).

In applications to human subjects, it may be desirable to use radioisotopes other than  $^{125}\text{I}$  for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances require). Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred

radiolabels are for example, <sup>99m</sup>Tc, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>90</sup>Y, <sup>111</sup>In, <sup>113m</sup>In, <sup>123</sup>I, <sup>186</sup>Re, <sup>188</sup>Re or <sup>211</sup>At.

The radiolabeled analyte binding reagent may be prepared by various methods. These include radiohalogenation by the chloramine-T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography), for example as described by Gutkowska et al (1987). Other known method of radiolabeling can be used, such as IODOBEADS™.

For animal models, such as mice or rats, the animal may be sacrificed after administration of the analyte binding reagent and regions which have been subjected to neurotoxic stress imaged on immobilized brain slices.

Diagnostic kits are also within the scope of this invention. Such kits include monoclonal or polyclonal antibodies that can rapidly detect tissue hypoxia.

#### VIII. General Screening Methods

Each of the genes identified by means of the present invention can be used as a candidate gene in a screening assay for identifying and isolating inhibitors of hypoxia or other neurotoxic stress. Many types of screening assays are known to those of ordinary skill in the art. The specific assay which is chosen will depend to a great extent on the activity of the candidate gene or the protein expressed thereby. Thus, if it is known that the expression product of a candidate gene has enzymatic activity, then an assay which is based on inhibition of the enzymatic activity may be used. If the candidate protein is known to bind to a ligand or other



interactor, then the assay can be based on the inhibition of such binding or interaction. When the candidate gene is a known gene, then many of its properties will also be known, and these can be used to determine the best screening assay.

5 If the candidate gene is novel, then some analysis and/or experimentation will be appropriate in order to determine the best assay to be used to find inhibitors of the activity of that candidate gene. The analysis may involve a sequence analysis to find domains in the sequence which would shed

10 light on its activity. Other experimentation described herein to identify the candidate gene and its activity, which experiment would not amount to undue experimentation, may also be engaged in so as to identify the type of screen that would be appropriate to find inhibitors or enhancers, as the case

15 may be, for the candidate gene or the protein encoded thereby.

As is well known in the art, the screening assays may be *in vivo* or *in vitro*. An *in vivo* assay is a cell-based assay using any eukaryotic cell. One such cell-based system is particularly relevant in order to directly measure the

20 activity of candidate genes which are pro-apoptotic functional genes, i.e., expression of the gene will cause apoptosis or otherwise cause cell death in target cells. One way of running such an *in vivo* assay uses tetracycline-inducible (Tet-inducible) gene expression. Tet-inducible gene

25 expression is well known in the art (Hofmann et al, 1996). Tet-inducible retroviruses have been designed incorporating the Self-inactivating (SIN) feature of a 3' LTRenhancer/promoter retroviral deletion mutant. Expression of this vector in cells is virtually undetectable in the

30 presence of tetracycline or other active analogs. However, in



the absence of Tet, expression is turned on to maximum within 48 hours after induction, with uniform increased expression of the whole population of cells that harbor the inducible retrovirus, indicating that expression is regulated uniformly within the infected cell population.

When dealing with pro-apoptotic function candidate genes, Tet-inducible expression causes apoptosis in target cells. One can screen for small molecules or peptides able to rescue the cells from the gene-triggered apoptosis.

If the gene product of the candidate gene phosphorylates with a specific target protein, a specific reporter gene construct can be designed such that phosphorylation of this reporter gene product causes its activation, which can be followed by a color reaction. The candidate gene can be specifically induced, using the Tet-inducible system discussed above, and a comparison of induced vs. non-induced genes provides a measure of reporter gene activation.

In a similar indirect assay, a reporter system can be designed that responds to changes in protein-protein interaction of the candidate protein. If the reporter responds to actual interaction with the candidate protein, a color reaction will occur.

One can also measure inhibition or stimulation of reporter gene activity by modulation of its expression levels via the specific candidate promoter or other regulatory elements. A specific promoter or regulatory element controlling the activity of a candidate gene is defined by methods well known in the art. A reporter gene is constructed which is controlled by the specific candidate gene promoter or

regulatory elements. The DNA containing the specific promoter or regulatory agent is actually linked to the gene encoding the reporter. Reporter activity depends on specific activation of the promoter or regulatory element. Thus, inhibition or stimulation of the reporter will be a direct assay of stimulation/inhibition of the reporter gene.

Various *in vitro* screening assays are also well within the skill of those of ordinary skill in the art. For example, if enzymatic activity is to be measured, such as if the candidate protein has a kinase activity, the target protein can be defined and specific phosphorylation of the target can be followed. The assay may involve either inhibition of target phosphorylation or stimulation of target phosphorylation, both types of assay being well known in the art.

One can also measure *in vitro* interaction of a candidate protein with interactors. In this screen, the candidate protein is immobilized on beads. An interactor, such as a receptor ligand, is radioactively labeled and added. When it binds to the candidate protein on the bead, the amount of radioactivity carried on the beads (due to interaction with the candidate protein) can be measured. The assay would indicate inhibition of the interaction by measuring the amount of radioactivity on the bead.

Any of the screening assays, according to the present invention, will include a step of identifying the small molecule or peptide which tests positive in the assay and may also include the further step of producing that which has been so identified. The use of any such molecules

identified for inhibiting hypoxia or other neurotoxic stress is also considered to be part of the present invention.

Specific screening methods suitable for use with the currently most preferred embodiment, gene comprising SEQ ID NO: 94 can be found at the end of Section X below.

#### **IX. Therapeutic Methods Relating to Good Genes**

In accordance with these findings, the present invention extends to the treatment of stroke by the administration of a stroke-ameliorating or stroke-inhibiting amount of an agent capable of at least partially preventing brain damage, or averting the occurrence or reducing the size and severity of an ischemic infarct due, for example, to stroke, aneurysm, cerebrovascular accident, apoplexy or other trauma.

The present invention therefore extends to methods for the treatment of stroke and to corresponding pharmaceutical compositions, comprising and including without limitation as active ingredients a protein encoded by a good gene, such as a protein encoded by a polynucleotide of the sequence of any one of SEQ ID NOs: 2, 3, 7-57, 61-63, 78-84 and 93-85, preferably SEQ ID NOs: 49, 50, 51, 65, 67, 85 and 87, as well as analogs, active fragments, functional derivatives or salts thereof.

Within minutes after cessation of local cerebral blood flow, a region of densely ischemic brain tissue becomes infarcted and dies. This infarcted core is surrounded however, by a zone of ischemic but potentially viable tissue termed the "ischemic penumbra," which receives suboptimal perfusion via collateral blood vessels. The volume of the

penumbra that ultimately becomes infarcted after an acute  
arterial occlusion is determined by a variety of factors that  
mediate neurotoxicity within this zone during the hours  
following interrupted blood flow. The nature of these factors  
5 (including glutamate, superoxide radicals, and nitric oxide)  
is only partially understood, as are the complex interactions  
that will determine whether ischemic tissue will die or  
recover. Some of these factors are intrinsic to the locus of  
ischemia, and others are delivered to the penumbra via the  
10 circulation. The net result of signaling interactions between  
these factors can greatly enhance neuronal cytotoxicity in the  
ischemic penumbra, causing a significantly larger volume of  
brain damage and necrosis, with corresponding increases in  
functional damage. The good genes, in accordance with the  
15 present invention, participate in mediating increased volumes  
of cerebral infarction during focal cerebral ischemia.

Good genes may also be used as the target of  
screening processes to find agents capable of enhancing the  
expression of a good gene. Thus, the amount of mRNA produced  
20 by a cell, before and after subjecting the cell to a  
neurotoxic stress and administering a test agent, will  
determine whether that test agent causes further enhancement  
of expression of that good gene, as compared to a control in  
which no test agent is added. Such testing can reveal agents  
25 which are useful in the treatment of stroke. Screening  
methods are discussed in Section VIII, hereinabove.

#### **X. Therapeutic Methods Relating to Bad Genes**

The ability of an agent to inhibit expression of bad  
genes provides an additional therapeutic mechanism in the  
30 treatment of stroke since it would be expected to result in a

reduction in the size and severity of the infarction. An example of a sequence which is part of a bad gene includes SEQ ID NOs:1, 4-6, 68-71, 74-77 and 82, and most preferably 94, also identified as KIAA 0538, which is a currently most preferred embodiment according to the present invention, as exemplified in detail herein.

The present invention thus includes a method of screening for an agent capable of providing a neuroprotective effect and thus reducing the size and severity of infarct size in stroke, which method comprises administering a test agent concurrent with, or subsequent to, an infarct-producing amount of a product of a bad gene and measuring the resultant decrease in infarct size vis-a-vis a control dose of the infarct-producing amount of the polyamine. Such testing can reveal agents which are useful in the treatment of this aspect of stroke. General screening methods are discussed in Section VIII, hereinabove

Specific screening methods suitable for use with the currently most preferred embodiment SEQ ID NO: 94 (which is a fragment of KIAA 0538) will now be presented in detail. The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (including but not limited to peptides, peptido-mimetics, small molecules or other drugs) which bind to KIAA0538 or have an inhibitory effect on KIAA0538 expression or an inhibitory effect on KIAA0538 activity.

It is known that KIAA0538 is a member of the Ras GTPase-activating-protein family of proteins, recently shown to be a calcium ion dependent Ras-GAP, also known as  $Ca^{2+}$

promoted Ras inactivator or "CAPRI" (Lockyer et al, 2001). The members of this family of Ras-GAP proteins have distinct phosphoinositide binding specificities (Minagawa et al., 2001). CAPRI, however, though possessing a recognizable PH domain involved in phosphoinositide binding, has several changes in critical for phosphoinositide binding amino acid position, thus rendering a protein that was shown to be insensitive to phosphoinositide stimulation/interaction. Alternatively, its activation and translocation to the plasma membrane from the cytosol pool was demonstrated to be regulated by increased concentration of intracellular calcium. Whenever used in this invention KIAA0538 or "CAPRI" is defined as: any member of the KIAA0538 gene family, either full-length, mutant, splice variant, as a chimera with other proteins, or a polypeptide or biologically active fragment or domain of KIAA0538, or of any member of the KIAA0538 gene family, having similar biological activity. KIAA0538 or KIAA0538 gene family member may be present in different forms, including: soluble protein; membrane-bound; bead-bound; or any other form of presenting KIAA0538 protein or fragments and polypeptides derived therefrom.

As used herein, a "target molecule" is a molecule with which KIAA0538 or a KIAA0538 gene family member binds or interacts in nature; for example, an ion, a molecule associated with the cell membrane or a cytoplasmic molecule. As an example, a target molecule may also be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to membrane-bound receptor) through the cell membrane and into the cell. The target, for example, can be a

second intercellular protein that mediates downstream signaling from KIAA0538. One such known example is the small GTP-binding protein p21Ras. Several signaling pathways have been identified downstream to p21Ras (Kolch (2000) Biochem. J. 351:289), the best understood being that which culminates in Elk and SAP transcription factor activation, further leading to specific gene transcription. This pathway is known to involve the sequential activation of the MAP kinases Raf, Mek and Erk.

As used herein, "cell stimulation" may be induced by many different stimuli that activate intracellular signaling processes, including (but not excluding): G-coupled receptor activation; activation of ion channels; receptor tyrosine kinase activation; etc. As an example, "cell stimulation" relates to any extracellular or intracellular agent, be it exogenous or endogenous that acts to increase intracellular free calcium ion ( $[Ca^{2+}]_i$ ) concentration.

In one embodiment, the invention provides assays for screening candidates or test compounds that bind to, modulate the activity of, influence the subcellular localization of, or affect the expression level of KIAA0538. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial and non-combinatorial library methods known in the art, including: Biological libraries (proteins, peptides, etc.); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods; and natural product libraries.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al.



(1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med. Chem. 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner USP '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390); (Devlin (1990) Science 249:404-406); (Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87:6378-6382); (Felici (1991) J. Mol. Biol. 222:301-310).

In one embodiment, an assay is a cell-based assay in which a cell (e.g., of mammalian origin, preferably a neuronal cell ) that expresses KIAA0538 is contacted with a test compound and the ability of the test compound to modulate the sub-cellular localization of KIAA0538 is determined. Determining the ability of the test compound to modulate the sub-cellular localization of KIAA0538 can be accomplished, for example by determining its effect on the stimulation-induced translocation of KIAA0538 to the plasma membrane following cell stimulation. This translocation is monitored, for example, by expressing a green fluorescent protein (GFP)-KIAA0538 fusion protein and determining its subcellular localization by fluorescence microscopy. Alternatively, the translocation of KIAA0538 to the plasma membrane may be monitored in cells expressing wild-type KIAA0538 by subcellular fractionation to separate the plasma membrane



fraction. The amount of KIAA0538 that is associated with the plasma membrane fraction is then determined by resolving individual plasma membrane proteins using SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by protein transfer  
5 to an appropriate membrane (e.g., PVDF) and analysis of transferred proteins by Western blot analysis using KIAA0538 - specific antibodies.

In another embodiment, an assay is a cell-based assay in which a cell (e.g., of mammalian origin, preferably a neuronal cell) that expresses KIAA0538 is contacted with a  
10 test compound and the ability of the test compound to modulate the association of CAPRI with its downstream effectors and/or its target molecule(s) is determined. One example for an identified target molecule of KIAA0538 is p21Ras. Determining  
15 the ability of the test compound to modulate the association between KIAA0538 and p21Ras following cell stimulation can be accomplished, for example by specifically precipitating KIAA0538 from whole cell lysates and determining the amount of co-precipitated p21Ras. Such co-precipitation and specific  
20 immunoblotting techniques are well known in the art.

In a preferred embodiment of the invention an assay is a cell-based assay in which a cell that expresses KIAA0538, e.g. a mammalian cell, preferably a neuronal cell is contacted with a test compound and the ability of the test  
25 compound to modulate (i.e., stimulate or inhibit) the activity of KIAA0538 is determined. Determining the ability of the test compound to modulate the activity of CAPRI can be accomplished, preferably, by monitoring its effect on p21Ras-mediated GTP hydrolysis. Since KIAA0538 acts as a GTPase  
30 activating protein (GAP) for p21Ras, it is expected that CAPRI

activation will result in increased GTP hydrolysis by p21Ras. This will result in a decrease in the amount of p21Ras-bound GTP. The p21Ras binding domain (RBD) in the signaling protein Raf has been identified and previously used for specifically precipitating the GTP-bound form of p21Ras. This assay can therefore be employed for determining the state of KIAA0538 activation. As an example, a typical assay is comprised of stimulating a KIAA0538 -expressing cell in the presence of a test compound and determining the effect of the latter on the amount of p21Ras-associated GTP by lysing the cells in an appropriate lysis buffer and using RBD (as its fusion with glutathione S-transferase) to extract GTP-bound p21Ras. These extracts are then subjected to SDS-PAGE, followed by protein transfer to appropriate membranes (e.g., PVDF) and analysis of transferred proteins by Western blot analysis using p21Ras-specific antibodies. The intensity of the p21Ras-specific signal should correlate with the cellular level of GTP-bound p21Ras, which in turn is indicative of the level of CAPRI activation.

In another preferred embodiment, determining the ability of the test compound to modulate the activity of CAPRI can be accomplished, for example, by determining the effect of a test compound on a known downstream signaling activity of KIAA0538. For example, the ability of a test compound to modulate the activity of KIAA0538 is determined by following the phosphorylation of cellular proteins downstream to KIAA0538 by, for example, immunoblot analysis using phosphorylation state-specific antibodies. As a specific example, the activation of KIAA0538 should lead to p21Ras inactivation, further leading to dephosphorylation of the



to the known compound. This can be accomplished, for example, by radio-labeling the compound known to bind to KIAA0538 and monitoring its displacement from its complex with KIAA0538 as a result of the interaction with the unlabeled test compound.

5           In another embodiment, an assay is a cell-free assay comprising contacting KIAA0538 with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of KIAA0538. Determining the ability of the test compound to modulate the activity of  
10 CAPRI can be accomplished, for example, by determining the ability of the test compound to block the GTPase activity of the complex of KIAA0538 with p21Ras. This assay can be set up by incubating together recombinant KIAA0538, recombinant p21Ras and gamma-<sup>32</sup>P-labeled GTP and following the amount of  
15 residual radioactive label in GTP by any of the several techniques known in the art.

          The cell-free assays of the present invention are compatible with the use of both, the soluble form or the membrane-bound form of KIAA0538. In more than one embodiment  
20 of the above assay methods of the present invention, it may be desirable to immobilize either KIAA0538 or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to  
25 KIAA0538, or interaction of KIAA0538 with its target molecule in the presence and/or absence of a candidate test compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a  
30 fusion protein can be provided which adds a domain that allows

one or both of the proteins to bind to a matrix. For example, glutathione-S-transferase/ KIAA0538 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads or glutathione derivatized microtitre plates, which are then combined with the test compound and either the non-adsorbed target protein or KIAA0538 (appropriately), and the mixture incubated under conditions suitable for complex formation. Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads and the amount of formed complex is determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of CAPRI binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either KIAA0538 or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated KIAA0538 or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with CAPRI or its target molecules but which do not interfere with binding of CAPRI to its target molecule can be bound to the wells of the plate, and free target or KIAA0538 trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes,

include immunodetection of complexes using antibodies reactive with CAPRI or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity of KIAA0538 or that associated with CAPRI or its target molecule.

5                   In another embodiment, modulators of CAPRI expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of KIAA0538 mRNA or protein in the cell is determined. The level of expression of KIAA0538 mRNA or protein in the presence of  
10 the candidate compound is compared to the level of expression of KIAA0538 mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of KIAA0538 expression based on this comparison. For example, when expression of KIAA0538 mRNA or protein is  
15 greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of KIAA0538 mRNA or protein expression. Alternatively, when expression of KIAA0538 mRNA or protein is less in the presence of the candidate compound than in its absence, the candidate  
20 compound is identified as an inhibitor of KIAA0538 mRNA or protein expression. The level of KIAA0538 mRNA or protein expression in the cells can be determined by methods described herein for detecting KIAA0538 mRNA or protein.

                  In yet another aspect of the invention, KIAA0538  
25 protein can be used as "bait protein" in a two-hybrid or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and  
30 Brent WO94/10300), to identify other proteins which bind to or

interact with KIAA0538 (target molecules) and modulate KIAA0538 activity. Such KIAA0538 -binding proteins are also likely to be involved in the propagation of signals by KIAA0538 as, for example, upstream or downstream elements of  
5 the KIAA0538 signaling pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct,  
10 the gene that codes for KIAA0538 is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation  
15 domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a KIAA0538 -dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter  
20 gene (e.g., LacZ) which is linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the  
25 protein which interacts with KIAA0538.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.



The production and administration of antisense sequences and ribozymes that specifically bind and cleave a particular mRNA sequence are discussed in Sections XII and XIII hereinafter. Such ribozymes and antisense sequences relating specifically to bad genes and the mRNA they describe will inhibit the expression of these bad genes and, thus, will provide an additional therapeutic mechanism in treating the effects of stroke, hypoxia and/or ischemia.

#### **XI. Antibodies**

10           The present invention also comprehends antibodies specific for the proteins encoded by a naturally-occurring cDNA which is part of the present invention as discussed above. Such an antibody may be used for diagnostic purposes to identify the presence of any such naturally-occurring  
15 proteins. Such antibody may be a polyclonal antibody or a monoclonal antibody or any other molecule that incorporates the antigen-binding portion of a monoclonal antibody specific for such a protein. Such other molecules may be a single-chain antibody, a humanized antibody, an F(ab) fraction, a  
20 chimeric antibody, an antibody to which is attached a label, such as fluorescent or radioactive label, or an immunotoxin in which a toxic molecule is bound to the antigen binding portion of the antibody. The examples are intended to be non-limiting. However, as long as such a molecule includes the  
25 antigen-binding portion of the antibody, it will be expected to bind to the protein and, thus, can be used for the same diagnostic purposes for which a monoclonal antibody can be used. The antibodies to the novel polypeptides encoded by the novel polynucleotides of this invention are also novel, and  
30 are considered an integral aspect of this invention .

## XII. Antisense Sequences

In order to manipulate the expression of a bad gene, it is desirable to produce antisense RNA in a cell. To this end, the complete or partial cDNA of a bad gene in accordance  
5 with the present invention is inserted into an expression vector comprising a promoter. The 3' end of the cDNA is thereby inserted adjacent to the 3' end of the promoter, with the 5' end of the cDNA being separated from the 3' end of the promoter by said cDNA. Upon expression of the cDNA in a cell,  
10 an antisense RNA is therefore produced which is incapable of coding for the protein. The presence of antisense RNA in the cell reduces the expression of the cellular (genomic) copy of the bad gene.

For the production of antisense RNA, the complete  
15 cDNA may be used. Alternatively, a fragment thereof may be used, which is preferably between about 9 and 2,000 nucleotides in length, more preferably between 15 and 500 nucleotides, and most preferably between 30 and 150 nucleotides.

20 The fragment is preferably corresponding to a region within the 5' half of the cDNA, more preferably the 5' region comprising the 5' untranslated region and/or the first exon region, and most preferably comprising the ATG translation start site. Alternatively, the fragment may correspond to DNA  
25 sequence of the 5' untranslated region only.

A synthetic oligonucleotide may be used as antisense oligonucleotide. The oligonucleotide is preferably a DNA oligonucleotide. The length of the antisense oligonucleotide is preferably between 9 and 150, more preferably between 12  
30 and 60, and most preferably between 15 and 50 nucleotides.

Suitable antisense oligonucleotides that inhibit the production of the protein of the present invention from its encoding mRNA can be readily determined with only routine experimentation through the use of a series of overlapping  
5 oligonucleotides similar to a "gene walking" technique that is well-known in the art. Such a "walking" technique as well-known in the art of antisense development can be done with synthetic oligonucleotides to walk along the entire length of the sequence complementary to the mRNA in segments on the  
10 order of 9 to 150 nucleotides in length. This "gene walking" technique will identify the oligonucleotides that are complementary to accessible regions on the target mRNA and exert inhibitory antisense activity.

Alternatively, an oligonucleotide based on the  
15 coding sequence of a protein capable of binding to a bad gene or the protein encoded thereby can be designed using Oligo 4.0 (National Biosciences, Inc.). Antisense molecules may also be designed to inhibit translation of an mRNA into a polypeptide by preparing an antisense which will bind in the region  
20 spanning approximately -10 to +10 nucleotides at the 5' end of the coding sequence.

The mechanism of action of antisense RNA and the current state of the art on use of antisense tools is reviewed in Kumar et al (1998). The use of antisense oligonucleotides  
25 in inhibition of BMP receptor synthesis has been described by Yeh et al (1998). The use of antisense oligonucleotides for inhibiting the synthesis of the voltage-dependent potassium channel gene Kv1.4 has been described by Meiri et al (1998). The use of antisense oligonucleotides for inhibition of the  
30 synthesis of Bcl-x has been described by Kondo et al (1998).

The therapeutic use of antisense drugs is discussed by Stix (1998); Flanagan (1998); Guinot et al (1998), and references therein.

Modifications of oligonucleotides that enhance  
5 desired properties are generally used when designing antisense oligonucleotides. For instance, phosphorothioate bonds are used instead of the phosphoester bonds that naturally occur in DNA, mainly because such phosphorothioate oligonucleotides are less prone to degradation by cellular enzymes. Peng Ho et al  
10 teach that undesired in vivo side effects of phosphorothioate oligonucleotides may be reduced when using a mixed phosphodiester-phosphorothioate backbone. Preferably, 2'-methoxyribonucleotide modifications in 60% of the oligonucleotide is used. Such modified oligonucleotides are  
15 capable of eliciting an antisense effect comparable to the effect observed with phosphorothioate oligonucleotides. Peng Ho et al teach further that oligonucleotide analogs incapable of supporting ribonuclease H activity are inactive.

Therefore, the preferred antisense oligonucleotide  
20 of the present invention has a mixed phosphodiester-phosphorothioate backbone. Preferably, 2'-methoxyribonucleotide modifications in about 30% to 80%, more preferably about 60%, of the oligonucleotide are used.

In the practice of the invention, antisense  
25 oligonucleotides or antisense RNA may be used. The length of the antisense RNA is preferably from about 9 to about 3,000 nucleotides, more preferably from about 20 to about 1,000 nucleotides, most preferably from about 50 to about 500 nucleotides.

In order to be effective, the antisense oligonucleotides of the present invention must travel across cell membranes. In general, antisense oligonucleotides have the ability to cross cell membranes, apparently by uptake via  
5 specific receptors. As the antisense oligonucleotides are single-stranded molecules, they are to a degree hydrophobic, which enhances passive diffusion through membranes. Modifications may be introduced to an antisense oligonucleotide to improve its ability to cross membranes.  
10 For instance, the oligonucleotide molecule may be linked to a group which includes partially unsaturated aliphatic hydrocarbon chain and one or more polar or charged groups such as carboxylic acid groups, ester groups, and alcohol groups. Alternatively, oligonucleotides may be linked to peptide  
15 structures, which are preferably membranotropic peptides. Such modified oligonucleotides penetrate membranes more easily, which is critical for their function and may, therefore, significantly enhance their activity. Palmityl-linked oligonucleotides have been described by Gerster et al  
20 (1998). Geraniol-linked oligonucleotides have been described by Shoji et al (1998). Oligonucleotides linked to peptides, e.g., membranotropic peptides, and their preparation have been described by Soukchareun et al (1998). Modifications of antisense molecules or other drugs that target the molecule to  
25 certain cells and enhance uptake of the oligonucleotide by said cells are described by Wang (1998).

The antisense oligonucleotides of the invention are generally provided in the form of pharmaceutical compositions. These compositions are for use by injection, topical  
30 administration, or oral uptake.

Preferred uses of the pharmaceutical compositions of the invention by injection are subcutaneous injection, intravenous injection, and intramuscular injection. Less convenient routes of administration may include  
5 intraperitoneal, intradural, intra-theal administration or intra-arterial administration when required.

The pharmaceutical composition of the invention generally comprises a buffering agent, an agent which adjusts the osmolarity thereof, and optionally, one or more carriers,  
10 excipients and/or additives as known in the art, e.g., for the purposes of adding flavors, colors, lubrication, or the like to the pharmaceutical composition.

Carriers may include starch and derivatives thereof, cellulose and derivatives thereof, e.g., microcrystalline  
15 cellulose, xanthan gum, and the like. Lubricants may include hydrogenated castor oil and the like.

A preferred buffering agent is phosphate-buffered saline solution (PBS), which solution is also adjusted for osmolarity.

20 A preferred pharmaceutical formulation is one lacking a carrier. Such formulations are preferably used for administration by injection, including intravenous injection.

The preparation of pharmaceutical compositions is well known in the art and has been described in many articles  
25 and textbooks, see e.g., Remington's Pharmaceutical Sciences, especially pp 1521-1712 therein.

Additives may also be selected to enhance uptake of the antisense oligonucleotide across cell membranes. Such agents are generally agents that will enhance cellular uptake  
30 of double-stranded DNA molecules. For instance, certain lipid

10024399-131304

molecules have been developed for this purpose, including the transfection reagents DOTAP (Boehringer Mannheim), Lipofectin, Lipofectam, and Transfectam, which are available commercially. For a comparison of various of these reagents in enhancing antisense oligonucleotide uptake, see e.g., Quattrone et al (1995) and Capaccioli et al (1993). The antisense oligonucleotide of the invention may also be enclosed within liposomes. The preparation and use of liposomes, e.g., using the above-mentioned transfection reagents, is well known in the art. Other methods of obtaining liposomes include the use of Sendai virus or of other viruses. Examples of publications disclosing oligonucleotide transfer into cells using the liposome technique are, e.g., Meyer et al (1998), Kita et al (1999), Nakamura et al (1998), Abe et al (1998), Soni et al (1998), Bai et al (1998), see also discussion in the same Journal p. 819-20, Bochot et al (1998), Noguchi et al (1998), Kanamaru et al (1998), and references therein. The use of Lipofectin in liposome-mediated oligonucleotide uptake is described in Sugawa et al (1998). The use of fusogenic cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes) is described in Waelti et al (1998).

The above-mentioned cationic or nonionic lipid agents not only serve to enhance uptake of oligonucleotides into cells, but also improve the stability of oligonucleotides that have been taken up by the cell.

### XIII. Ribozymes

Given the known mRNA sequence of a gene, ribozymes, which are RNA molecules that specifically bind and cleave said mRNA sequence (see, e.g., Chen et al (1992), Zhao et al



(1993), Shore et al (1993), Joseph et al (1993), Shimayama et al (1993), and Cantor et al (1993), may be designed.

Accordingly, a ribozyme-encoding RNA sequence may be designed that cleaves the mRNA of a bad gene of the present invention. The site of cleavage is preferably located in the coding region or in the 5' nontranslated region, more preferably, in the 5' part of the coding region close to the AUG translational start codon.

A DNA encoding a ribozyme according to the present invention may be introduced into cells by way of DNA uptake, uptake of modified DNA (see modifications for oligonucleotides and proteins that result in enhanced membrane permeability, as described above for oligonucleotides and described below for proteins), or viral vector-mediated gene transfer.

#### **XIV. Introduction of Proteins, Peptides, and DNA into Cells**

The present invention provides proteins encoded by good genes, peptides derived therefrom, antisense DNA molecules corresponding to bad genes, and oligonucleotides. A therapeutic or research-associated use of these tools necessitates their introduction into cells of a living organism or into cultured cells. For this purpose, it is desired to improve membrane permeability of peptides, proteins and oligonucleotides. Ways to improve membrane permeability of oligonucleotides have been discussed above. The same principle, namely, derivatization with lipophilic structures, may also be used in creating peptides and proteins with enhanced membrane permeability. For instance, the sequence of a known membranotropic peptide as noted above may be added to the sequence of the peptide or protein. Further, the peptide or protein may be derivatized by partly lipophilic structures

such as the above-noted hydrocarbon chains, which are substituted with at least one polar or charged group. For example, lauroyl derivatives of peptides have been described by Muranishi et al (1991). Further modifications of peptides and proteins include the oxidation of methionine residues to thereby create sulfoxide groups, as described by Zacharia et al (1991). Zacharia and coworkers also described peptide or derivatives wherein the relatively hydrophobic peptide bond is replaced by its ketomethylene isoester ( $\text{COCH}_2$ ). It is known to those of skill in the art of protein and peptide chemistry these and other modifications enhance membrane permeability.

Another way of enhancing membrane permeability is to make use of receptors, such as virus receptors, on cell surfaces in order to induce cellular uptake of the peptide or protein. This mechanism is used frequently by viruses, which bind specifically to certain cell surface molecules. Upon binding, the cell takes the virus up into its interior. The cell surface molecule is called a virus receptor. For instance, the integrin molecules CAR and Adv have been described as virus receptors for Adenovirus (Hemmi et al, 1998, and references cited therein). The CD4, GPR1, GPR15, and STRL33 molecules have been identified as receptors/coreceptors for HIV (Edinger et al, 1998 and references cited therein).

By conjugating peptides, proteins or oligonucleotides to molecules that are known to bind to cell surface receptors, the membrane permeability of said peptides, proteins or oligonucleotides will be enhanced. Examples of suitable groups for forming conjugates are sugars, vitamins, hormones, cytokines, transferrin, asialoglycoprotein, and the

like molecules. Low et al U.S. Patent 5,108,921 describes the use of these molecules for the purpose of enhancing membrane permeability of peptides, proteins and oligonucleotides, and the preparation of said conjugates.

5           Low and coworkers further teach that molecules such as folate or biotin may be used to target the conjugate to a multitude of cells in an organism, because of the abundant and nonspecific expression of the receptors for these molecules.

10           The above use of cell surface proteins for enhancing membrane permeability of a peptide, protein or oligonucleotide of the invention may also be used in targeting the peptide, protein or oligonucleotide of the present invention to certain cell types or tissues. For instance, if it is desired to target neural cells, it is preferable to use a cell surface  
15   protein that is expressed more abundantly on the surface of those cells.

20           The protein, peptide or oligonucleotide of the invention may therefore, using the above-described conjugation techniques, be targeted to a certain cell type. For instance, if it is desired to protect from neurotoxic stress in neural cell, a good gene, or protein encoded thereby, or an antisense or ribozyme of the invention designed to inhibit a bad gene, may be targeted at such cells, for instance, by using molecules that are expressed on these cells. The skilled  
25   person will recognize the possibilities of using a cell surface marker selected from a multitude of known markers of neural and other cells, and of these, further selecting those that are expressed constitutively or inducibly.

## XV. Virus-Mediated Cellular Targeting

The proteins, peptides and antisense sequences of the present invention may be introduced into cells by the use of a viral vector. The use of a vaccinia vector for this purpose is described in Chapter 16 of Ausubel et al (1994-2000). The use of adenovirus vectors has been described, e.g., by Teoh et al (1998), Narumi et al (1998), Pederson et al (1998), Guang-Lin et al (1998), and references therein, Nishida et al (1998), Schwarzenberger et al (1998), and Cao et al (1998). The use of SV-40 derived viral vectors and SV-40 based packaging systems has been described by Fang et al (1997). The use of papovaviruses which specifically target B-lymphocytes, has been described by Langner et al (1998).

When using viruses as vectors, the viral surface proteins are generally used to target the virus. As many viruses, such as the above adenovirus, are rather unspecific in their cellular tropism, it may be desirable to impart further specificity by using a cell-type or tissue-specific promoter. Griscelli et al (1998) teach the use of the ventricle-specific cardiac myosin light chain 2 promoter for heart-specific targeting of a gene whose transfer is mediated by adenovirus.

Alternatively, the viral vector may be engineered to express an additional protein on its surface, or the surface protein of the viral vector may be changed to incorporate a desired peptide sequence. The viral vector may thus be engineered to express one or more additional epitopes which may be used to target said viral vector. For instance, cytokine epitopes, MHC class II-binding peptides, or epitopes derived from homing molecules may be used to target the viral

vector in accordance with the teaching of the invention. The  
above Langer et al. (1998) reference teach the use of  
heterologous binding motifs to target B-lymphotrophic  
papoaviruses. For brain delivery, the preferred vectors are  
5 HSV-based and lentiviral ones.

#### **XVI. Pharmaceutical Compositions**

The pharmaceutical compositions of the invention are  
prepared generally as known in the art. Thus, pharmaceutical  
compositions comprising nucleic acids, e.g., ribozymes,  
10 antisense RNA or antisense oligonucleotides, are prepared as  
described above for pharmaceutical compositions comprising  
oligonucleotides and/or antisense RNA. The above  
considerations apply generally also to other pharmaceutical  
compositions. For instance, the pharmaceutical composition of  
15 the invention may contain naked DNA, e.g., good genes or  
fragments or derivatives thereof and a pharmaceutically  
acceptable carrier as known in the art. A variety of ways to  
enhance uptake of naked DNA is known in the art. For  
instance, cationic liposomes (Yotsuyanagi et al, 1998),  
20 dicationic amphiphiles (Weissig et al, 1998), fusogenic  
liposomes (Mizuguchi et al, 1996), mixtures of stearyl-poly(L-  
lysine) and low density lipoprotein (LDL), (terplex, Kim et  
al, 1998), and even whole bacteria of an attenuated mutant  
strain of *Salmonella typhimurium* (Paglia et al, 1998) have  
25 been used in the preparation of pharmaceutical compositions  
containing DNA.

Administration of virus particles has been described  
in prior art publications, see, e.g., U.S. Patent 5,882,877,  
where Adenovirus based vectors and administration of the DNA  
30 thereof is described. The viral DNA was purified on a CsCl

gradient and then dialyzed against Tris-buffered saline to  
remove CsCl. In these preparations, viral titers (pfu/ml) of  
10<sup>14</sup> to 10<sup>10</sup> are preferably used. Administration of virus  
particles as a solution in buffered saline, to be preferably  
5 administered by subcutaneous injection, is known from U.S.  
Patent 5,846,546. Croyle and coworkers (Croyle et al, 1998)  
describe a process for the preparation of a pharmaceutical  
composition of recombinant adenoviral vectors for oral gene  
delivery, using CsCl gradients and lyophilization in a  
10 sucrose-containing buffer.

Where the pharmaceutical composition of the  
invention includes a peptide or protein according to the  
present invention, the composition will generally contain  
salts, preferably in physiological concentration, such as PBS  
15 (phosphate-buffered saline), or sodium chloride (0.9% w/v),  
and a buffering agent, such as phosphate buffer in water or in  
the well-known PBS buffer. In the following section, the term  
"peptide" is meant to include all proteins or peptides  
according to the invention. The preparation of pharmaceutical  
20 compositions is well known in the art, see e.g., U.S. Patents  
5,736,519, 5,733,877, 5,554,378, 5,439,688, 5,418,219,  
5,354,900, 5,298,246, 5,164,372, 4,900,549, 4,755,383,  
4,639,435, 4,457,917, and 4,064,236.

The peptide of the present invention, or a  
25 pharmacologically acceptable salt thereof is preferably mixed  
with an excipient, carrier, diluent, and optionally, a  
preservative or the like, pharmacologically acceptable  
vehicles as known in the art, see, e.g., the above U.S.  
patents. Examples of excipients include, glucose, mannitol,  
30 inositol, sucrose, lactose, fructose, starch, corn starch,

microcrystalline cellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, polyvinylpyrrolidone and the like. Optionally, a thickener may be added, such as a natural gum, a cellulose derivative, an acrylic or vinyl polymer, or  
5 the like.

The pharmaceutical composition is provided in solid, liquid or semi-solid form. A solid preparation may be prepared by blending the above components to provide a powdery composition. Alternatively, the pharmaceutical composition is  
10 provided as a lyophilized preparation. The liquid preparation is provided preferably as an aqueous solution, aqueous suspension, oil suspension or microcapsule composition. A semi-solid composition is provided preferably as hydrous or oily gel or ointment. About 0.001 to 60 w/v %, preferably  
15 about 0.05 to 25 w/v % of peptide is provided in the composition.

A solid composition may be prepared by mixing an excipient with a solution of the peptide of the invention, gradually adding a small quantity of water, and kneading the  
20 mixture. After drying, preferably in vacuo, the mixture is pulverized. A liquid composition may be prepared by dissolving, suspending or emulsifying the peptide of the invention in water, a buffer solution or the like. An oil suspension may be prepared by suspending or emulsifying the  
25 peptide of the invention or protein in an oleaginous base, such as sesame oil, olive oil, corn oil, soybean oil, cottonseed oil, peanut oil, lanolin, petroleum jelly, paraffin, Isopar, silicone oil, fatty acids of 6 to 30 carbon atoms or the corresponding glycerol or alcohol esters.  
30 Buffers include Sorensen buffer (Ergeb Physiol, 12:393, 1912),



Clark-Lubs buffer (J Bact, 2 (1):109, 191, 1917), MacIlvaine buffer (J Biol Chem, 49:183, 1921), Michaelis buffer (Die Wasserstoffionenkonzentration, p. 186, 1914), and Kolthoff buffer (Biochem Z, 179:410, 1926).

5           A composition may be prepared as a hydrous gel, e.g., for transnasal administration. A hydrous gel base is dissolved or dispersed in aqueous solution containing a buffer, and the peptide of the invention, and the solution warmed or cooled to give a stable gel.

10           Preferably, the peptide of the invention is administered through intravenous, intramuscular or subcutaneous administration. Oral administration is expected to be less effective, because the peptide may be digested before being taken up. Of course, this consideration may apply  
15 less to a peptide of the invention which is modified, e.g., by being a cyclic peptide, by containing non-naturally occurring amino acids, such as D-amino acids, or other modifications which enhance the resistance of the peptide to biodegradation. Decomposition in the digestive tract may be lessened by use of  
20 certain compositions, for instance, by confining the peptide of the invention in microcapsules such as liposomes. The pharmaceutical composition of the invention may also be administered to other mucous membranes. The pharmaceutical composition is then provided in the form of a suppository,  
25 nasal spray or sublingual tablet. The dosage of the peptide of the invention may depend upon the condition to be treated, the patient's age, bodyweight, and the route of administration, and will be determined by the attending physician.

The uptake of a peptide of the invention may be facilitated by a number of methods. For instance, a non-toxic derivative of the cholera toxin B subunit, or of the structurally related subunit B of the heat-labile enterotoxin of enterotoxic *Escherichia coli* may be added to the composition, see U.S. Patent 5,554,378.

In another embodiment, the peptide of the invention is provided in a pharmaceutical composition comprising a biodegradable polymer selected from poly-1,4-butylene succinate, poly-2,3-butylene succinate, poly-1,4-butylene fumarate and poly-2,3-butylene succinate, incorporating the peptide of the invention as the pamoate, tannate, stearate or palmitate thereof. Such compositions are described, e.g., in U.S. Patent 5,439,688.

In a further embodiment, a composition of the invention is a fat emulsion. The fat emulsion may be prepared by adding to a fat or oil about 0.1-2.4 w/w of emulsifier such as a phospholipid, an emulsifying aid, a stabilizer, mixing mechanically, aided by heating and/or removing solvents, adding water and isotonic agent, and optionally, adjusting adding the pH agent, isotonic agent. The mixture is then homogenized. Preferably, such fat emulsions contain an electric charge adjusting agent, such as acidic phospholipids, fatty acids, bilic acids, and salts thereof. Acidic phospholipids include phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, and phosphatidic acid. Bilic acids include deoxycholic acid, and taurocholic acid. The preparation of such pharmaceutical compositions is described in U.S. Patent 5,733,877.

## **XVII. Knock-Out or Transgenic Animals**

10091330.131204

**Transgenic Mice.** The introduction of gene constructs into the genome of mice (transgenic mice) is a well-established procedure. Transgenic mice provide the opportunity to examine the phenotypic outcome of over-  
5 expression or ectopic expression of genes (gain-of-function experiments). Specific phenotypes obtained after such expression is a very strong predictor of gene function. Many human genes have been expressed in transgenic mice and in most cases they function appropriately. Thus ,for the purpose of  
10 examining gain-of-function, human genes can be used. Specific plasmid vector constructs are available. They carry any of a variety of promoters that allow expression of the gene in specific tissues. For example, promoters that are brain specific are available, liver specific promoters, vascular-  
15 endothelial cell specific promoters, bone specific promoters, cardiac muscle specific promoters and many more.

**Knockout Mice.** Loss-of-function experiments in mice are mostly done by the technique of gene knockout. The technology is well established. It requires the use of mouse  
20 genes for the purpose of generating knockout of the specific gene in embryonic stem (ES) cells that are then incorporated into the mouse germ-line cells from which mice carrying the gene knockout are generated. From a human gene there are several ways to recover the homologous mouse gene. One way is  
25 to use the human gene to probe mouse genomic libraries of lambda phages, cosmids or BACs. Positive clones are examined and sequenced to verify the identity of the mouse gene. Another way is to mine the mouse EST database to find the matching mouse sequences. This can be the basis for  
30 generating primer-pairs or specific mouse probes that allow an

efficient screen of the mouse genomic libraries mentioned above by PCR or by hybridization. For the vast majority of genes the mouse homologue of the human gene retains the same biological function. The loss-of-function experiments in mice indicate the consequences of absence of expression of the gene on the phenotype of the mouse and the information obtained is applicable to the function of the gene in humans. On many occasions a specific phenotype observed in knockout mice was similar to a specific human inherited disease and the gene was then proved to be involved and mutated in the human disease.

#### **XVIII. Promoters**

As promoters and regulatory elements of the candidate genes in accordance with the present invention are also useful in the screening assays described in Section VIII, the present invention is also directed to the sequence of such promoters and/or other regulatory agents. Once the gene has been identified, it is within the routine skill in the art for one ordinary skill to identify the sequence of the promoter region or other regulatory regions. This may be accomplished as discussed below.

It is well recognized that promoters are generally located upstream of the coding sequence. There are numerous methods used conventionally in the art for determining a promoter region and portions of that region essential for promoter activity. For example, Kähäri et al (1990) made constructs in which a region from -2260 to -14 upstream of the ATG initiation codon of the human elastin gene was systematically truncated from -2260 towards -14 to create a set of nested deletions, all with the same -14 end point, which is linked to and controls the expression of a coding

sequence for a reporter molecule (chloramphenicol  
acetyltransferase). The constructs are assayed for the  
expression of the reporter as a measure of the promoter  
activity of the truncated DNA fragments. Using this type of  
5 deletion analysis, Kähäri et al isolated a 497 bp fragment  
which provided maximal gene expression.

The above method is directed to locating the  
promoter region, as well as identifying the portions thereof  
essential for activity. Other mutagenesis techniques, such as  
10 linker scanning, which generate a series of clustered point  
mutations can also be used to fine map the sequence elements  
required for promoter function.

Although in a great majority of cases the 5'-  
flanking region is sufficient to promote gene expression, it  
15 has been reported that in some instances intron, or even the  
3'-untranslated sequences, provide regulatory sequences that  
contribute to promoter activity. For example, intron I  
sequences were found to be important for high-level and  
tissue-specific expression of an alpha-skeletal actin gene, a  
20 beta-globin gene and a peripherin gene (Reecy et al, 1998;  
James-Pederson et al, 1995; Belecky-Adams et al, 1993). In  
view of these examples of introns or 3'-untranslated sequences  
contributing to promoter activity, promoter constructs (i.e.,  
fused to reporter gene) may include intron I sequences of the  
25 candidate gene and, when necessary, 3'-untranslated sequences.  
In the former case, a DNA fragment can be isolated that spans  
the 5'-flanking region, the first exon and the first intron,  
followed by the reporter gene. The translation initiation  
codon of the candidate gene could also be mutated to avoid  
30 translation of truncated candidate gene product.

## XIX. Examples

The specific sequences found in accordance with the present invention are set forth and discussed in the Examples hereinafter.

### 5 A. Chip Design

Two proprietary DNA chips were used in the present experimentation:

Human Apoptosis Chip (HAP-chip): A "functional" human apoptosis DNA microarray, containing 10,000 cDNA clones, was constructed from cDNA clones selected by functional profiling, which potentially identifies cDNA fragments that correspond to genes with pro- or anti-apoptotic activity.

cDNA clones were selected in the following functional screens:

15 Differentiated neuroblastoma (BE2C cells) subjected to:

- dopamine selection
- glutamate selection
- hypoxia selection

20 HeLa cells subjected to apoptotic stimuli:

- FAS selection
- serum starvation
- taxol
- irradiation

25 Thus, the HAP chip contains cDNA clones related to cell death. The microarray contains 5,000 clones.

Rat Stroke Chip: The Stroke cDNA microarray was constructed by combining two types of cDNA libraries (Table 1): (1) a library generated by sequence-dependent gene identification (SDGI) (U.S. application no. 09/538,709, now

30





Table 1

| Type of Library                                     | Material              |  | Time points |    |     |     |
|---|-----------------------|--|-------------|----|-----|-----|
|   | <i>In vivo</i>        | <i>In vitro</i>  | 3h          | 6h | 16h | 24h |
| Subtraction library<br>(five independent libraries) | [MCAO] - [Sham]       |  |             |    |     |     |
|   | [MCAO+FK506] - [MCAO] |  | +           | +  |     |     |
|   |                       | Primary neurons:<br>[Hypoxia + FK506]-<br>[Normoxia+FK506] | +           | +  | +   | +   |
| SDGI library<br>(pool of 6 conditions)              | MCAO                  |  | +           |    |     |     |
|   | MCAO + FK506          |  | +           |    |     |     |
|   | Sham + FK506          |  | +           |    |     |     |
|   |                       | Primary neurons:<br>[Hypoxia]                              |             |    |     |     |
|   |                       | Primary neurons:<br>[Hypoxia+FK506]                        |             |    |     |     |

The design of the Stroke chip: library types and cDNA sources. Each library is in a different shade of gray. Note that the four libraries found at the different time points in the third line of the table were combined into a single library, as were the four libraries of the seventh line.

#### B. Hybridization Scheme

Human Apoptosis (HAP) Chip: Eleven hybridizations were performed on the Human Apoptosis Chip (Table 2). The probes used for these hybridizations were derived from rats'

brains. Rats were either untreated (Sham-operated) or treated (middle cerebral artery occlusion) with or without FK506.

Table 2

| HAP  | Probe 1  |             |              |            | Probe 2  |             |                |            |
|------|----------|-------------|--------------|------------|----------|-------------|----------------|------------|
| chip | Probe ID | Probe label | Treatment    | Probe type | Probe ID | Probe Label | Treatment      | Probe type |
| hvh. |          |             |              |            |          |             |                |            |
| 681  | FJ1B     | Cy3         | MCAO 3Hr     | Total      | FJ1A     | Cy5         | Common control | Total      |
| 683  | FJ3B     |             | Sham 3Hr     | Nuclear    | FJ3A     |             |                |            |
| 684  | FJ4A     |             | MCAO 3Hr     | Nuclear    | FJ4A     |             |                |            |
| 685  | FJ5A     |             | MCAO 3Hr +   | Nuclear    | FJ5A     |             |                |            |
| 686  | FJ6A     |             | MCAO 3Hr +   | Total      | FJ6A     |             |                |            |
| 687  | FJ7A     |             | MCAO 6Hr     | Total      | FJ7A     |             |                |            |
| 688  | FJ8A     |             | MCAO 6Hr +   | Total      | FJ8A     |             |                |            |
| 689  | FJ9A     |             | SHR Sham 3Hr | Total      | FJ9A     |             |                |            |
| 690  | FJ10A    |             | SHR Sham 6Hr | Total      | FJ10     |             |                |            |
| 691  | FJ11A    |             | SHR MCAO 3Hr | Total      | FJ11     |             |                |            |
| 692  | FJ12A    |             | SHR MCAO 6Hr | Total      | FJ12     |             |                |            |

Probes used for hybridizations on the Human Apoptosis Chip: Common control probe (a mixture of total RNA extracted from cortex of sham operated rats and from primary neurons); The "Nuclear" probe type is the Nuclear RNA probe described in WO99/58718, the entire contents of which are hereby incorporated

5

Stroke Chip: Hybridizations were performed on the Stroke Chip. Probes were derived from brains of SD and SHR rats, and from primary neurons exposed to 16 hours of hypoxia (with or without FK506).

**Table 3**

**In Vivo Set**

| Probe name | LABEL | Treatment      | 2 blocks:                     |
|------------|-------|----------------|-------------------------------|
| FJ39B      | Cy3   | SD MCAO 3Hr FK |                               |
| FJ39A      | Cy5   | Common control |                               |
| FJ40B      | Cy3   | SD Sham 3Hr FK | Probes 39 40 41 divided by 46 |
| FJ40A      | Cy5   | Common control |                               |
| FJ41B      | Cy3   | SD MCAO 3Hr    | Probes 42 43 45 divided by 47 |
| FJ41A      | Cy5   | Common control |                               |
| FJ42B      | Cy3   | SHR Sham 6Hr   |                               |
| FJ42A      | Cy5   | Common control |                               |
| FJ43B      | Cy3   | SHR Sham 3Hr   |                               |
| FJ43A      | Cy5   | Common control |                               |
| FJ44B      | Cy3   | SHR MCAO 3Hr   | * 44 Not Included in this run |
| FJ44A      | Cy5   | Common control |                               |
| FJ45B      | Cy3   | SHR MCAO 6Hr   |                               |
| FJ45A      | Cy5   | Common control |                               |
| FJ46B      | Cy3   | SD control     |                               |
| FJ46A      | Cy5   | Common control |                               |
| FJ47B      | Cy3   | SHR control    |                               |
| FJ47A      | Cy5   | Common control |                               |

**In Vitro Set**

| Probe name | dye | Treatment, RNA source |
|------------|-----|-----------------------|
| FJ31B      | Cy3 | PN normoxia           |
| FJ31A      | Cy5 | Common probe          |
| FJ32B      | Cy3 | PN normoxia FK        |
| FJ32A      | Cy5 | Common probe          |

- Divided By Biological Control: Probe No 31

|       |     |                    |
|-------|-----|--------------------|
| FJ33B | Cy3 | PN hypoxia 16hr    |
| FJ33A | Cy5 | Common probe       |
| FJ34B | Cy3 | PN hypoxia 16hr FK |
| FJ34A | Cy5 | Common probe       |
| FJ35B | Cy3 | PN normoxia        |
| FJ35A | Cy5 | Common probe       |
| FJ36B | Cy3 | PN normoxia FK     |
| FJ36A | Cy5 | Common probe       |
| FJ37B | Cy3 | PN hypoxia 16hr    |
| FJ37A | Cy5 | Common probe       |
| FJ38B | Cy3 | PN hypoxia 16hr FK |
| FJ38A | Cy5 | Common probe       |

### C. Functional Analysis

In order to identify genes responsible for hypoxia-, glutamate- or dopamine-induced neuronal cell death, positive selection was performed using expression cDNA libraries in retroviral vector. Libraries were prepared from mRNA of human glioma or neuroblastoma cell lines and in both cases mRNA from both healthy and dying cells was used. Positive selection by hypoxia, by glutamate or by dopamine was done in the established human neuroblastoma cell line BE2C.

Differentiated human neuroblastoma cells BE2C are a suitable and reliable model for *in vitro* study of processes that occur in brain of patients suffering from acute and chronic neuronal damage. BE2C is a subclone of SK-N-BE(2) human neuroblastoma cell line. Unlike the parental cell line, which grows as a mixed population of adherent and floating cells, BE2C cells are strictly adherent. The cells have

polygonal form and grow as clusters of flattened neuroblasts with numerous short cytoplasmic processes, while few cells may also have one long neurite. The BE2C cells exhibit moderate levels of tyrosine hydroxylase and dopamine beta hydroxylase activity. They contain neurofilaments and specifically express D2-dopaminergic, alpha2-adrenergic, m2/m4-muscarinic and delta-opioid receptors. We have modified BE2C cells to express the retroviral ecotropic receptor. This manipulation made the modified cells suitable for retroviral gene delivery. The library was delivered by retroviral transduction with further induction of cell differentiation into a neuron-like phenotype. Every cell after differentiation expresses a unique library-derived cDNA (i.e., cells that obtained a cDNA fragment with an anti-apoptotic activity will not die upon application of hypoxia, dopamine, or glutamate). The protecting sequences were rescued from the surviving cells by RT-PCR and further analyzed. Several rounds of selection were performed for additional enrichment of protective elements. The corresponding full-length genes are likely to code for neuronal cell death-related proteins in hypoxic/ischemic neurons.

#### **D. Bioinformatics Analysis**

The data obtained from all microarray hybridization experiments were analyzed by bioinformatics experts, in several steps:

1. Selection of cDNA clones from expression data: cDNA clones were selected by comparison of gene expression patterns according to pre-defined criteria (See Sections XIX G and H for Apoptosis and Stroke chip, respectively). Selected clones were sequenced.

2. Sequence annotation: All sequences were annotated using a sequence annotation platform which includes:

- Sensitive filtering of repetitive sequences (Smith-Waterman algorithm).
- 5 • Homology searches in the non-redundant protein database (nr), (Frame\_n2p algorithm), nucleotide database (nt) (gapped Blast algorithm) and ESTs database (dbEST) (Smith-Watermann algorithm).
- 10 • Assembly of EST contigs for unidentified sequences, by automated EST-clustering software.

3. Literature analysis: The annotated sequences were studied in light of the biomedical literature, in order  
15 to select preferred gene candidates for further research.

#### **E. Preparation of Tissues for *in situ* Hybridization**

Coronal sections were prepared from paraffin blocks of sham operated rat brains and brains subjected to MCAO. A trial *in situ* hybridization experiment was performed using PGK  
20 probe to define the optimal prehybridization treatment of sections. After establishing the optimal conditions for *in situ* hybridization additional sections were hybridized to c-fos specific probe. Results of this hybridization demonstrated upregulation of c-fos expression at the side  
25 ipsilateral to occluded artery in all MCAO samples. Microscopically, hybridization signal locates to the cortical and striatal neurons. It must be noted that in most of the sham-operated samples, a weak activation of c-fos was detected in some cortical neurons at the side ipsilateral to operation.  
30 This could point to a possibility that other genes could show

similar behavior, thus diminishing differential expression assessed by comparison between MCAO and sham-operated samples. Altogether, suitability of obtained paraffin blocks for in situ hybridization study was demonstrated allowing further  
5 validation of candidate genes.

#### **F. *In vitro* experiments in Primary Neuron Cultures**

Due to the relatively small proportion of neurons in brains (compared to glia cells), cultured primary neurons exposed to hypoxia were used as an additional *in vitro* model  
10 system. A primary neuron culture derived from cerebellum of 7 day old rat pups was used. The duration of hypoxia and FK506 concentrations were optimized for exerting an optimal neuroprotective effect *in vitro*, and 16h hypoxia and 100 ng/mL of FK506 were selected (Figure 1). The extracted RNA was used  
15 both for probes and for Stroke chip preparation.

#### **G. Hybridizations on the HAP Chip**

Differential expression data obtained by the 11 hybridizations on the HAP microarray (Table 2), was analyzed according to several pre-set criteria. Since a common  
20 reference probe was used in all hybridizations (common control, Table 2), different experiments could be compared to each other.

The criteria used for this analysis was a significant increase or decrease from control 3 hours after  
25 MCAO using either a nuclear or a total probe, and either with or without FK506, or 6 hours after MCAO using a total probe, with or without FK506. In order to distinguish between FK506 dependence and MCAO dependence, the differentially regulated genes were compared following MCAO treatment with those



particularly enhanced by FK506 after MCAO. Three genes are reported here which were upregulated by MCAO treatment (without FK506) vs. sham but were downregulated when FK506 was present (vs. MCAO). These would be expected to be bad genes,  
5 as is the gene found to be upregulated after MCAO treatment. The two genes in Table 4 which were upregulated when FK506 was present would be expected to be good genes which could serve as potential indicators of the protective effect of FK506 in stroke.

10 The total and nuclear probes yielded distinct sets of differentially expressed genes, stressing the role of the different cDNA probes in highlighting different molecular events. It should be noted that at 3 hours MCAO (without FK506 treatment), a substantially higher number of  
15 differentially expressed genes was detected by a nuclear probe compared to a total probe, albeit in different rat strains. This further stresses the importance of the nuclear probe in detecting early gene transcription events, implicated in acute responses.

20 All clones were sequenced, annotated, and evaluated where possible in light of the biomedical literature. Table 4 lists certain novel genes that were selected according to their potential interest.

Table 4

Genes Selected for Further Analysis from the HAP Chip

| Clone    | SEQ<br>ID NO | Annotation                                   | MCAO<br>Dependent  | FK506<br>Dependent  | Good/<br>Bad |
|----------|--------------|--|--------------------|---------------------|--------------|
| HAP-91F7 | 1            | Similar to EST03783<br>Homo sapiens (T05894) | 6h Total<br>(2.14) |                     | bad          |
| HAP-2F5  | 2            | Novel  |                    | 6 h Total<br>(2.09) | good         |
| HAP-2E5  | 3            | Novel  |                    | 6 h Total<br>(4.72) | good         |
| HAP-8C7  | 4            | Novel  | 3h Total<br>(2.07) | 3h Nuc.<br>(-2.08)  | bad          |
| HAP-2C3  | 5            | Novel  | 3h Total<br>(2.16) | 3h Nuc.<br>(-2.33)  | bad          |
| HAP-6C1  | 6            | Novel  | 3h Total<br>(2.33) | 3h Nuc.<br>(-2.17)  | bad          |

5

**H. Hybridizations on the Stroke Chip**

Thirty-four hybridizations were performed on the stroke chip (Table 3). Table 5 lists genes that were selected on the basis of these hybridizations. The genes identified using the STR chip are grouped in Table 5 according to results of hybridization with different probes. The same gene may be listed in more than one group.

**Group 1:** Genes upregulated by hypoxia in vitro. This group contains 38 novel genes which give differentials higher than 1.6 upon hybridization with probes representing RNA from primary rat neurons incubated for 16h in hypoxic conditions, in the presence of FK506 or without it (see

columns FJ33B, FJ37B, FJ34B and FJ38B of Table 5, in conjunction with Table 3).

**Group 2:** Genes upregulated in brains of rats after 3 h of MCAO and also in sham operated Sprague-Dawley rats (SD rats) with FK506, as well as upregulated in SHR rats after 6h of MCAO (see columns FJ39B, FJ40B, FJ41B and FJ45B of Table 5). This group includes two novel genes.

**Group 3:** Genes upregulated only in SD rats which have received either MCAO or a sham operation (see columns FJ39B, FJ40B and FJ41B of Table 5). This group includes 4 novel genes.

**Group 4:** Genes upregulated only in SHR rats (see particularly column FJ42B of Table 5). This group includes one novel gene.

**Group 5:** Genes downregulated by hypoxia in primary neurons (see particularly columns FJ33B, FJ37B, FJ34B and FJ38B of Table 5). This group includes 3 novel genes.

**Group 6:** Genes downregulated only in SD rats (see columns FJ39B, FJ40B and FJ41B of Table 5). This group includes one novel gene.

**Group 7:** Genes oppositely regulated in operated SD rats versus primary neurons in hypoxia (compare columns FJ39B, FJ40B and FJ41B with columns FJ33B, FJ34B, FJ37B and FJ38B of Table 5). This group includes three novel genes.

**Group 8:** Genes oppositely regulated in SHR rats after MCAO versus primary neurons in hypoxia (compare column FJ45B with columns FJ39B, FJ34B, FJ37B and FJ38B of Table 5). This group includes one novel gene.

**Group 9:** Genes coregulated in vivo in MCAO model and in vitro in primary neurons in hypoxia (compare columns

FJ39B, FJ41B and FJ45B with columns FJ33b, FJ34B, FJ37B and FJ38B in Table 5). This group includes two novel genes.

**Group 10:** Genes influenced by FK506 in the tests using probes derived from cells subjected to stress *in vitro* (see columns FJ34B and FJ38B in Table 5) or in the tests using probes derived from cells subjected to stress *in vivo* (see column FJ39B in Table 5). This group includes 15 novel genes.

While the genes in most of these groups could conceivably be either good or bad genes, as discussed above, the categorization can be accomplished without undue experimentation. It is expected, however, that those genes which were upregulated by MCAO without FK506 treatment (vs. sham), but downregulated when treated with FK506 (vs. MCAO without FK506) are bad genes. Those genes in Table 5 which are upregulated in column FJ41B and downregulated in column FJ39B are in this category. Thus, genes incorporating SEQ ID NOs:60, 84 and 89 may be categorized as bad genes. As SEQ ID NO:93 is downregulated in column FJ41B and upregulated in column FJ39B, it may be categorized a good gene. Those genes upregulated in hypoxia cells sixteen hours after FK506 treatment (column FJ34B or FJ38B) fall into the category of good genes. These include genes incorporating SEQ ID NOs:7-57, 61-63, 78-81 and 83-85. More preferred of these are SEQ ID NOs: 49 (KIAA0893), 50, 51 ( both corresponding to KIAA0911), 85 (KIAA0735) and 87 (corresponding to, KIAA0323). Conversely, those genes downregulated in the same columns may be categorized as bad genes, i.e., genes incorporating SEQ ID NOs: 68-71, 74-77 and 82.

Table 5

| Seq ID #                                 | Gene Description                    | Gene ID   | FJ43B | FJ42B | FJ40B | FJ41B | FJ39B | FJ45B | FJ35B | FJ32B | FJ36B | FJ33B | FJ37B | FJ34B | FJ38B |
|--|-------------------------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Group 1: Upregulated by Hypoxia in Vitro |                                     |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 7  | none:01_STR_39H12_T7.fa             | STR-39H12 | 1.2   | 1     | -1.1  | -1.1  | -1    | -1.1  | 1     | 1.2   | 1.3   | 2.2   | 2.3   | 2.5   | 2.8   |
| 8  | none:04_STR_36F1_T7.fa              | STR-36F1  | 1.1   | 1.1   | -1.2  | -1.1  | 1     | -1    | 1.2   | 1.3   | 1.5   | 2.8   | 2.6   | 2.9   | 3     |
| 9  | none:05_STR_36F12_T7.fa             | STR-36F12 | 1.1   | 1.1   | -1.1  | -1.1  | 1.1   | -1.1  | -1    | 1.2   | 1.2   | 1.7   | 1.6   | 2     | 1.9   |
| 10                                       | none:06_STR_83F10_T7_F01_014.ab1.fa | STR-83F10 | 1.1   | 1.1   | -1.2  | -1.1  | -1.3  | 1.1   | 1.2   | 1.3   | 1.2   | 3.4   | 2.9   | 2.3   | 2.5   |
| 11                                       | none:08_STR_36H3_T7.fa              | STR-36H3  | 1.1   | 1.3   | 1.4   | -1.1  | 1.2   | -1    | 1.3   | 1     | 1.1   | 2.3   | 2.5   | 2.9   | 2.7   |
| 12                                       | none:09_STR_19B3_T7.ab1.fa          | STR-19B3  | -1.1  | 1     | -1.1  | -1.2  | 1     | -1.1  | 1.2   | 1     | 1.2   | 2.4   | 2.7   | 2.7   | 2     |
| 13                                       | none:09_STR_55A6_M13F.fa            | STR-55A6  | -1    | 1     | -1.1  | -1.1  | -1.5  | 1.2   | 1.1   | -1.1  | -1    | 3     | 2.9   | 3     | 3     |
| 14                                       | none:09_STR_55A6_M13R.fa            |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 15                                       | none:33_STR_55A6_1_T7.ab1.fa        |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 16                                       | none:08_STR_37B5_M13F.fa            | STR-37B5  | 1.1   | 1.1   | -1.1  | -1.3  | -1.1  | -1.2  | 1     | -1.1  | -1    | 1.9   | 1.9   | 1.9   | 1.8   |
| 17                                       | none:11_STR_37B5_T7.fa              |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 18                                       | none:13_STR_55B3_T7_E02_018.ab1.fa  | STR-55B3  | -1    | 1.1   | -1.1  | 1     | -1.5  | 1.2   | 1     | -1.1  | -1    | 2.9   | 2.7   | 2.9   | 2.5   |
| 19                                       | none:14_STR_55E2_T7_F02_026.ab1.fa  | STR-55E2  | 1     | 1.3   | -1.1  | -1    | -1.6  | 1.2   | -1.2  | -1.4  | -1.3  | 2.4   | 2.4   | 2.6   | 2.4   |
| 20                                       | none:66_STR_55E2_T7_B09_076.ab1.fa  |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 21                                       | none:15_STR_55F12_T7_G02_019.ab1.fa | STR-55F12 | 1     | 1.2   | -1.1  | -1.1  | -1.4  | 1     | -1.1  | -1.2  | -1.1  | 2.8   | 2.5   | 2.5   | 2.3   |
| 22                                       | none:16_STR_55H7_T7_H02_027.ab1.fa  | STR-55H7  | 1     | 1.1   | -1.1  | -1.1  | -1.4  | 1     | -1.1  | -1.2  | -1.1  | 2.6   | 2.7   | 2.6   | 2.9   |
| 23                                       | none:17_STR_55H8_T7_A03_020.ab1.fa  | STR-55H8  | -1.1  | 1.1   | -1.1  | -1.1  | -1.4  | -1    | 1     | -1.2  | 1     | 3.2   | 2.6   | 2.8   | 2.3   |
| 24                                       | none:17_STR_65C12_M13F.fa           | STR-65C12 | 1.2   | -1.1  | 1.1   | 1.1   | 1     | -1.1  | -1.3  | -1.3  | -1.2  | 2     | 2     | 1.7   | 1.7   |
| 25                                       | none:38_STR_65C12_1_T7.ab1.fa       |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 26                                       | none:18_STR_55H11_T7_B03_028.ab1.fa | STR-55H11 | 1.2   | 1.1   | 1     | -1    | -1.4  | 1     | -1.1  | -1.1  | -1.2  | 2.6   | 2.7   | 2.5   | 2.5   |
| 27                                       | none:18_STR_65E6_M13F.fa            | STR-65E6  | -1.2  | -1.2  | 1     | 1.1   | -1.1  | -1.1  | -1.2  | -1.3  | -1.2  | 1.9   | 1.9   | 1.7   | 1.8   |
| 28                                       | none:20_STR_65E6_M13F.fa            |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 29                                       | none:20_STR_65E6_M13R.fa            |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 30                                       | none:19_STR_101D5_M13F.fa           | STR-101D5 | 1.2   | 1.2   | 1     | -1    | 1     | 1.2   | 1.2   | 1.3   | 1.4   | 2.3   | 2     | 1.8   | 1.9   |
| 31                                       | none:20_STR_S.12_5_T7.fa            |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 32                                       | none:49_STR_101D5_1_T7.ab1.fa       |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 33                                       | none:26_STR_41F5_M13R.fa            | STR-41F5  | 1.2   | 1.1   | -1    | -1.1  | 1     | 1     | -1.1  | 1.2   | 1.3   | 2.3   | 2.5   | 2.4   | 2.7   |
| 34                                       | none:26_STR_5D12_T7.ab1.fa          | STR-5D12  | -1.2  | -1.4  | -1    | -1.3  | -1.1  | -1.3  | 1.2   | -1    | 1     | 2.3   | 2.5   | 2.5   | 2.2   |
| 35                                       | none:30_STR_55C5_M13F.fa            | STR-55C5  | -1    | -1.2  | 1.1   | 1.1   | -1.1  | -1.1  | 1     | 1     | 1.1   | 2.1   | 1.7   | 1.7   | 1.8   |

| Seq ID #   | Gene Description  | Gene ID    | FJ43B | FJ42B | FJ40B | FJ41B | FJ39B | FJ45B | FJ35B | FJ32B | FJ36B | FJ33B | FJ37B | FJ34B | FJ38B |
|--|---|------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 36   | none:32_STR_38D9_T7.fa  | STR-38D9   | -1.1  | -1.1  | 1     | -1.2  | -1    | -1.2  | 1.1   | 1.1   | 1.3   | 2.8   | 2.6   | 3.2   | 3     |
| 37   | none:38_STR_42C8_T7.fa  | STR-42C8   | -1.2  | -1.2  | -1.1  | -1.4  | -1.4  | -1.2  | 1     | 1     | 1.1   | 2.3   | 2.4   | 2.2   | 2     |
| 38   | none:41_STR_8B9_T7.ab1.fa   | STR-8B9    | 1.1   | 1     | 1.1   | -1.1  | 1.4   | 1.1   | -1    | -1.1  | 1.1   | 3.4   | 3.8   | 3.7   | 3.5   |
| 39   | none:43_STR_95H10_T7_C06_049.ab1.fa   | STR-95H10  | 1.2   | 1.1   | -1    | -1.2  | -1.6  | 1.1   | 1.1   | -1.1  | -1    | 3.3   | 3.1   | 2.8   | 3     |
| 40   | none:56_STR_95H10_T7_H07_063.ab1.fa   |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 41   | none:44_STR_65E3_T7_D06_057.ab1.fa  | STR-65E3   | -1.2  | 1     | -1.2  | 1.2   | -1.1  | -1.1  | -1.1  | -1.2  | -1.1  | 2.1   | 2.7   | 1.8   | 2.1   |
| 42   | none:45_STR_42F8_T7.fa  | STR-42F8   | 1.1   | 1.1   | 1     | -1    | 1.1   | -1.1  | 1.1   | 1.2   | 1.3   | 2.1   | 2.1   | 2.6   | 2.6   |
| 43   | none:55_STR_47E5_T7_G07_055.ab1.fa  | STR-47E5   | 1.3   | 1.4   | 1.1   | 1.1   | 1.2   | 1.3   | 1.1   | 1.1   | 1.2   | 1.8   | 1.6   | 1.7   | 2.1   |
| 44   | none:78_STR_50B9_T7_F10_090.ab1.fa  | STR-50B9   | 1     | -1    | -1.2  | -1.1  | 1     | 1     | 1.1   | 1.2   | 1.4   | 3     | 2.8   | 3.6   | 2.7   |
| 45   | none:01_STR_42H7_M13F.fa  | STR-42H7   | 1.1   | 1.1   | -1.1  | -1.1  | 1     | -1.1  | -1.1  | 1.2   | 1.2   | 2.1   | 1.9   | 2.2   | 2.3   |
| 46   | none:01_STR_42H7_M13R.fa  |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 47   | none:10_STR_48B6_M13F.fa  | STR-48B6   | 1.2   | 1.1   | -1    | -1    | 1     | -1    | 1.1   | 1.4   | 1.4   | 2.7   | 2.7   | 2.8   | 3.2   |
| 48   | none:10_STR_48B6_M13R.fa  |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 49   | Homo sapiens KIAA0893 protein (KIAA0893), mRNA; nt_non_genomic(identity):25_STR_5D2_T7.ab1.fa | STR-5D2    | 1     | -1.1  | 1.1   | -1.1  | 1     | 1     | 1.1   | 1.3   | 1.2   | 2.8   | 3.1   | 3.4   | 3     |
| 50   | none:13_STR_32D4_1_T7.ab1.fa  | STR-32D4   | -1    | -1.4  | -1    | -1    | 1     | -1.4  | 1     | 1.4   | 1.4   | 1.6   | 1.6   | 1.7   | 1.8   |
| 51   | none:90_STR_32D4_M13F_B12_096.ab1.fa  |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 52   | none:82_STR_50E5_T7_B11_092.ab1.fa  | STR-50E5   | -1    | -1.1  | -1    | -1    | -1    | -1.1  | 1.1   | 1.2   | 1.1   | 1.5   | 1.7   | 1.6   | 1.8   |
| 53   | none:74_STR_76C2_1_T7.ab1.fa  | STR-76C2   | 1.1   | 1.1   | -1.1  | 1.1   | -1.5  | 1.2   | 1     | -1.1  | -1.3  | 3     | 2.8   | 2.7   | 2.4   |
| 54   | none:14_STR_39E12_M13F.fa   | STR-39E12  | -1.2  | -1    | -1    | 1.3   | 1.1   | 1     | 1     | 1     | 1.1   | 1.6   | 1.8   | 1.8   | 1.9   |
| 55   | none:12_STR_S60_6_T7.fa   | STR-102H10 | 1     | -1.4  | 1.1   | 1     | -1    | -1.1  | 1.1   | 1.4   | 1.2   | 2.3   | 1.6   | 1.9   | 1.8   |
| 56   | none:31_STR_59E12_M13F.fa   | STR-59E12  | -1    | -1.1  | -1.2  | -1.2  | -1.2  | 1.1   | -1    | -1.2  | -1.2  | 2.1   | 1.9   | 2.3   | 1.9   |
| 57   | none:34_STR_59E12_1_T7.ab1.fa   |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Group 2: Upregulated by 3 hrs MCAO/Sham-FK in SD Rats and 6 hrs MCAO in SHR Rats |   |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 58   | none:45_STR_8G3_T7.ab1.fa   | STR-8G3    | 1.6   | 1.4   | 1.8   | 2.3   | 2.7   | 1.8   | 1.1   | 1.3   | 1.2   | 1.2   | 1.1   | 1.3   | 1.2   |
| 59   | none:54_STR_15G9_T7_F05_046.ab1.fa  | STR-15G9   | 1.2   | 1     | 1.4   | 4.8   | 2.7   | 3     | -1.1  | -1.3  | -1.2  | 1.1   | -1.1  | -1.1  | -1.3  |
| 60   | none:95_STR_15G9_T7.ab1.fa  |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Group 3: Upregulated Only in SD Rats   |   |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 61   | none:24_STR_S35_6_T7.fa   | STR-102A2  | 1     | 1.2   | 2.5   | 3.4   | 3.1   | 1.2   | -1    | 1.3   | 1.3   | 1.6   | 1.2   | 1.6   | 1.3   |
| 62   | none:20_STR_77E1_T7_D03_029.ab1.fa  | STR-77E1   | 1.1   | 1.2   | 2.8   | 3.7   | 3.7   | 1.1   | 1.1   | 1.2   | 1.4   | 1.4   | 1.3   | 1.5   | 1.7   |
| 63   | none:85_STR_77E1_T7_E11_086.ab1.fa  |            |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 64   | none:92_STR_15C5_T7.ab1.fa  | STR-15C5   | 1.4   | -1.1  | 1.6   | 1.8   | 1.7   | 1.1   | 1     | -1.2  | -1.1  | -1.4  | -1.4  | -1.4  | -1.4  |
| 65   | none:68_STR_11D5_T7.ab1.fa  | STR-11D5   | 1.2   | -1.1  | 2.8   | 3.2   | 4.1   | 1.3   | 1.2   | 1.4   | 1.4   | 1.2   | -1.1  | 1.3   | 1.6   |

| Seq ID #  | Gene Description  | Gene ID   | FJ43B | FJ42B | FJ40B | FJ41B | FJ39B | FJ45B | FJ35B | FJ32B | FJ36B | FJ33B | FJ37B | FJ34B | FJ38B |
|---|---|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Group 4: Upregulated Only in SHR Rats   |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 66  | none:10_STR_71H11_M13R.fa   | STR-71H11 | 1.4   | 1.6   | 1     | 1.2   | 1.1   | 1.5   | 1     | 1.2   | 1.1   | 1.1   | -1.1  | 1.1   | 1     |
| 67  | Homo sapiens KIAA0103 gene product (KIAA0103), mRNA non_genomic(identity):35_STR_71H11_M13F.fa                |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Group 5: Downregulated by Hypoxia in Primary Neurons                          |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 68  | none:33_STR_60H2_T7_A05_036.ab1.fa  | STR-60H2  | 1.2   | 1.1   | -1    | -1.1  | -1.1  | 1.1   | -1.1  | -1.3  | -1.3  | -1.5  | -1.6  | -1.6  | -1.6  |
| 69  | none:16_STR_8H4_M13F.fa   | STR-8H4   | -1.1  | 1     | -1    | -1.1  | -1.1  | -1    | -4.5  | -4.3  | -5.2  | -5.1  | -4.5  | -5    | -5    |
| 70  | none:29_STR_8H4_M13R.fa   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 71  | none:06_STR_54A11_T7_F01_014.ab1.fa   | STR-54A11 | 1     | -1.1  | -1.3  | -1.2  | -1.3  | -1    | -1.1  | 2.3   | 1.1   | -1.6  | -1.8  | -1.9  | -1.6  |
| Group 6: Downregulated Only in SD Rats  |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 72  | none:21_STR_S54_5_T7.fa   | STR-102F3 | -1.3  | -1    | -2.8  | -1.7  | -1.6  | -1.2  | 1.1   | 1.2   | 1.3   | 1     | -1.1  | 1.2   | 1.2   |
| 73  | none:55_STR_102F3_1_T7.ab1.fa   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Group 7: Oppositely Regulated in Operated SD Rats and Primary Neurons/Hypoxia |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 74  | none:19_STR_21A8_T7.ab1.fa  | STR-21A8  | 1.7   | -1.1  | 1.8   | 1.8   | 1.5   | 1.2   | 1     | -1.1  | -1.1  | -2.8  | -3    | -3.3  | -3.1  |
| 75  | none:22_STR_21H9_T7.ab1.fa  | STR-21H9  | 1.7   | -1.1  | 1.7   | 1.5   | 1.4   | 1.3   | 1.3   | 1.1   | 1.2   | -2.6  | -2.4  | -2.8  | -2.6  |
| Group 8: Oppositely Regulated in SHR/MCAO and in Primary Neurons/Hypoxia      |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 76  | Homo sapiens EST from clone 251760, 5' end;   | STR-31G6  | -1    | -1.1  | 1.2   | 1.2   | 1.1   | 1.7   | 1.1   | 1.1   | -1.1  | -2.4  | -1.8  | -2.3  | -1.8  |
| 77  | nt_non_genomic(identity):24_STR_31G6_T7_Hnon_9_enomic(identity):65_STR_31G6_T7.ab1.fa                         |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| Group 9: Genes Coregulated in MCAO and in Primary Neurons/Hypoxia             |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 78  | 7e62e09.x1 Soares_NSF_F8_9W_OT_PA_P_S1<br>Homo sapien ; est(identity):69_STR_11E11_T7.ab1.fa                  | STR-11E11 | 1.6   | 1.6   | 1.6   | 2     | 2.1   | 1.7   | -1    | 1.1   | 1.2   | 1.7   | 1.5   | 1.7   | 1.6   |
| Group 10: Genes Influenced by FK506   |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| In Vitro  |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 79  | none:09_STR_40E1_T7.fa  | STR-40E1  | 1     | -1    | -1.2  | -1.1  | 1     | -1    | -1.1  | 1.2   | 1.2   | 1.5   | 1.6   | 1.9   | 2.1   |
| 80  | none:16_STR_41A8_T7.fa  | STR-41A8  | -1    | 1     | -1    | -1    | 1     | -1.1  | -1.1  | 1.2   | 1.2   | 1.3   | 1.2   | 1.7   | 1.6   |
| 81  | none:24_STR_41D5_T7.fa  | STR-41D5  | 1.2   | 1.1   | -1.1  | 1     | 1     | -1.1  | -1    | -1    | 1.2   | 1.4   | 1.5   | 1.7   | 1.9   |
| 82  | none:72_STR_75D9_T7_H09_079.ab1.fa  | STR-75D9  | -1.2  | -1.3  | -1.2  | 1.1   | 1.1   | -1.1  | -1.4  | -1.5  | -1.2  | -1.5  | -1.4  | -1.7  | -1.9  |
| 83  | none:64_STR_31G3_T7.ab1.fa  | STR-31G3  | -1.1  | -1.4  | -1.1  | -1.3  | -1.1  | -1.5  | 1.3   | -1    | 1.4   | 1.4   | 1.4   | 1.8   | 1.9   |
| 84  | none:52_STR_98F5_T7_D07_061.ab1.fa  | STR-98F5  | -1.1  | -1    | -1.2  | 1.1   | -1.4  | 1.3   | 1.1   | 1.1   | 1.3   | 1.4   | 1.3   | 2     | 1.9   |
| 85  | Homo sapiens KIAA0735 gene product; synaptic vesicle; nt_non_genomic(identity):07_STR_84C12_T7_G01_007.ab1.fa | STR-84C12 | 1.2   | 1.3   | 1.3   | 1     | 1.1   | 1.3   | -1    | 1.2   | 1.2   | 1.3   | 1.4   | 1.7   | 1.6   |



| Seq ID # | Gene Description  | Gene ID   | FJ43B | FJ42B | FJ40B | FJ41B | FJ39B | FJ45B | FJ35B | FJ32B | FJ36B | FJ33B | FJ37B | FJ34B | FJ38B |
|----------|---|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 86       | none:43_STR_65B9_T7_C06_049.ab1.fa  | STR-65B9  | 1.5   | -1    | 1.6   | 2.3   | 1.9   | 1.4   | -1.4  | -1.4  | -1.5  | 2     | 1.9   | 1.5   | 1.4   |
| In Vivo  |   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 87       | Human mRNA for KIAA0323 gene, partial cds; nt_non_genomic(identity):46_STR_12B5_T7_F04_042.ab1.fa | STR-12B5  | 1     | -1.1  | -1.4  | -1.4  | -1.7  | -1.1  | 1     | 1.1   | 1.2   | -1    | 1     | -1.1  | 1     |
| 88       | Human mRNA for KIAA0323 gene, partial cds; nt_non_genomic(identity):73_STR_12B5_T7.ab1.fa         |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 89       | none:08_STR_86B5_T7_H01_015.ab1.fa  | STR-86B5  | 1     | -1.2  | -1.1  | 1.1   | -1.6  | 1     | 1     | 1.2   | 1.4   | 1.1   | -1.1  | 1     | -1.1  |
| 90       | none:43_STR_80G8_1_M13F.fa  | STR-80G8  | 1     | -1.1  | -1.2  | -1.2  | -1.8  | -1.1  | 1.1   | 1.5   | 1.4   | 1.2   | -1    | 1     | 1.2   |
| 91       | none:31_STR_77A12_T7.fa   | STR-77A12 | 1.1   | -1    | -1.2  | -1.2  | -1.6  | -1.2  | 1     | -1.2  | -1.1  | -1    | 1.1   | 1.1   | 1.2   |
| 92       | none:81_STR_77A12_T7_A11_084.ab1.fa   |           |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 93       | none:23_STR_91B4_T7_G03_023.ab1.fa  | STR-91B4  | 1     | 1     | -1    | -1.1  | 1.7   | -1.1  | -1    | 1.4   | 1.2   | 1     | -1.2  | -1.1  | -1.1  |

Six of the genes in Table 5 have been disclosed as undefined ESTs in sequence databases. Table 6 shows the known accession numbers with respect to these genes.

**Table 6**

| Gene ID   | Accession No.                       | SEQ ID NO |
|-----------|-------------------------------------|-----------|
| STR-5D2   | gi 7662363 ref NM_014969.1          | 49        |
| STR-71H11 | gi 7661909 ref NM_014673.1          | 67        |
| STR-31G6  | gi 8670869 emb AL359650.1 IROEST123 | 76        |
|           | gi 8670869 emb AL359650.1 IROEST123 | 77        |
| STR-11E11 | gi 9969291 gb BE644980.1 BE644980   | 78        |
| STR-84C12 | gi 7662269 ref NM_014848.1          | 85        |
| STR-12B5  | gi 2224586 dbj AB002321.1 AB002321  | 87        |
|           | gi 2224586 dbj AB002321.1 AB002321  | 88        |

5

### **I. Results of Functional Profiling**

As described, positive selection in BE2C cells was employed in order to select for neuronal cell death-related proteins in hypoxic/ischemic neurons. The efficiency of the selection was illustrated in two ways:

1. BE2C cells infected with control empty retroviral vector (Figure 2A) and with the sub-library of elements obtained after two rounds of enrichment (Figure 2B). A significant portion of the cells infected with the enriched sub-library was protected against the toxic effect of glutamate.

2. Library elements from survived cell clones were rescued by PCR, after 4-5 rounds and after 1-2 rounds of

selection, and separated by 2.5% agarose gel electrophoresis. As seen in Figure 3 nice discrete bands were observed after 4-5 rounds of selection (Figure 3A), in comparison to DNA smears in earlier rounds (Figure 3B).

5           Thus, a library of decreased complexity and increased effect is obtained with repeated rounds of selections.

10           The output of functional analysis comprised many genes, some of which were found to be novel. Some were identical to those found as differentially expressed by hybridization analysis. Table 7 is a list of genes from the functional analysis output which are either novel or whose function was previously unknown.

Table 7

## Functional Genes

| SEQ ID # | Name of Gene            | Name of Clone             | Accession No. |
|----------|-------------------------|---------------------------|---------------|
|          | <b>KIAAs</b>            |                           |               |
| 94       | KIAA0538 (Ras-GAP like) | FUNDII1.53;<br>FUNDII1.36 | AB011110      |
| 95       | KIAA0399                | FUNH1III.12               | AB007859      |
| 96       | KIAA0494                | FUNGIII1.13               | AB007963      |
| 97       | KIAA0638                | FUNDIII2.22               | AB014538      |
| 98       | KIAA0750                | FUNH5III.15               | AB018293      |
| 99       | KIAA0100                | FUNDIII3.59               | D43947        |
| 100      | KIAA0239                | FUNGII1.44                | D87076        |
| 101      | KIAA1014                | FUNH2III.20               | AB023231      |
|          |                         |                           |               |
|          | <b>ESTs</b>             |                           |               |
| 102      |                         | FUNHII1.75                | AA059375      |
| 103      |                         | FUNGIII1.1                | AA300642      |
| 104      |                         | FUNGII1.21                | AA305249      |
| 105      |                         | FUNDII1.37                | AA325087      |
| 106      |                         | FUNHII1.85                | AA610691      |
| 107      |                         | FUNGII1.46                | AA730668      |
| 108      |                         | FUNGII1.23                | AA737193      |
| 109      |                         | FUNDII1.33                | AA960916      |
| 110      |                         | FUNH4III.9                | AA974390      |
| 111      |                         | FUNGII1.15                | AA984133      |
| 112      |                         | FUNDII1.54                | AA524678      |
| 113      |                         | FUNGIII1.24               | THC216469     |
| 114      |                         | FUNDIII3.55               | AI003295      |
| 115      |                         | FUNDII1.29                | AI003295      |
| 116      |                         | FUNDII1.49                | AI057127      |

|     |  |             |           |
|-----|--|-------------|-----------|
| 117 |  | FUNDIII2.39 | AI085933  |
| 118 |  | FUNHII1.76  | AI124570  |
| 119 |  | FUNDII1.75  | AI222354  |
| 120 |  | FUNH2III.7  | AI423961  |
| 121 |  | FUNGIII2.32 | THC175379 |
| 122 |  | FUNDII1.18  | H10578    |
| 123 |  | FUNHII1.71  | H94806    |
| 124 |  | FUNHII1.64  | N28509    |
| 125 |  | FUNHII1.59  | N51767    |
| 126 |  | FUNGII1.5   | R16526    |
| 127 |  | FUNGIII1.23 | THC221157 |
| 128 |  | FUNDII1.5   | U92985    |
| 129 |  | FUNH2III.3  | W31179    |
| 130 |  | FUNGII1.37  | THC212363 |
| 131 |  | FUNH5III.8  | Z21350    |

#### J. Literature Review of Candidate Genes

The selected and annotated sequences were studied in light of the biomedical literature. We have currently completed the analysis of results obtained from differential expression profiling with the Apoptosis array (HAP). Preliminary results are presented for the Stroke array (STR) and functional profiling (FUN). Note, however, that several promising candidates have already emerged from this data, and further analysis and verification may yield additional ones.

Currently more preferred polynucleotides according to the present invention are SEQ ID Nos: 49 (corresponding to KIAA 0893), 50 and 51 (corresponding to KIAA0911), 65 (corresponding to KIAA0284), 67 (corresponding to KIAA0103), 85 (corresponding to KIAA0735), 87 (corresponding to

KIAA0323), and 94-100 (corresponding KIAA numbers presented in Table 7).

Currently most preferred embodiments according to the present invention are SEQ ID NO:65 (corresponding to KIAA 0284) and SEQ ID NO 94 (corresponding to KIAA0538, also identified as CAPRI), as discussed in detail herein above.

#### K. Validation of KIAA0538; in vitro results

In addition to the selection of candidate clones for use in screening assays, the utility of one of the currently most preferred embodiments KIAA 0538 was further validated by use of in vitro assays.

The aim of the experiment was validation of the fragment of KIAA0538 found using Dopamine selection (SEQ. I.D. No 94) which has 253 nucleotides . A slightly smaller fragment was used , wherein the first 12 of the nucleotides of SEQ. I.D. No 94 were replaced with 5 different nucleotides. The location of this smaller fragment (having 246 nucleotides) within the KIAA0538 cDNA is from nucleotide 2020 to nucleotide 2265. For purpose of validation, cells were studied either after decrease of the gene expression by means of transfection or transduction with an antisense expressing vector (the fragment rescued from the library during the functional screening), or after increased gene expression using transfection with a full length expression vector.

For experiment, BE2C cells were seeded into 6-well plates at density 100,000 cells/well. Retroviral vector expressing KIAA0538 antisense fragment (rescued in functional selection) fragment or empty vector (pLXSN) were introduced in neuroblastoma cells by two different methods - transfection

using Fugen6 reagent (Rosh) or by retroviral infection. Population of transfected/transduced cells was enriched by 3 days G418 selection. BE2C cells were further treated with different concentrations of Dopamine for 24 hours and assayed  
5 for viability by Neutral red staining (Figure 4 - infection; Figure 5 - transfection). As shown in Figure 4 and Figure 5 the antisense fragment of KIAA0538 is confers an increased cell survival at high Dopamine concentrations compared to control.

10                   The effect of the full length KIAA0538 cDNA on cell survival was tested in colony formation assay in non-differentiated P19 cells stably expressing Tet-activator (confers high level of expression from responsive promoters). P19 cells were transfected with either empty vector or the  
15 same vector containing the full-length KIAA0538 cDNA under the control of Tet-repressible promoter. The number of transfected cells further taken for colony formation assay was normalized by cotransfection with GFP, so that the equal number of GFP-positive cells was taken for the assay. The cells were further  
20 plated and grown in the absence of tetracycline (to ensure the gene's expression) and in the presence of hygromycin (selectable marker) for 48 hours. Then part of the plates were subjected to 16 hours ischemia (0.5% O<sub>2</sub> and no glucose) and following the transfer into normoxic conditions were further  
25 grown until the accomplishing of hygromycin selection (death of mock-transfected cells). The cell colonies grown in plates were fixed, stained with methylene blue and photographed with a CCD camera (Figure 6). The area of the colonies was quantified using the IMAGE-Pro program. As shown in Figure 6  
30 gain of function (i.e., increased expression of KIAA0538) is



detrimental to these cells even at normoxia and under hypoxia the cells overexpressing KIAA0538 are almost entirely non-viable

Thus, we have obtained the experimental evidence  
5 that while overexpression of antisense KIAA0538 fragment protects BE2C cells from dopamine-induced toxicity, overexpression of the full-length cDNA is moderately cytotoxic under normoxic conditions and dramatically cytotoxic under ischemic conditions. Dopamine-induced  
10 cytotoxicity is known to have oxidative stress as its component (Offen, D. et al., 1999, Adv. Neurol, 80, 265-269) The same is true for ischemia (Shoshani et al., 2002, Mol Cell Biol.). It is known that buffering of intracellular calcium protects neuronal cells from death elicited by oxidative  
15 stress. The presence of calbindin in rat cortical neurons protects in vitro from oxidative stress. (Hugon J, Hugon F, Esclaire F, Lesort M, Diop AG, Brain Res 1996 Jan 29;707(2):288-92). Thus, Ca<sup>2+</sup> appears as a mediator of cytotoxicity produced by oxidative stress. It is also known  
20 that ischemic injury in stroke is associated with excitotoxicity (Horn J, Limburg M.

Calcium antagonists for ischemic stroke: a systematic review. Stroke. 2001 Feb;32(2):570-6) and that KIAA0538 is  
25 activated by increased Ca concentrations. Thus, activation of KIAA0538 should accompany numerous ischemic and neurodegenerative disorders making the ischemic cells more vulnerable to the injury. In accord, we have demonstrated the rescue of cells from apoptotic death by virtue of  
30 overexpression of KIAA0538 antisense fragment. Moreover,

activated KIAA0538 was shown to suppress both Ras and ERK2 activation while the corresponding pathway is known to be involved in cell survival (Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999 Nov 12;286(5443):1358-62). Altogether, our experimental and literature data argue that KIAA0538 is an attractive target for inhibition by drugs for treatment of ischemic and neurodegenerative diseases.

10

15

#### L. In vivo utility

The pharmaceutical compositions of the present invention can be used for treatment of many diseases. By treatment of disease is meant prevention or amelioration of the disease or of symptoms associated with the disease, or minimizing subsequent worsening of the disease or of symptoms associated with the disease. The diseases to be treated include acute ischemic diseases, such as stroke, preferably, but also include myocardial infarction, acute renal failure, retinal artery occlusion, renal infarct, mesenteric ischemia and peripheral embolic events. The conditions to be treated also include chronic ischemic events such as peripheral vascular disease (PVD) and retinopathy. The diseases to be treated also include degenerative diseases causing chronic degenerative damage such as Parkinson's

30

disease, Huntingdon's Chorea, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, Shy-Drager Syndrome depression, bipolar diseases and Schizophrenia. Treatment of the effects of neurotoxicity, hypoxia, and/or ischemia in different organs, like e.g. brain, heart, liver, kidney is also envisaged as an aspect of the invention .

It will be appreciated that the most appropriate administration of the pharmaceutical compositions of the present invention will depend on the type of injury or disease being treated. Thus, the treatment of an acute event will necessitate systemic administration of the active composition comparatively rapidly after induction of the injury. On the other hand, diminution of chronic degenerative damage will necessitate a sustained dosage regimen.

The potential of preventing or reducing CNS injury by regulating gene expression or by modulating the action of the gene product of the invention is evaluated in animal models.

The models represent varying levels of complexity, by comparison of control animals to the treated animals. The efficacy of such treatment is evaluated in terms of clinical outcome, neurological deficit, dose-response and therapeutic window.

1. Closed Head Injury (CHI) - Experimental TBI produces a series of events contributing to neurological and neurometabolic cascades, which are related to the degree and extent of behavioral deficits. CHI is induced under anesthesia, while a weight is

allowed to free-fall from a prefixed height (Chen et al, J. Neurotrauma 13, 557, 1996) over the exposed skull covering the left hemisphere in the midcoronal plane.

2. Transient middle cerebral artery occlusion (MCAO) - a 90 to 120 minutes transient focal ischemia is performed in adult, male Sprague Dawley rats, 300-370 gr. The method employed is the intraluminal suture MCAO (Longa et al., Stroke, 30, 84, 1989, and Dogan et al., J. Neurochem. 72, 765, 1999). Briefly, under halothane anesthesia, a 3-0-nylon suture material coated with Poly-L-Lysine is inserted into the right internal carotid artery (ICA) through a hole in the external carotid artery. The nylon thread is pushed into the ICA to the right MCA origin (20-23 mm). 90-120 minutes later the thread is pulled of, the animal is closed and let recover.

3. Permanent middle cerebral artery occlusion (MCAO) - occlusion is permanent, unilateral-induced by electrocoagulation of MCA. Both methods lead to focal brain ischemia of the ipsilateral side of the brain cortex leaving the contralateral side intact (control).

Evaluation Process: The efficacy of the treatment is determined by mortality rate, weight gain, infarct volume and by short and long term clinical and neurological outcomes in surviving animals. Infarct volumes are assessed histologically (Knight et al., Stroke, 25, 1252, 1994, and Mintorovitch et al., Magn. Reson. Med. 18, 39, 1991). The staircase test (Montoya et al., J. Neurosci. Methods 36, 219, 1991) or the motor disability scale according to Bederson's method

(Bederson et al., Stroke, 17, 472, 1986) are employed to evaluate the functional outcome following MCAO. The animals are followed for different time points, ranging from hours up to two months. At each time point (24h, 1 week, 3, 6, 8 weeks), animals are scarified and cardiac perfusion with 4% formaldehyde in PBS is performed. Brains are removed and serial coronal sections (200 m thick for example), are prepared for processing and paraffin embedding. They are stained with suitable dyes such as TCC. The infarct area is measured in these sections using computerized image analyzer.

Utilization of the treatments as is exemplified in the above animal models provides new possibilities for treatment of human brain injury or damage.

Table 8 is a list of all the sequences referred to hereinabove.

**Table 8**

**SEQ ID NO:1**

>HAP\_91F7\_RF

CCAACTTGCCCGTTGTCCACGGGTCCCACCCCTTCTTGCCGCTCCTCCTCTGCAGGTCCCGC  
CCTCTCCCCCTGCCTCACTCCCAATGTCTCCTTTGGCTAAGCCCCCTCCACAGGCCCCACCT  
GCTCTGGCCACACCTCCTCTGCAGGCCCTTCCTCTCCGCCTGCCTCATTCCTGGGCAGGC  
CCCTTTCTCACCTCTGCCTCACTCCCAATGTCTCCTTTGGCCACGCCTCCTCCACAGGCC  
CACCTGTTCTGTAGTTAGTTA

**SEQ ID NO:2**

>HAP\_2F5\_RF

CCAAGTCCACCCGATCACAAGGCTCAGCTCTTAAGTGCTCTGCGATACTGCTTTTCTAACAA  
TGCCTGGTGCCTCCCTGAGTGAATTCCCAATAGGAGTCTTTCCACTTTAGTCCAACATGAGG  
CAAGTAGTTGCAGGTGCCAGGTAACATAATGAGCTCCACCTTGGTAATCACTCTGAGTAGAC  
AATGCTCAAAAAAACAGAGCACCACATAATGTATCAACCCTAACAGTCACCCTTCTGACATC  
TCTATTGGAAAGAGGGGATAAGTAGTTAGTTA

**SEQ ID NO:3**

>HAP\_2E5\_RF

CCTTTAAATTTTACACTATCACACTTTATTTATTCAATCACCAAGCCCCACCTTATCTATT  
CCCCTGCTCACACACAAATCCACTATTCTAATCCTGCTTACACACCCCTTCCACAGGGTTTT  
ATCTCACTTATGATAAAATCCAAAACCTCACAGCATAGCCACTCTCCCCAAAGCATACTATGC  
TTTAACCACACTGGTCTTTTCTAAAAGTTTCTCCTATTCCCCAATCTTTCTTCCTTACTCTA  
AGGTAGTTAGTTA

**SEQ ID NO:4**

>HAP\_8C7\_RF

TAACTAACTAGGGAACCTGGGGGCCAAGGGGCCCCAGCAGTCAGCACCAATGCAATAGTCCT  
TGAAGATCACGGCCAAAGCTATACTTGCTCTGGACAGGTAACTCCCCCTTTCATGGGCAGGG  
GTGGTAAAAGGAGCAAGCAGAAGCAAAAAGGAATTTTCCTCTAAAAACAGAATTGCTGAAAG  
GCACTTAATAGAGGGATAGGGGCCAGACACGGTGGCTCACACCTATAATCCCAGTACTTTAA  
TAGGAAGAGGCTG

**SEQ ID NO:5**

>HAP\_2C3\_RF

TAACTAACTATGCCAAAGGGAAATGTTAAGCTTGGGAACTGAGTCACGCAATAGCCTTTTGT  
CCCTAAGCAGATGGCTGTAAGACAGAAGGTCACCTATCTCCCGAGTGG

**SEQ ID NO:6**

>HAP\_6C1\_RF

TAACTAACTAGATAAGTGATCTGTGGCCACATTTGCAGTACGTGATCCTGACCCACTGGCCA  
CTGCTAATTGGATAATAAGCAGCTACCACATCCAGTATGAGCCAGTCAGATCCTCTCTCTTG  
GGAAACTAGCATTACAGCCAGTGCCTCTACAGAGAAGGAAGCATAAGCATTTAGAAAGATA  
GTTCTCCTGACTCTAGGGGGCCACTGGTAATAACAATCTCAGTTTCTGAGGCTTTCCAGTTT  
CTGGATCC

**SEQ ID NO:7**

01\_STR\_39H12\_T7.fa

CCTCAGTAGGAGGGAGCGCGTGTGTGTGTGTGTGCGCGTGTGTGAGTGTGTGTAACAACCCA  
GAAAGCTGGTAAGAGCTGCAGAGAGGCAGTGTTTATTAGATTCACACTTAGACACTGATTGT  
GGGTTCTGGTTTAGCTCTTTTATAATTGTAAAGTTATATTTTTGCTGCTTTGTAATAGGATA  
ATTCTTAAGCATCATCTTAAATAGAGGTATTTTGATTCTTTTTTGTGGAGCTGTGACTAAA  
GTGCAGNGTCTCACATAGGCTAAGCAAGTGCTGTGCACTGAGTTGAACCCAGCAGAAGTAG  
GTGCTGCAAGTGTAACAAGGCTAAAGGGCCTAATGCACACAGCCTGTGCAGGCCGCGAGT  
GCACCGACTATAAGCCCCATGCTATTAAAGC

**SEQ ID NO:8**

04\_STR\_36F1\_T7.fa

CCTCAGTAGGAGGGAGCGCGTGTGTGTGTGTGTGCGCGTGTGTGAGTGTGTGTAACAACCCA  
GAAAGCTGGGAAGAGCTGCAGAGAGGCAGTGTTTATTAGATTCACACTTAGACACTGATTGT  
GGGTTCTGGCTTAGCTCTTTTATAATTGTACAGCTATATTTTTGCTGCTTTGTAATAGGATA  
ATTCTTAAGCATCATCTTAACATAGAGGTATTTTGCTTCTTTTTTGTGGCGCTTGACATTAA  
GTGCAGCCTCTCACATAGGCTAAGCAAGTGCTGCGCACTTGAGTGAAGTGCAGCAGAAGTAG  
TCGCTGCACGTGTAAAACAAGGCTACAGATTCTAATGCACACAGCCTGTGCAGACCGCGTGT  
CCACCGTCTATAAGGCATGGCTATAACGG



**SEQ ID NO:9**

05\_STR\_36F12\_T7.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCACAAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAGAATTATCCTATTACAAAGCAGCANAAATATAACTT  
TACAATTATAAAAGAGCTAAACCAGGACCCACAATCAGTGTCTAAGTGTGAATCTAATAAAC  
ACTGCCTCTCTGCAGCTCTTACCAGCTTTCTGGGTTGGTACACACACTCACACACGCGCACA  
CACACACACACGCGCTCCCTCCTACTGAGG

**SEQ ID NO:10**

06\_STR\_83F10\_T7\_F01\_014.ab1.fa

TGGAGCTAATTGCGCGCGGCCGCGGTACGACGAACCTGCCCCTGATGACCCTCACCCCTTTT  
GCATAGGTCACTGGATCCCCTGTCCTTCCTCGGTGCTTACACACTTTACAGACCCTTTAGG  
CGAGCCCTTGCATAGAGCGTTATCTCAGTGCTCCATTCCAGTCCTGACTCCCTGTGGCCATT  
GAGACTTTGGATTTAAGAACTCACATTGCTAGGGAGAGGGGCTTTGCTGGGAAAGGTGACTC  
CTCTGTAACCTAGCCTCTTGTGCTCCTCCATGACAGAAATGCTGGGTGGAGTTTTACATTTG  
CCAATGGCCAGCTTGTGAATATCTTCATATACACTTTCTATTCATGTTACTGTAGTTTCTGT  
TTTGAAATAAACTTCTGAATGTAAAAAAAAAAAAAAAAA

**SEQ ID NO:11**

08\_STR\_36H3\_T7.fa

CTTGGTCACAGTGCTTTCCTTACACCCTTATGATGAAAGTCACTGTAAGAAGGGCTGCTGGC  
AGTCCAGGCACACCCTGTGTGCAGAGTCGGCCATGCTTTGGGAGGGTGTCAGGAAAGAGTCA  
TTTACTTTGACTGCCTGTGGGCTGACTTCAGAACTTCAGGTCTTAAGGTTTGCTGGCTTCTG  
AAAACACTTTCTAAAGAGCCCATGAAATATAAATATAACTAACTTAGAAAGCCCTG

**SEQ ID NO:12**

09\_STR\_19B3\_T7.ab1.fa

TTTTTTTTTTTTTTTTTTTTTTTTTTTAAAAATTCAAGGATGGGGTTAAAGGGGAATTCCCGG  
GGGGGGG

**SEQ ID NO:13**

09\_STR\_55A6\_M13F.fa

GGTACGGCGTACCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAGCCTGCCTCCT  
TGACATGCTGTATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCT  
AAAAATAAAAGTAAATTTTAACAGTCAAAAAAAAAAAAAAAAAA

**SEQ ID NO:14**

09\_STR\_55A6\_M13R.fa

TTTTTTTTTTTTTTTTTTGGACGGTAAAAATTAACCTTTAATTTTAAGCACACCTGAGTTAAGGG  
GGGAACAATGAAACAAATCCAATAGAATTTTACAGCATGTAAAGGAGGCAGGTTTAAAAGC  
CATGCTATAAAAAAGAGAAACTGGAAGGCAGGTACGCCGTACCGGGC

**SEQ ID NO:15**

33\_STR\_55A6\_1\_T7.ab1.fa

CTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAGCCTGCCTCCTTGACATGCTGT  
ATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAAAATAAAAG  
TAAATTTTAACAGTCAAAAAAAAAAAAAAAAAAAGG

**SEQ ID NO:16**

08\_STR\_37B5\_M13F.fa

CCATACAGTGCGCACTTCGAGTATAACAACGCGAGTGCAATGCTTTACCATGATGCATGAAG  
AAACTGAGGAGACAGATCAGCTACTATCGTAGCCATTACAGCTGAAGAGATTCAAAATTGG  
AAGGCACTAACTGATTGCGTTAAGACGCATTCTATCAAGGTTATCATAGATGAAAGATCATA  
GAAACTGGAAGGCATAAACTGAG

SEQ ID NO:17

11\_STR\_37B5\_T7.fa

CCATACAGTGCGCACTGCGAGACTCACAACGCGAGTGCAACGCATTACCATGATGCATGAAG  
 AAAACTGAGGAGACAGATCAGCTACTATCGAAGCCATTACAGCTGGAGAGATACTTACTGGG  
 AAGCCGCTAACTGATTGCGTTACGTGAAATGTATCAAGGTTATCATAGATGAGAGATCATA  
 GAAACTGCTAGGCATACACTGAGCATTAAAGCTTATCGACACCGTGGAGCTCGAGGTGAGTCC  
 ACGCACCAGCTGTGGGACCGTGTAGGGACTGNTACCTACGAGCATGGCGAGATCATAGGCAT  
 AGNNTNGTANTCA

SEQ ID NO:18

13\_STR\_55B3\_T7\_E02\_018.ab1.fa

CTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGACATGCNTG  
 ATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAAAATAAAAG  
 TAAATTTTAACAGTCAAAAAAAAAAAAAAAAAAAGG

SEQ ID NO:19

14\_STR\_55E2\_T7\_F02\_026.ab1.fa

CGACGAACCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGA  
 CATGCTGTATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAA  
 AATAAAAGTAAATTTTAACAGTCAAAAAAAAAAAAAAAAAA

SEQ ID NO:20

66\_STR\_55E2\_T7\_B09\_076.ab1.fa

CTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGACATGCTGNATATATTCTATT  
 GTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAAAATAAAAGTAAATTTTAACA  
 GTCAAAAAAAAAAAAAAAAAA

4001333.13104

SEQ ID NO:21

15\_STR\_55F12\_T7\_G02\_019.ab1.fa

CGACGACCCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGA  
CATGCNTGATATATTCTATTGGATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAA  
AATAAAAGTAAATTTTAACAGTCAAAAAAAAAAAAAAAG

SEQ ID NO:22

16\_STR\_55H7\_T7\_H02\_027.ab1.fa

CGACGAACCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGA  
CATGCTGTATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAA  
AATAAAAGTAAATTTTAACAGTCAAAAAAAAAAAAAA

SEQ ID NO:23

17\_STR\_55H8\_T7\_A03\_020.ab1.fa

GGTACGACGAACCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCC  
TTGACATGCTGTATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGC  
TAAAAATAAAAGTAAATTTTAACAGTCAAAAAAAAAAAAAA

SEQ ID NO:24

17\_STR\_65C12\_M13F.fa

GATCTGAGACCCACTTTGCAGACATGTGCACAGATGTGTTCCATTTCCCTATTTTTGCTGTA  
GAGAAACAAGTAAATTTTCTTAGAGAATGAAAAAAAAAAAAAAAAA

SEQ ID NO:25

38\_STR\_65C12\_1\_T7.ab1.fa

CTAATTGCGCGCGGCCGCGGTACGACGACCCTGCGATCTGAGACCCACTTTGCAGACATGTG  
CACAGATGTGTTCCATTTCCCTATTTTTGCTGTAGAGAAACAAGTAAATTTTCTTAGAGAAT  
GAAAAAAAAAAAAAAAAATAGGGCGCGCCTTTAAAACGGTTCCGATTTTTGGGCC

**SEQ ID NO:26**

18\_STR\_55H11\_T7\_B03\_028.ab1.fa

ACGACGACCCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTG  
ACATGCTNGATATATTCTATTGGATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAA  
AAATAAAAGTAAATTTTAACGGTCAAAAAAAAAAAAAAAAAA

**SEQ ID NO:27**

18\_STR\_65E6\_M13F.fa

GATCTGAGACCCACTTTGCAGACATGTGCACAGATGTGTTCCATTTCCCTATTTCTGCTGTA  
GAGAAACAAGTAAATTTTCTTAGAGAATGAAAAAAAAAAAAAAAAAAAA

**SEQ ID NO:28**

20\_STR\_65E6\_M13F.fa

GGCGACGTACCTGCGATCTGAGACCCACTTTGCAGACATGTGCACAGATGTGTTCCATTTCC  
CTATTTCTGCTGTAGAGAAACAAGTAAATTTTCTTAGAGAATGAAAAAAAAAAAAAAAAAAAA

**SEQ ID NO:29**

20\_STR\_65E6\_M13R.fa

TTTTTTTTTTTTTTTTTTTAAATTCTTTAAAAAATTTACTGGTTTCTTTACAGCAAAAATAGG  
GAAATGGAACACATTTGGGCACATGTTTGCAAAGGGGGTCTAAAATCGCAGGTACGTGGTAC  
CGG

**SEQ ID NO:30**

19\_STR\_101D5\_M13F.fa

GGACGACGTACCTGCATGATTGGTTCCACCTAATAAGCAAGGAAAGAATACTTGACCTTCAA  
ACTCATCCAGTGTTGGAGATCTCCATAATACCTTCCATCCTTTGGACCATGCCTTGGATGGA  
GACAGACACTACTGGAGAAAGGGGCTGCTTACCCCAGAGAGAATACTACCTAAATGCTGCTA  
CATCAGAGACTATCCATGACGAGCATCTCATATAAGGAT

SEQ ID NO:31

20\_\_STR\_S.12\_5\_T7.fa

ATGATTGGTTCCACCTAATAAGCAAGGAAAGAATACTTGACCTTCAAACATCCAGTGTTG  
GAGATCTCCATAATACCTTCCATCCTTTGGCCCATGCCTTGGATGGAGACAGACACTACTGG  
AGAAAGGGGCTGCTTTCCCCAGAGAGAATACTACCTAAATGCTGGTTCATCAGAGAATATCC  
ATGAAGAGCATCTCAGATAAGGATTGAAAAGGGGGTGCTGGGTAGAGTATAGTAGAGGAGGA  
CTTGTTAAGTTCACTGATGCTGGGAAGAACTTCCTGTAATGCCTACAGCATTCCATGGGCC  
ATAGAGTACCAATATGGTATGCCTCTTTACAGAGTCAATCTCAGCCCCCAGAAAGTGTATTC  
TACTGTGCTCAGGCCCAAAGGCAGTGTGGTGGTCAAAGGGCAACTGGCCTCCTGAACCCAGT  
AGAGCCTTGCAAAGTGC

SEQ ID NO:32

49\_STR\_101D5\_1\_T7.ab1.fa

GGTACGACGACCCTGCATGATTGGTTCCACCTAATAAGCAAGGAAAGAATACTTGACCTTCA  
AACTCATCCAGTGTTGGAGATCTCCATAATACCTTCCATCCTTTGGCCCATGCCTTGGATGG  
AGACAGACACTACTGGAGAAAGGGGCTGCTTTCCCCAGAGAGAATACTACCTAAATGCTGGT  
TCATCAGAGAATATCCATGAAGAGCATCTCAGATAAGGATTGAAAAGGGGGTGCTGGGTAGA  
GTATAGTAGAGGAGGACTTGTTAAGTTCACTGATGCTGGGAAGAACTTCCTGTAATGCCTA  
CAGCATTCCATGGGCCATAGAGTACCAATATGGTATGCCTCTTTACAGAGTCAATCTCAGCC  
CCCAGAAAGTGTATTCTACTGTGCTCAGGCCCAAAGGCAGTGTGGTGGTCAAAGGGCAACTG  
GCCTCCTGAACCCAGAAGAGCCTTGCAAAGTGCTGGCAGTCAGGGAGGTGCCATACATGATT  
CTTGTCTTT

40043364304

**SEQ ID NO:33**

26\_STR\_41F5\_M13R.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCCACAAAAAGAAACAAA  
TACCTCTATTTTAAGATGATGCTTAAGAATTATCCTAATTCAAAGCAGCAAAAATATAACTT  
TACAATTATAAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGTGAATCTAATAAAC  
ACTGCCTCTCTGCAGCTCTTACCAGCTTTCTGGGTTGTTACACACACTCACACACGCGCACA  
CACACACACACGCGCTCCCTCCTACTGAGG

**SEQ ID NO:34**

26\_STR\_5D12\_T7.ab1.fa

TTTTTTTTTTTTTTTTTTTTTTTTTTGGGGCTTTCGGCGGTTTTTTTTTTTGAAGGAAACCCATG  
GGGGGGGGTTTGGGGGGGGGGGGCCCCCTAAAAATAACCTGGGGTTCAAAGGGCCCCCAAAC  
CTTACTGGAAAGGCCGGGGGACAAAACCATGGTTTCAACCGGACCACTTGTTACCAAGGTGG  
GGGCCCCAAGAGGGCTTCAGGGGGGGGGGGGGGGCCCTTTAAAGAAAGCGGGAAGTGGGGGGG  
GCAAACCCTGGGCCACCTTTGACCCCCTTGAAAAAAAAAAAAAAAAA

**SEQ ID NO:35**

30\_STR\_55C5\_M13F.fa

CTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGACATGCTGTATAT  
ATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAAAATAAAAGTAAA  
TTTTAACAGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGAAAAAAAAA  
AAAAAAGGGCCCCCCTTTAAAGGGTCCCAAATTTTGGGCCCCCTTTTGA AAAA ACTTT  
TTTTTAAACCCCCGGGGGGATTAAATTTTTTTTGGGGG



SEQ ID NO:36

32\_STR\_38D9\_T7.fa

CATTAGTGGAGAGGTGTGCAGTGGGACTGTGAGTGCAACTACTTTAGTGCAGATGTGTGCAG  
TGGGCCTGTGAGTGCAGAATCATTAGTGCAGATGTGTGTAGTGGGCCTGTGAGTGCAGGCAC  
ATTAGTGCAGAGGTGTGAAGTGGGCCTGTCAGTGCAGGCACATTAGTGGAGAGGTGTGAAGT  
GGGCCTGTGAGTGCAGG

SEQ ID NO:37

38\_STR\_42C8\_T7.fa

CAAGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTTTTTGGCGGTTTTATTTTTGGCAGGAAAC  
CCTGGGGGGGGGGTGTGGTGGGGGGGGCCCCCTTAAAAATACCCCGGAGGTCAAGGGGGTTC  
AAAACTTTTTTTAAAAGGCTGGG

SEQ ID NO:38

41\_STR\_8B9\_T7.ab1.fa

CCTTTTTCTCCCCCATGGAAGCGAAGACTCTGAACACAGAGTGGTCTGTATTGTGGGGTTG  
GGGGTTGCCTCCCTATCGCTGGGTAGCCTGAAGCGTGAGTCCAGACTAGACGTGTGAGGGGA  
ATGATCTATGCCGTGCTCGAATAGCTGGGAGGTCCCTTTGTCCCTGAGACCAGAACGGGAAA  
TGGTTATCCGCACTGGGAAGCTGCCTCTCAAGTAGAACTGCCAGATAACTTTCTGGGCTGG  
GAATTCTGTCAACTTAACTGAAGCCTGGCAGCATCCGCCCCAAAGCAATTTAAATTAGGGAG  
AGTCCTGGGCTGTCCCAGGTGCCCTTAGGTAACTTGACAGACTGCTGAG

SEQ ID NO:39

56\_STR\_95H10\_T7\_H07\_063.ab1.fa

CTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGACATGCTGTATAT  
ATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAAAATAAAAGTAAA  
TTTAAACAGTCAAAAAAAAAAAAAAAAAA

[illegible]

CGACGACCCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGA  
CATGCTGTATATATTCTATTGTATTTGTTTCATTGTCCACACTTAACTCAGGTGTGCTAAA  
AATAAAAGTAAATTTTAAACAGTCAAAAAAAAAAAAAAAAAA

44 STR 65E3 T7 D06 057.ab1.fa

SEQ ID NO: 42

CCTCAGTAGGAGGGAGCGCGTGTGTGTGTGTGTGCGCGTGTGTGAGTGTGTGTAAACAACCCA  
GAAAGCTGGTAAGAGCTGCAGAGAGGCAGTGTTTATTAGATTCACACTTAGACACTGATTGT  
GGGTTCTGGTTTAGCTCTTTTATAAGTGTAAGCTATATTTTGTCTGCTTTGGAATAGGATA  
ATTCTTAAGCATCATCTT

55 STR 47E5 T7 G07 055.ab1.fa

- 131 -

**SEQ ID NO:44**

78\_STR\_50B9\_T7\_F10\_090.ab1.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGACCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGAGCTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGAGAGACCCTGCACTTAATGCCCAGCACCACAAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAGAATTATCCTATTACAAAGCAGCAAAAATATAACTT  
TACAATTATAAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGTGAATCTAATAAAC  
ACTGCCTCTCTGCAGCTCTTACCAGCTTTCTGGATTGTTACACACACTCACACACGCGCACA  
CACACACACGCGCTCCCTCCTACTGAGG

**SEQ ID NO:45**

01\_STR\_42H7\_M13F.fa

CCTCAGTAGGAGGGAGCGCGTGTGTGTGTGTGTGTGCGCGTGTGTGAGTGTGTGTAACAACCCA  
GAAAGCTGGTAAGAGCTGCAGAGAGGCAGTGTTTATTAGATTCACACTTAGACACTGATTGT  
GGGTTCTGGTTTAGCTCTTTTATAATTGTAAAGTTATATTTTTGCTGCTTTGTAATAGGATA  
ATTCTTAAGCATCATCTTAAAAT

**SEQ ID NO:46**

01\_STR\_42H7\_M13R.fa

CTTTAATAGTCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCACAAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAAGAATTATCCTATTACAAAGCAGCAAAAATATAACT  
TTACAATTATAAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGTGAATCTAATAAA  
CACTGCCTCTCTGCAGCTCTTACCAGCTNTCTGNGTTGTTACACACACTCACACACGCGCAC  
ACACACACACACGCGCTCCCTCCTACTGAGG

**SEQ ID NO:47**

10\_STR\_48B6\_M13F.fa

CCTCAGTAGGAGGGAGCGCGTGTGTGTGTGTGTGCGCGTGTGTGAGTGTGTGTAACAACCCA  
GAAAGCTGGTAAGAGCTGCAGAGAGGCAGTGTTTATTAGATTCACACTTAGACACTGATTGT  
GGGTTCTGGTTTAGCTCTTTTATAATTGTAAAGTTATATTTTGTCTGCTTTGTAATAGGATA  
ATTCTTAAGCATCATCTTAAAATAGAGGGTATTTTGTCTTTTGTGGTGCTGGGCATTA  
AGTGCAGGGTCTCACATAGGCTAAGCAAGTGCTGTGCACTGAGTTGAACCCCAGCAGAAGTA  
GGTGCTGCAAGTGTAACAAGGCTAAAGGGCTAATGCACACTAGCTGTGCAGGCCGCGTGG  
TCATCGTCTATAANGCCATGGCTAATAAAGTT

**SEQ ID NO:48**

10\_STR\_48B6\_M13R.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCACAAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAAGATTAATCCTATTACAAAGCAGCAAAAATATACT  
TTACAATTATAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGTGAATCTAATAAA  
CACTGCCTCTCTGCAGCTCTTACCAGCTTCTGGGTTGTTACACACACTCACACACGCGCAC  
ACACACACACACGCGCTCCCTCCTACTGAGG

**SEQ ID NO:49**

25\_STR\_5D2\_T7.ab1.fa

CTGGCACCTCATTGCCAAGACTGTCCATTCCAATATTTAGTTCGCCAAGCTTTTGAATAGAC  
CTATTAAGGAATTGCTCAGTAAGATTCTGCTGCTGATCAGGACCGTCCTCTTGGTTCACACC  
TCCTTCAAGTAACATCTGCTGGTATATCTGCCGCTGTTGCTCCTTCTGTTCGAGATGCTGCT  
GATAGCGCAATCTTTGCCTATAATATTCTTGAAATTGTTTCAGTAGAATCTCGAAGCTCGTTT  
TTTTCTTGTTGTTTAGCTGGAAGTGGGTTCTGTGCTCCATTTGCAGGCTCTTTCTCTAACCC  
CGAACCCTGGCACATGGGTTCAATGCTCACAGGCTGCTGGGTCTCAACAGGGGTATCACTTC  
GCTCAGGAGATTCTTCATAGATACTATGACACTCTGTATTCTCAAGCAGAAGACTTCTGCT

**SEQ ID NO:50**

13\_STR\_32D4\_1\_T7.ab1.fa

CGAGGACCAGCACAGCAGTGAGGAGGAGGAAGAAGAGGAAGAGGAGGAGGAGAGTGAAGACG  
GGGAGGAGGAGGAGGACATCACCAGTGCCGAGTCAGAGAGCAGTGAGGAGGAGGAAGGCGGC  
CCCGGGGACGGCCAGAACACCACCCGGCAGCAGCAGCTAGAATGGGACTACTCCACACTCAG  
CTACTAAACACGCGCTCGCCCAGCACCTGCTCTCCAGACTCTCCCAGCCATCTTCCAGCCCC  
ACGGGTCCACGATG

**SEQ ID NO:51**

90\_STR\_32D4\_M13F\_B12\_096.ab1.fa

CGAGGACCAGCACAGCAGTGAGGAGGAGGAAGAAGAGGAAGAGGAGGAGGAGAGTGAAGACG  
GGGAGGAGGAGGAGGACATCACCAGTGCCGAGTCAGAGAGCAGTGAGGAGGAGGAAGGCGGC  
CCCGGGGACGGCCAGAACACCACCCGGCAGCAGCAGCTAGAATGGGACTACTCCACACTCAG  
CTACTAAACACGCGCTCGCCCAGCACCTGCTCTCCAGACTCTCCCAGCCATCTTCCAGCCCC  
ACGGGTCCACGATG

**SEQ ID NO:52**

82\_STR\_50E5\_T7\_B11\_092.ab1.fa

CTTCTTGATGATGCGTAACATGTTCTGGTAGGAGTTCCAAGTGTTGTGAGCCACCAGGAGAT  
CATGGCTGCCGGGCAGCAGCTTGATGAGGGCAGAGCACGAACCGGAGCCCACGGAAGGCTTG  
GTGTTGGTCTTATTCAGGGCTGGCTCTAGGTCTTCCAGATCTCCAGAGATCTGCAGCAGGAG  
GAACCCCAAGGGTTTGATGTTGAACCTCCCAGTTGGGAAGGTTAAACGGCCTTCATAGCTGT  
CCTCCAGGCCTTTCAGCTGCAAGAGGGTCAGCCGCACCTGGTGCCAGTATGGCGAGTCCGGG  
CTAAGCTCCATTTCCCTCTGCATCCACTCCAGGTTGGCCTCCAGGAAGCTCTTGAGCTTCTC  
ACAGTAGCCGACTTCG

|      |      |
|------|------|
| 0.0  | 0.0  |
| 0.1  | 0.1  |
| 0.2  | 0.2  |
| 0.3  | 0.3  |
| 0.4  | 0.4  |
| 0.5  | 0.5  |
| 0.6  | 0.6  |
| 0.7  | 0.7  |
| 0.8  | 0.8  |
| 0.9  | 0.9  |
| 1.0  | 1.0  |
| 1.1  | 1.1  |
| 1.2  | 1.2  |
| 1.3  | 1.3  |
| 1.4  | 1.4  |
| 1.5  | 1.5  |
| 1.6  | 1.6  |
| 1.7  | 1.7  |
| 1.8  | 1.8  |
| 1.9  | 1.9  |
| 2.0  | 2.0  |
| 2.1  | 2.1  |
| 2.2  | 2.2  |
| 2.3  | 2.3  |
| 2.4  | 2.4  |
| 2.5  | 2.5  |
| 2.6  | 2.6  |
| 2.7  | 2.7  |
| 2.8  | 2.8  |
| 2.9  | 2.9  |
| 3.0  | 3.0  |
| 3.1  | 3.1  |
| 3.2  | 3.2  |
| 3.3  | 3.3  |
| 3.4  | 3.4  |
| 3.5  | 3.5  |
| 3.6  | 3.6  |
| 3.7  | 3.7  |
| 3.8  | 3.8  |
| 3.9  | 3.9  |
| 4.0  | 4.0  |
| 4.1  | 4.1  |
| 4.2  | 4.2  |
| 4.3  | 4.3  |
| 4.4  | 4.4  |
| 4.5  | 4.5  |
| 4.6  | 4.6  |
| 4.7  | 4.7  |
| 4.8  | 4.8  |
| 4.9  | 4.9  |
| 5.0  | 5.0  |
| 5.1  | 5.1  |
| 5.2  | 5.2  |
| 5.3  | 5.3  |
| 5.4  | 5.4  |
| 5.5  | 5.5  |
| 5.6  | 5.6  |
| 5.7  | 5.7  |
| 5.8  | 5.8  |
| 5.9  | 5.9  |
| 6.0  | 6.0  |
| 6.1  | 6.1  |
| 6.2  | 6.2  |
| 6.3  | 6.3  |
| 6.4  | 6.4  |
| 6.5  | 6.5  |
| 6.6  | 6.6  |
| 6.7  | 6.7  |
| 6.8  | 6.8  |
| 6.9  | 6.9  |
| 7.0  | 7.0  |
| 7.1  | 7.1  |
| 7.2  | 7.2  |
| 7.3  | 7.3  |
| 7.4  | 7.4  |
| 7.5  | 7.5  |
| 7.6  | 7.6  |
| 7.7  | 7.7  |
| 7.8  | 7.8  |
| 7.9  | 7.9  |
| 8.0  | 8.0  |
| 8.1  | 8.1  |
| 8.2  | 8.2  |
| 8.3  | 8.3  |
| 8.4  | 8.4  |
| 8.5  | 8.5  |
| 8.6  | 8.6  |
| 8.7  | 8.7  |
| 8.8  | 8.8  |
| 8.9  | 8.9  |
| 9.0  | 9.0  |
| 9.1  | 9.1  |
| 9.2  | 9.2  |
| 9.3  | 9.3  |
| 9.4  | 9.4  |
| 9.5  | 9.5  |
| 9.6  | 9.6  |
| 9.7  | 9.7  |
| 9.8  | 9.8  |
| 9.9  | 9.9  |
| 10.0 | 10.0 |

CGACGACCCTGCCTCCCAGTCTTCTCTTTTCTATAGCATGGCTTTAAAGCCTGCCTCCTTGA  
CATGCTGTATATATTCTATTGTATTTGTTTCATTGTCCCACACTTAACTCAGGTGTGCTAAA  
AATAAAAGTAAATTTTAACAGTCAAAAAAAAAAAAAAAAAAAG

## 14\_STR\_39E12\_M13F.fa

SEQ ID NO: 55

12\_STR\_S.60\_6\_T7.fa

SEQ ID NO:56

31\_STR\_59E12\_M13F.fa

GGAGGCGGAGGATGAGTGCCAACACCCTCGACTGCCTGCTCTAGGCGATGAGGTTATAGAAA  
GGGAAGAGTTTCAGGATATGGCTGTGTGTGTAGGGGGCATGAAGGCAGGTTATAAACAAATA  
TATCCCAGCTGCCTAAGGAGTTGGTTGCTGTCCTCACTCTTAACAATCCAGTGGGATCTAGT  
GATCAACATCAGTTTGGAGACTCTAATCTTCATGCTCATGTATTCATCCTGACATTTTAACT  
TGCTATTCTGTGTGACCGAATACTTGTTATACCTAGAATACGACCTAAGTGCCTTCTGATTT  
CTCATGATTTCTTTTCAAACAGGGTCTAAGTCATCTACTTGCATTTT

**SEQ ID NO:57**

34\_STR\_59E12\_1\_T7.ab1.fa

GGAGGCGGAGGATGAGTGCCAACACCCTCGACTGCCTGCTCTAGGCGATGAGGTTATAGAAA  
GGGAAGAGTTTCAGGATATGGCTGTGTGTGTAGGGGGCATGAAGGCAGGTTATAAACAAATA  
TATCCCAGCTGCCTAAGGAGTTGGTTGCTGTCCTCACTCTTAACAATCCAGTGGGATCTAGT  
GATCAACATCAGTTTGGAGACTCTAATCTTCATGCTCATGTATTCATCCTGACATTTTAACT  
TGCTATTCTGTGTGACCGAATACTTGTTATACCTAGAATACGACCTAAGTGCCTTCTGATTT  
CTCATGATTTCTTTTCAAACAGGGTCTAAGTCATCTACTTGCAATTTTGCCAGAAGCTCTCCG  
GAAAACAAAGCATACAAAATCTACTTGCTATTTCTCT

**SEQ ID NO:58**

45\_STR\_8G3\_T7.ab1.fa

CAAGGCTACAGGCCTAGGCCTAGGGATACAACAGCGAAGGAACCACTCTGGTCTCAGCCCAA  
GCAGCACAGCTGGAGCGCAGCTCTCTTCTCGCTTTCATCTTTACGGAGACTTGGGTGGAAGG  
GCGGGCCCTTTGACATCTTTGTCGTCGGCCTTGGAATCAGAGATGGCCAGCTTATTCTGCAG  
GGAGCACAGCAGCTGGAGGTAGCTCTGGTTCCTCTGCAGCTTCTCCTGCTCCTGTCCTGCTT  
GCTGCTTCAAGGTTTCAAGTTCCTGGTGAGAACCATCAAGCTTCTCCAGAGCTCTCTTCCGG  
CGTCTCTTGACCTCAGCAGAAATCTTTGTCAGATTCTGCAAACGCTTCTGCTGCAGCACCCA  
CTGCTTCTGAGCTAACTGCAGTTTCTCCTCAAGGACTCGCTTCTTAGCCTCAAGTTGCTCAA  
AAGCCTTCTGAAGCTCGGCG

**SEQ ID NO:59**

54\_STR\_15G9\_T7\_F05\_046.ab1.fa

TTTTTTTTTTTTTTTTTTTTTTTTTTTCCCTTTGGGAGGTTTTTTTCAAAAACCCCGGAAAAATTG  
GCCCTGGTTCCGGGGGGTTTTTGAAAAAATAAAAACGGGAACCAACCGGGGGGGGGGAAA

**SEQ ID NO:60**

95\_STR\_102A2\_T7.ab1.fa

TTTTTTTTTTTTTTTTTTTTTTTTTTTCCCTTTGGGAGGTTATTTTCAAAAAGCCCGGAAAAATTG  
GCCCTGGTTTCGGGGGGTTTTTGAAAAACCAAAAACGGGAACCAACCGGGGGGGGGGAAA

**SEQ ID NO:61**

24\_\_STR\_S.35\_6\_T7.fa

GGAGAGAATGGAGGAGGCGGTCATGTCAATTCTGCACAACCTTAGAGATGAAGAACACTGAGA  
TCCATGAGAACAACCGTAAGGTGAAGAAGGAGATTACCTTCTCTAGAAACCTGCTCAGCCAG  
CTCCTGATGGAGAACACATGTAGGAAGAAGTTGCTCCCACTGAAGCAGGAGAGCAAGGAGGG  
ACATCTTGAGTGTGCAATGAACCAGAAATATTTGGTTGACTTCAACAAGAAAGATAAAGACC  
AGCAACCTCCAGACCCAGCATCATCAGGTCTCAGAAAGTGCAAGAGAGCTGGAATTGGACAC  
ACAGCAGTAAGAGAGCTTCCTGAAGAATAAGTTGCTTTCTCACGAGTCCCTGATGACAAACA  
TCCTGAACGAAAACATCACTTGAGAGACAACCTGGGGGACCGCCTTTCATTATGTGTGCTAG  
AGGAGAAACAGCAATACATCTGTGCTTCTAAATGTTTCGTTAAGAATATGCTGTTTAGAAATA  
TTTTTGTTATGATTNTAAATGAGGTNTCTTTTTGTGGTTCATATTTATATGGTCTTGGTACT  
ATNTTTACTTTCANATATTTTTTAAATATTTNTATTCATTATTNTAAATCCTGTTGGTGGA  
AATGATTCAATATGAATAAATATGTGTTTATTCTTGAAAAAAAAANAAAAA

**SEQ ID NO:62**

20\_STR\_77E1\_T7\_D03\_029.ab1.fa

GAGGAGGCGGTCATGTCAATTCTGCACAACCTTAGAGATGGAGAACACTGAGGTCCATGAGAA  
CAACCATAATCTGAAGAAGGAGATACCTTCTCTAGAAACCTGCTCAGCCAGCTCCTGATGGA  
GAACACATGTAGGAAGAAGTTGGTCCCACTGAAGCAGGAGAGCAAGGAGGTACATCTTGATT  
GTGCACTGAACCAGAAATATTTGGTTGACTTCAACAAGAAAGATAAAGACCATCAACGGCCA  
GAACCAGCATTATCAGGTCTCAGAAAGTGCAAGAGAGCTGGAATTGGACACACAGCAGTAAG  
AGAGCTTCCTGAAGAATAAGTTGCTTTCTCAGGAGTCCCTGATGACCAACATCCTGAATGAA  
AACAGCACTTGAGAGACAACCTGGGGGACCGCCTTTCATTATGTGTGCTAGAGGAGAAACAG  
CAATACGTCTGTGCTTCTAAATGTTTCGTTAAGAATATGCTTTTAGAAATATTTTTGTTATGA  
TTTATTTGAAGTTTTCTTTTTGGTGGTTCATATTTATATGTTCTTGTTACTATTTTTACTTT  
TCAATATTTTTAATATTTTTTATTCATTTAATCCTGTTTTGTTGGAAAAATGTATTTGTTATG  
AATAAAAATTGAATTCTAAAAAAAAAAAAAAAAA



**SEQ ID NO:63**

85\_STR\_77E1\_T7\_E11\_086.ab1.fa

GGAGAGAATGGAGGAGGCGGTCATGTCAATTCTGCACAACCTTAGAGATGGAGAACACTGAGG  
TCCATGAGAACAACCATAATCTGAAGAAGGAGATTACCTTCTCTAGAAACCTGCTCAGCCAG  
CTCCTGATGGAGAACACATGTAGGAAGAAGTTGGTCCCACTGAAGCAGGAGAGCAAGGAGGT  
ACATCTTGATTGTGCACTGAACCAGAAATATTTGGTTGACTTCAACAAGAAAGATAAAGACC  
ATCAACGGCCAGAACCAGCATTATCAGGTCTCAGAAAGTGCAAGAGAGCTGGAATTGGACAC  
ACAGCAGTAAGAGAGCTTCCTGAAGAATAAGTTGCTTTCTCAGGAGTCCCTGATGACCAACA  
TCCTGAATGAAAACAGCACTTGAGAGACAACCTTGGGGGACCGCCTTTCATTATGTGTGCTAG  
AGGAGAAACAGCAATACGTCTGTGCTTCTAAATGTTTCGTTAAGAATATGCTTTTAGAAATAT  
TTTTGTTATGATTTATTTGAAGTTTTCTTTTTTGGTGGTTCATATTTATATGTTCTTGGTACT  
ATNTTTACTTTCAAATATTTTAAATATTTTATTTCATNTAATCCTGNTTTGGTGGANAAATGT  
ATTTTGTATGAATAAAAAATGGATTCTAAAAA

**SEQ ID NO:64**

92\_STR\_15C5\_T7.ab1.fa

TGTTTTTTTTTTTTTTTTTTTTTCTTGCTATAGAGACTTGACTCTTTGCTCAACACCATGCCCC  
ACGTTTGGGAGAGGAAGATGGCAAAGACTGAAAGCACGATGCCGGGGGTATATTGCAACACC  
ATCAAAACAGAGCCCATAGCTGCCTGCCCCCGGTATAGTTAGAGACAGGCCGTGTGTTACC  
TCTACAATTAAAACGTACTTGTAGACTTGGNGGTAAGGGACCCTCCACCTATTTCAAATTCT  
GCCAGAAGACAGAAGGATGTTCACTCACCAATCAAGAACCCTTGGCTTCCTACTCCTGACTT  
TGTCGCTGGANTGCTGGCTACAGTACCAAACCTATGTAGAACTATCATCTTCAGTCGAGCCT  
CGGTGTAATTGGCAGAGATTCTGAGTCAACTACCATGCAGAGATCTCCGACCCTGTCTAGAG  
ACATTTACTAGAAGCTGTCTTACAGCCCTGTCTTTGAGGCGAGACACATACCAAATGTATGT  
TCCCCCAAGAGGAGACACACTCTATCTTCAGATATCTGTGAACCCANNNNNNAAAAAAAAA  
CCAGCCCGCCCCGGGGGGCGCACCTTGAATGACACAGGGGACATGGNTGGCTGCCCCGTATA  
GAAAGCCCCAGCTTNAACACAGNAAATGTG

**SEQ ID NO:65**

68\_STR\_11D5\_T7.ab1.fa

CAGAAGCAGTTAGAAGTCATCAATGCTATTGTGGACCCCAGCATGAACCCCGACCTACTGAT  
GGGAAACAGGGCTCCTGCAGGGTCCGTTTCAGCCAGGACTTGGGAAAGCCCGGCCAGCAGCTC  
AGAGCTCAGCTTCTCCTGCCTCGGTGGACACCTTGCTGCCAGCCATGCCTCTCAGGAGCTTC  
CCACAACGGGCAAACCTGCGGGCCCCCGGCCTCCCGGAGCCTGCCTTCCTTCCTGATGCTGA  
GAGGTTTCTGATCTAAGCTGTGAGGCGGGCAAGGCCAGCCTTCTTGTGCGCGTGTGTCCTGT  
GCATCACCCATCCCATGGCCCCACCTGCCTGGCTCAGGCAGTTCTGTGAAAACCCACATGTG  
CCATAACCCATGGACGGGTGCCTCCCATTTCCAGGCCTCTCCTCAGCCAGCACCCGAACCAC  
TTCATCCAGCTCATGGCTACCCCATCCCCACAGACCTCCTAGCCCAGCCC

**SEQ ID NO:66**

10\_STR\_71H11\_M13R.fa

TTTTTTTTTTTTTTTTTTTTTCCAAAAAACAGTAAATTTAATTTCTAAAGAGGGTTAAAT  
TTTCCTTTCCCCCCTAAAAATTAGGGAGATTCCAGTGTTAAAAATGTCCTCAAAATTTTAT  
GACCCTAA

**SEQ ID NO:67**

35\_STR\_71H11\_M13F.fa

GAGACCAAGAAGCCTGGCATGAACTTGCAGAACTTTATATCAATGAGCATGACTATGCCAAA  
GCAGCCTTATGCTTAGAGGAGCTGATGATGACAAATCCACATAACCACTTGTACTGTCAACA  
GGACGCAGAGGTCAAATACACCCAAGGTGGACTTGAAAACCTGGTGCT

**SEQ ID NO:68**

33\_STR\_60H2\_T7\_A05\_036.ab1.fa

AGGTTGATTCCTAGCAGCCACATGGAGCCAAATTGTCTGTAACTCTAGTTCCAGGGTCTCCA  
ACATCTACCCTTGACCATGGCTGGCACTGTGTGTATGTGGTGCACAAACACACGAAGGCAGA  
ACACCTAAAAGGGGTATATGTGCTATCATTTAAGTGTCTCTTAAATGAAAAGCCTTCAACCA  
GGATTTTCATCATTAGAAATAGAATTGATGTCCACCCTGTGTCATGGGAACTGAGAGGAAGGG  
CAGTATAAATCTGAGAGGTTCTTTGTGTGGTGGACCCCGAAGAAGAAAGCCCCATGGCTGA  
ACAGCTGTTGTCTCCTCCTACCCACAGCTTTCCTAATAAAGGGATTGTTATTTTGAAAAA  
AAAAAAAAAA

**SEQ ID NO:69**

16\_STR\_8H4\_M13F.fa

CTTCTCTAACATGTCGGTGGGCGTCACATCAGTGTTGACCTACTCTTCCGTCT

**SEQ ID NO:70**

29\_STR\_8H4\_M13R.fa

CAGGAGGCCCCAAGAGCTGCAGGCTAGTGGGTCCAGGCTAAGGACTTGGGAAGTGGGGTTCA  
GCTCAGGCTTGGCTGCAGATGTTAGATGCAGAGACTTCTGACCTGTCTAACAATTAGACCTG  
TTACTGCCAGTGTAGGGACAGATGGTTTCTTTGACTTCAAGAAGCCCATTAGTGGAAGACA  
TCTGACTTGGTATGTTACTAAGACAGCAATAACCCTGTAG

**SEQ ID NO:71**

06\_STR\_54A11\_T7\_F01\_014.ab1.fa

TGGAGCTAATTGCGCGCGGCCGCGGTACGACGAACCTGCGCCTATTAGAATGAGTGGAATGC  
CTCCATCCCTCAATCGTCTGAAGTGATCTGTTAGCTAAGAGCATGGCTCCCAGGGGGCCCGTC  
CTCAGCCACTTGTACTCCTGGGCTAGCCTTGTCATAAGATGCCACCTGGACACTGATGGAGT  
ATTGGAGCAGCAGGCCTGGCTCCTGACCTAAACTGACAGCTCAGACTCTGCAGGAGTCTGCT  
GGAAATCCAACATCTTACTCAACAACTGCCGGCCAGATGGGCGTGGGCGAGGGTGGGCCAAG  
ACAGGGTGCCTTATACTTTGTTCTAGCACATTCCAAGGTATTTTCAGGGCGTCAGCACCTGGA  
ATCCCATATGTCAAAGCCAGTATTAAAGCAAGTTTATGCATTCCTCGAAAAAAAAAAAAAAAAA

SEQ ID NO:72

55\_STR\_102F3\_1\_T7.ab1.fa

AGCTAATTGCGCGCGGCCGCGGTACGACGAACCTGCACCTCTGTCTTCTGCCCCCCTCCCTT  
GGACACATTCACACCTACCTCTAGGAGAGATTGGGGATACCTTTAGCTCTCTGACCGAGGAC  
CAAGCCTCTGACTCAGACCTGTATATGGCACCAAGTTACAACCCTTTCCAAAAGGCTCTTCC  
CAGGGGAGCACTTGGCATTCTTCTGGCAGACCCCATTTATCCCTTTCCCAATGCCCTCTCTCTG  
ACTTTGAGCATCAGGCCAGACTGCCTGAGATCTGGTGCCTGCCACAGTGCCTGGCCAGGGGT  
GAGGCTTTGGTTACCTTCTGTTGTATTTGTGTGGATAGATGGGCAGCTAACAATTGTAACAG  
GTCCTAGGGTCAGATGTGGATGGTCTCATAACAGTGGCTTCTAATGGAGAATGTATCTGAACC  
CATATCAAATCACCTCACTGTATTTTTCTCTTCCCTAACCTGTAACTAGCCATTGTTGTAG  
GGGGCTTTTGCACAGTGCCTCACTGTCTCACATGCTAAGTAAAGGAACTCCTGCTTTCAAAA  
AAAAAAAAAAAA

SEQ ID NO:73

21\_STR\_S.54\_5\_T7.fa

ACCTCTGTCTTCTGCCCCCCTCCCTTGGACACATTCACACCTACCTCTAGGAGAGATTGGGG  
ATACCTTTAGCTCTCTGACCGAGGACCAAGCCTCTGACTCAGACCTGTATATGGCACCAAGT  
TACAACCCTTTCCAAAAGGCTCTTCCCAGGGGAGCACTTGGCATTCTTCTGGCAGACCCCAT  
ATCCCTTTCCCAATGCCCTCTCTCTGACTTTGAGCATCAGGCCAGACTGCCTGAGATCTGGT  
GCCTGCCACAGTGCCTGGCCAGGGGTGAGGCTTTGGTTACCTTCTGTTGTATTTGTGTGGAT  
AGATGGGCAGCTAACAATTGTAACAGGTCCTAGGGTCAGATGTGGATGGTCTCATAACAGTGG  
CTTCTAATGGAGAATGTATCTGAACCCATATCAAATCACCTCACTGTATTTTTCTCTTCCCT  
AACCTGTAACTAGCCATTGTTGTAGGGGGCTTTTGCACAGTGCCTCACTGTCTCACATGCT  
AAGTAAAGGAACTCCTGCTTTCAAAAAAAAAAAAAAAAAAGGGCCCCCTTTAAACGG

**SEQ ID NO:74**

19\_STR\_21A8\_T7.ab1.fa

TTTTTTTTTTTTTTTTTTTTTTTTTTTCATGGGAAAAAAAAAAGGGTTTAAAAAATGGCTTG  
AAACCCGGGGGGGGGGGGGCCAAAACCTCCTTTTTTAATAAACCTTTACCGAAGAAGGGTTT  
TCAAAAGGA  
AA

**SEQ ID NO:75**

22\_STR\_21H9\_T7.ab1.fa

TTTTTTTTTTTTTTTTTTTTTTTTTTTCGAAAAAAAAAAGGGGTAAAAAAGGGGTTGAAACC  
CAGGGGGGGGGGGGGGCCAAAACCTCCTTTTTTAATAAACCTTTACCGAAGAAGGGTCCTCCAA  
AGGAA

**SEQ ID NO:76**

24\_STR\_31G6\_T7

CGAATACAGACCGTGAAAGCGGGGCCTCACGATCCTTCTGACCTTTTGGGTTTTAAGCAGGA  
GGTGTGTCAGAAAAGTTACCACAGGGATAACTGGCTTGTGGCGGCCAAGCGTTCATAGCGACGT  
CGCTTTTTTGATCCTTCGATGTCGGCTCTTCCTATCATTGTGAAGCAGAATTCACCAAGCGTT  
GGATTGTTACCCACTAATAGGGAACGTGAGCTGGGATTAGACCGTCGTGAGACAGGTTAGT  
TTTACCCTACTGATGATGTGTTGTTGCCATGGTAATCCTAGTCAG

**SEQ ID NO:77**

65\_STR\_31G6\_T7.ab1.fa

CGAATACAGACCGTGAAAGCGGGGCCTCACGATCCTTCTGACCTTTTGGGTTTTAAGGCCAG  
GAGGTGTGTCAGAAAAGTTACCACAGGGATAACTGGCTTGTGGCGGCCAAGCGTTCATAGCGAC  
GTCGCTTTTTTGATCCTTCGATGTCGGCTCTTCCTATCATTGTGAAGCAGAATTCACCAAGCG  
TTGGATTGTTACCCACTAATAGGGAACGTGAGCTGGGATTAGACCGTCGTGAGACAGGTTA  
GTTTTACCCTACTGATGATGTGTTGTTGCCATGGTAATCCTGCTCAG

SEQ ID NO:78

69\_STR\_11E11\_T7.ab1.fa

CTGCAGATATCGGGACTACCGGGACCCGCCGCATTCTTTGGCTCCCTATGGCTACACACTGC  
AGTTCTGGCATGTCCTCGCAGCTCGGCTGGCTTTCATCATTGTGTTTGAGCACCTCGTGTTT  
TGTATAAAGCACCTCATTTCTATCTGATACCAGACCTCCCGAAAGATCTAAGGGACCGGAT  
GAGGAGAGAGAAG

SEQ ID NO:79

09\_STR\_40E1\_T7.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCACATAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAGAATTATCCTATTACAAAGCAGCAGCAGATATAACT  
TTACAATTATAAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGCGAATCTAATAAA  
CACTGCCTCTCTGCAGCTCTTACCAGCTTTCTGNNGTGGTACACACACTCACACACGCGCAC  
ACACACACACACGCGCTCCCTCCTACTGTGNG

SEQ ID NO:80

16\_STR\_41A8\_T7.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCACAAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAGAATTATCCTATTACAAAGCAGCAAAAATATAACTT  
TACAATTATAAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGTGAATCTAATAAAC  
ACTGCCTCTCTGCAGCTCTTACCAGCTTTCTGGGTTGGTACACACACTCACACACGCGCACA  
CACACACACACGCGCTCCCTTCTACTGAGG

**SEQ ID NO:81**

24\_STR\_41D5\_T7.fa

CTTTAATAGCCATGGCCTTATAGACGGTGGCCACGCGGCCTGCACAGGCTGTGTGCATTAGG  
CCCTTTAGCCTTGTTTTACACTTGCAGCACCTACTTCTGCTGGGGTTCAACTCAGTGCACAG  
CACTTGCTTAGCCTATGTGAGACCCTGCACTTAATGCCCAGCACCACAAAAAGAAACAAAA  
TACCTCTATTTTAAGATGATGCTTAAGAATTATCCTATTACAAAGCAGCAAAAATAATAACT  
TTACAATTATAAAAGAGCTAAACCAGAACCCACAATCAGTGTCTAAGTGTGAATCTAATAAA  
CACTGCCTCTCTGCAGCTCTTACCAGCTTTCTGGGTTGGTACACACACTCACACACGCGCAC  
ACACACACACACGCGCTCCCTCCTACTGAGG

**SEQ ID NO:82**

72\_STR\_75D9\_T7\_H09\_079.ab1.fa

ATGCAGGATCATGTGTGTGTACAACGAATGCCTTTTCCTTCATGCAGCACTTGGACGGGGGT  
TTGGTTGGCGTTTTTGCATTATCACACAATTGGAGCTCCTTACTGTGTGAGCCAGCCTTCTCG  
ACGCCCCGGTGATTTTTTTTTTAAAGATGTCATGTCTGACTCAATACAATAATGTCATCTTAA  
ATTTTGGCCCCCTTATTTGAATACTATAGCTACAATCAAATAATTTGTTAAATTGCTTATAT  
TAAGAGTAAACATGGATATGACATTGGTTGTCCACCTGCAAACCTTTAGAACAATTTACTGTA  
GCTTGATGCTTAGCCAATTTTAAGTGAGGAATTCAACAT

**SEQ ID NO:83**

64\_STR\_31G3\_T7.ab1.fa

TTCTCCTCCTCACTGCTCTCTGACTCGGCACTGAGGATGTCCTCCTCCTCCTCCCCGGCTT  
CACTCTCCTCCTACTCTTCCTCTTCTTCCTCCTCCTCACTGCTGTGCTGACCCTCG

**SEQ ID NO:84**

52\_STR\_98F5\_T7\_D07\_061.ab1.fa

TTGGAGCTAATTGCGCGCGGCCGCGGTACGACGACCCTGGCACAGAGCCCATGGCGCCAGGA  
CAGCAGGCTAGCCTTGGGACCTTTTTGTGGAGTAGTTTGCAGTGAGGTAACGGTGCAATAAA  
GTACAGCAAGCGTGAAAAAAAAAAAAAAAAAGG

[illegible]

GAGCTAATTGCGCGCGGCCGCGGTACGACGAACCTGCAGCTCTGTCTTCTACATTACATTTA  
TGGCTCCTTAAACTGATTGCCTAACCAACCAAGGGCAATTCCCATCCATCCATCACATGGGT  
TGTGGGAAGGATGCAGCCATGGTGTGCAGCTTCCTTCATGAAGGATTATCTGGCCATGGTAC  
CTGACTGCTTCACAACTTGCTGTCACTCTGGGTGAGATAATGTGTCTTTAAAAACAGTCCCT  
GTGGCAGGTCACTGGGATATAATGTACAACATTCTTAGCCATCATTTCTTTTCTTTTTTTTT  
CTTTTTTTTTGGTTTGCCCTGAGAGACTCCCAGTGGTTTCTACTGAGGGCTAAAGGGACGAGC  
TGTTCCCTCATTGAGCAAGACCGTTCGCTGTTTCATGATGTGTTTTATGATGGCTTCTTTGGG  
AGTTGCTTCTTCAACAGTCTCAACTGTGCTGNGGGATCTCCTGATGCTGACTTTTGACCTTC  
GTTTTATTAAACTAATTAGTGAAAAAAAAAAAAAAAAA

43\_STR\_65B9\_T7\_C06\_049.ab1.fa

GGTACGACGACCCTGCGATCTGAGACCCACTTTGCAGACATGTGCACAGATGTGTTCCATT  
CCCTATTTCTGCTGTAGAGAAACAAGTAAATTTTCTTAGAGAATGAAAAAAAAAAAAAAAAA

46\_STR\_12B5\_T7\_F04\_042.ab1.fa

AATCTTTGGACGAGAGCGTGCCATCATGCTGTTGGAAGGCCAGAAAGTGGTCCCCCGGAGGA  
CACTGGCCACGGGCTACCAGTATTCCTTCCCAGAGTTAGGAGCTGCCTTAAAGGATGTTGTA  
ACCTAAGTAGAGAAGGGAGCCCCAAGGCAGGAGGTGGGGCCTGTTCCTGCATTCTGAGAAGT  
GAGTCAGGTGATTGCTGTGCTTGACTGAGATCAGAAGCCATCTGGCTCTTAGACTCTCTCTC  
TCTCCCCTTTCTTCCCATGTTCTGTTGATCCACCTCTCTCCAAGAACTCCAGTCTCAAGGA  
TCTAATCTCATTCTAACCTTAACCTCCTCAACTTCTT



**SEQ ID NO:88**

73\_STR\_12B5\_T7.ab1.fa

AATCTTTGGACGAGAGCGTGCCATCATGCTGTTGGAAGGCCAGAAAGTGGTCCCCCGGAGGA  
CACTGGCCACGGGCTACCAGTATTCCTTCCCAGAGTTAGGAGCTGCCTTAAAGGATGTTGTA  
ACCTAAGTAGAGAAGGGAGCCCCAAGGCAGGAGGTGGGGCCTGTTCTGCATTCTGAGAAGT  
GAGTCAGGTGATTGCTGTGCTTGACTGAGATCAGAAGCCATCTGGCTCTTAGACTCTCTCTC  
TCTCCCCTTTCTTCCCATGTTCTGTTGATCCACCTCTCTCCAAGAACTCCAGTCTCAAGGA  
TCTAATCTCATTCTAACCTTAACCTCCTCAACTTCTTGTGGCTTCTGTGTCACATTGTTGCC  
CTGGTTCTCCTACATGCTATGTAGACAAAGTTCTACAGTTGTGGCAATAAAGGTAGACTGTG  
TCTG

**SEQ ID NO:89**

08\_STR\_86B5\_T7\_H01\_015.ab1.fa

TGGAGCTAATTGCGCGCGGCCGCGGTACGACGAACCTGCGACGTGAGACCGTTTTAATAAAA  
GTGCCACCTTACAAAAAAAAAAAAAAAAAAAA

**SEQ ID NO:90**

43\_STR\_80G8\_1\_M13F.fa

CTCGTAGAGGCACAGCGAATATGCGAAATTGCACTCTCGCAAACAAGACTCCGTCAACATAC  
CTAAGACATAGAGACGCCCCGGGGGAGCTAGGTCAAAGGCATGGAACCAGCGGTGCGCCG

SEQ ID NO:91

31\_STR\_77A12\_T7.fa

GGTCGACGGTAGCCGCGGCAGCCGAACACGCACAGAGCTGCGCTTTCCCCAAAGCGAAGGGT  
AGGAAATGGAAAGGGCCTTGCGGCCGGGAATGGCTGAGCTAGGCTCCTGCAGCTACCAACTC  
CAGGCAGTTTAAAGCACCTTTCTTGACGCCCCGACCTCGTGAGTGGAGTCTAGCTGGAGAA  
ACAAAGGCTCTTCTTTGTAGAAAGAACTCTCCCACAAAGAGAGAGAAAAATTCTCTCAAGAGAA  
GCTGTGACTTGCCCTTGGGTCACACGTGGCAAACCTCTCCCGTGAACCCGAGACCCAGAGCCA  
AGGCCTTTATCTCCGTAACAGTTATCCCTGTAAAGAATTCTCTTGAGTCCTTTACAGTTA  
CTCTGGCATCTCATATGTATGCGTATATGCATCAGATGAACTGGTTTCCATCCCTTTGATGT  
TCTATAAATAGACTCTATCACGGANNAAAAAAAAAA

SEQ ID NO:92

81\_STR\_77A12\_T7\_A11\_084.ab1.fa

AGGGTAGGAAATGGAAAGGGCCTTGCGGCCGGGAATGGCTGAGCTAGGCTCCTGCAGCTCCC  
AACTCCAGGCAGTTTAAAGCACCTTTCTTGACGCCCCGACCTCGTGAGTGGAGTCTAGCTG  
AAGAAACAAAGGCTCTTCTTTGTAGAAAGAACTCTCCCACAAAGAGAGAGAAAAATTCTCTCA  
GAGAAGCTGTGACTTGCCCTTGGGTCACACGTGGCAAACCTCTCCCGTGAACCCGAGACCCAG  
AGCCAAGGCCTTTATTCCCGGATAACAGTTATCCCTGTAAAGAATTCTCTTGAGTCCTTT  
ACAGTTACTCTGGCATCTCATATGTATGCGTATATGCATCAGATGAACTGTTTTCCATCCCT  
TTGATGTTCTATAAATAGACTCTATCACGGAAAAAAAAAAAAAAAAA

SEQ ID NO:93

23\_STR\_91B4\_T7\_G03\_023.ab1.fa

GGAGCTAATTGCGCGCGGCCGCGGTACGACGAACCTGCGCATGGATACGAAGTGGGGTGGGA  
GAAGCTCACCCACTGTGACTTTTAAGAACTCCTGTGTGATGGGAGGAAGGTACAGGTTTCCTC  
ACCATCCCCAGCCCTTCCTCTGGATGAGGATGTGAAGGACAGAGGCATCTCCAAAATGGGCT  
ACTTTTGGTATAGACCTTAGGAGTGTGGGGCTGGTGTAAGCTCTTGGTTCCTTTAAAAGGAG  
AATTTTATTTTGTGTTTGTTCAGTTTAGACATTCCTGGATGCAGTTTGATTGGTTAAATTAAA  
AGTTGATTTTTTTTTTCCAGTAAAAAAAAAAAAAAAAA

SEQ ID NO:94

FUNDII1.36

TTAAAACTGCTTACCAGTGGCTGTCTGCGCTGCGGAAGGTGAGCATCAACAACACGGGACTG  
TTGGGCTCCTACCACCCTGGCGTCTTCCGTGGGGACAAGTGGAGCTGCTGCCACCAAAAAGA  
GAAGACAGGTCAGGGCTGCGATAAGACCCGGNCACGGGTGACCCTGCAGGAGTGGAATGACC  
CTNTTGACCGTGACCTTGAGGCCCANCTCATCTACCGGCACCTGCTGGGCGNGGAGGCCATG  
CTGTG

SEQ ID NO:95

FUNH1III.12

CNCCCCAGGCTAAAGAGCAGGTGGGTGGGCTTGGACTGGGCGTGCTCCATGGCAGAGATCCT  
GCGGTCACTCAACAGTGCCCCACTGTGGCGTGATGTCATTGCCACCTTCACAGACCACTGCA  
TCAAGCAGCTGCCATTCCCTTATCGTCGTCGTCCT

SEQ ID NO:96

FUNGIII1.13

GATAAGAGAATCCTTCATCTTTGACCTGGCTTTTTTTCGCCCTTTGGGAGATAAAGGTCCT  
CTCCACCCTCTACTAACACTCTGCACCCAAGGCCTTATCCTTTGGGGTCACCAGCTCCTTGG  
CCATTTCTATGTGATTTCCCCCACCCTCTGAGTTCCAGTTTCCTCTGGGCTCCAATCTCCA  
GTCCCTGGCGGATCTGGTCAGTCCCACCCCTAGG

SEQ ID NO:97

FUNDIII2.22

GATAAGCACACGGACCTTGAGCTGCTCCACGTGCCCCAGCACCTGAGCCCGCTCTTCTTCCA  
GGGCTAGCACCTCTCCCTGGAGCTTGGTGCTAGGTGCATCTTCGTGCTCCTGCTGGGTGCTC  
TCAGTGCCGCTGCACTCCTCCTTGAGATTTTCCTCATCTGAGCGCTCCATACTCTCCCATAG  
GCGTTGGGTGGCAACTAGTTAGTTAG

**SEQ ID NO:97**

FUNH5III.15

CATTGTCCTTGTAATCGATGGACGAATAGCGGAAAGTCGTGCACGAACACCAAGTGTCTCAT  
AGTTGGGCTTATCGTCGTCGTCCTTGTAATCCATGGTG

**SEQ ID NO:99**

FUNDIII3.59

GATAAGTGAGTGACCAGTTGTGTGGCATTCTGCCTGCCAGACGGATGACATATAACAACCGA  
AACTGCCTTATTGAATTGGTCAACTGTCAGATGGTTCTTCGTGGAGCAGAGACAGAAGGCTG  
TGTCATTGTGTCAGCTGCCAAAGCCCAACTGCTGCAGTGCCAGCACCATCCAGCCTGGTATG  
GTGATACATTGAAGCAAAAGACATCCTGGACTTGCCTCTTGGTAGTTAGTTAG

**SEQ ID NO:100**

FUNGIII1.44

CTGCCTGCATCCTGGCCCCAGGTCTTCTTGGGGGCTTTGTCTGGA

**SEQ ID NO:101**

FUNH2III.20

CNAAACACAAACAAATGAAGTGACTTGGGAGTTACCCCAATATCTTGCCACACAGGTACAGG  
GATTACAGCATTACCAACCCAGTTCTGTGCCAGGTGCTGAAACTAGTTTTGTGGTAAATACA  
GACATATATTCTAAGGAGAAAACGATTTCTGCTTATCGTCGTCGTCCT

**SEQ ID NO:102**

FUNHII1.75

CCCGGTGGCCAGGGAACCCACTTCCAAGCGCAGGGACGCCGGCCTCCAGCTGGTTTGTGCTA  
AGGCTCCGTCCTGACTGCCCTGTGCCCTGGAAAAGCAGCAATAGCATCCGCCCCTTAGAGCC  
CTCTTATCGTCGTCGTCCTTGTAATCCATGGT

**SEQ ID NO:103**

FUNGIII1.1

AAGCTTGGAGAGATGCGCCTGAAGGAGGCGGGCACGGTGGGGAGAGGAGGTGGGCAGGAGGA  
ACGGCCCTTTGTGGCCCGGTTTGGATTTGACGTGGTGACGTGCTGTGGATACCTCC

**SEQ ID NO:104**

FUNDII1.21

TTCCTTAGCAGCTAAGCATTTGAATCAGACTTCTCATAGCANTGTTATGGGCTGTCTGATAT  
ATTCAGGATTTGTTGAGCAGATAAGCTGTGTGTGATCTTACTCATTCTCAGCCATGCCGCAG  
ACATACCCATTTCCCTTTAGTAATTTTTTAATACAGAGAATGCTATTAAC

**SEQ ID NO:105**

FUNDII1.37

AAGCACAAGCGTGGTAGTAGATCAGGTACTGTATCAAAGAGGCAGAGGGCTGTAAGTATGAG  
TGGGCTGGGCTGCAAGACTTCTATACCATCCTAGATCACTAGACCGCACCCAGCATANAGAT  
GGAGGAAGGAGGCCC

**SEQ ID NO:106**

FUNHII1.85

CCCTTAGACCTTCCCTCAACAGAGGACACTGAGCCCAACGGAGTTCTGGGATGGGAGGGGTG  
GGAGCATGGGAAGGGAGGCATCCCACCCCAAGAAGAACTGAATAAAGATTGCTGAGCTTAT  
CGTCGTCGTCCTTGTAATCCATGGT

**SEQ ID NO:107**

FUNGII1.46

CCTGTGGATTTGACCTCAGAGATAAGTGGGACAGAGCTTGGTAGAAGCACCAGTGTGGGCAA  
AGGTCCTGAGTCTGAACAGAACATGGCATGTGAGGAATGAAGCAGCCTGGCCCTAGGNGAAG  
CTGANAAAACCCTGCAGGTCCTTGNAATCCATGGT

SEQ ID NO:108

FUNGII1.23

TCCCCACGGGGTCCCGCANGGTACCACCCCACTCCGCTCCTCAAACGGGGCCGACATAATCC  
AGTCCCTCCCGGCCGCGGCCGCACCACCCCACTCCGCTTATCGTCGTCGTCCTTGTAATCCA  
TGGT

SEQ ID NO:109

FUNDII1.33

TCCCTCTTTCAGAACCCTGNCAGACACCACCTCCTTTGTAACCTTAAAGCAGGTTACAGAC  
TATCTCCTGGTTCTTAGGGATTTCTTCTGTCGAAAAGAGTTCTNAAAAATAACAGNAACCTG  
AGATACCATCTGTAAATNCTTAAGCAATTTTCGCATGCCTTATGAGACCNTGCTGATTAAAA  
ACATCTAGTCTTGTTTTCTTTTTTTTGAGACGAANTCTCGCTCTGTCA

SEQ ID NO:110

FUNH4III.9

TTCCTGAGGAGCGACATGTGGTTGAACGCCTGGACGGGACACAAGCGGACCAAGGAAAGAGT  
GGCATGGTCCACCCTCTCAAGGGCCTAGCTATCATGATACGAGGCGAATGGG

SEQ ID NO:111

FUNGII1.15

TTAATCCGTTTGAACTCATCAGGATTTGNCAGGGGAGTCGGATGAGCTTGGCATTTCACAG  
GATGAGCAGCTATCCAAGTTTAGTTTAAGGGAAACCACAGGCTCCGAGAGTGATGGGGGTGA  
CTCAAGCAGCACCAAGTCTGAAGGTGCCAACGGGACAGTGGCAACTGCAGNAATCCAGCCCA  
AGAAAGTTAAGCTTATCGTCGTCGTCCTTGTAATCCATGGT

**SEQ ID NO:112**

FUNDII1.54

TGTAATACCGTTGGTTACAGGACACGCGGGGCANGGGAGCGTGAGGCTTAGGAGCAATTAGG  
AGACAAAGGTTCTGCTTTCCACCAAACCTTCTTCGGTCTGGGCCCTCCCTTAGCAACCCTGG  
GGCTTTAGACTCTCTCTCCACCAATCCCTGATGACCCCGGTGGTGCCTCACAATGGGCATTC  
CAAGTAGCGCCCG

**SEQ ID NO:113**

FUNGIII1.24

GATAAGTTTCATTTTTGGAAGGGCTGCATTAACAAATATTTGATTTCTTAGTTCACAGTCAA  
GGACCTGTTGAGAAATCTGAGCTCGACTTGTAGGCTTAATTAGTTAGTTAGGATCCTAACTA  
ACTAGGGACCTGGACAGCATCTTCCGCCGTATCAGGACGCTGAAAGGGAACTGGCCAGGCA  
GCACCCAGAGGCCTTCAGCCATATCCCAGAGGCATCCTTCCTGGAGGAAGAGGATGCTTATC  
GTCC

**SEQ ID NO:114**

FUNDIII3.55

GATAAGCCAGGGGGCAGAAGGTAGAGCCCATGGGGCTGCTCTGGCTGTAGGTTTAGGCCAG  
CACCCCTCCCGAGGCAGCATAAGCAGGAGAGAAGAAGGCTAGTCCTTGGCACCACAAGGCCC  
CGAGGGCAGCCACAGCCTCGGCCTGGTAGTTAGTTAG

**SEQ ID NO:115**

FUNDII1.29

CTTTTTTTCCTTAACACNCCGGCCGNGGCTGTGGCTGCCCTCGGGGCCTTGTGGTGCCAAGG  
ACTAGCCTTCTTCTCTCCTGCTTATGCTGCCTCGGGAGGGGTGCTGGGCCTAAACCTACAGC  
CAGAGCAGCCCCATGGGCTCTACCTTNTGCCCCCTGG

SEQ ID NO:116

FUNDII1.49

TTTATACCTTAAGNCTTCCCTGTCCCCTCTACCCAGATCATTTGGGAAATATAAATGTGCAG  
TCCTAAGCGCTGCCCCGAGGGTCGCGATGTCTGCCAGGTACTGCTGGCTGGCTCTAGACACC  
AGCAGCAGTGATAAGAAACAAAGCAGAGGAGACGTTGAGGCAGCAGAGACAGCAGATCCG

SEQ ID NO:117

FUNDIII2.39

GATAAGCTTTTCAGTAACATTTTATACATCTACTTGTCAATGTATTTGAGACATTCACAGCC  
AAAAGCCTGGGACTCTTTGTGAAGGTCCTCCTCACCTCTATCTTTCTTTCTCTCTCTCAA  
ACTTTCCTTAAAGTTCTCATTGCCTTTGCACTGCTTCTGTGAACAGTCTTTGTCTCCTCCCC  
ACCTTTGGTGGGAAGTGCGGNGCAGTCCTGGTCAAGACACTCATGCCCTGGCAATGTGGCTG  
CCTAGTTAGTTAG

SEQ ID NO:118

FUNHII1.76

TGAGATGCACACAAAGGAAAGGTGTGAGAGTGCTTGGAAGCATCCAGCTGAGCCCCTGGAT  
GAAAATCAGACGATAGGGCCTCCTGTTGTAATCTTATCGTCGTCGTCCTTGTAATCCATGGT

SEQ ID NO:119

FUNDII1.75

CCTTTGGACAGAACGACTCGATGCTATGGGGCGCCGCGGCCAGCTGACTCGGATCTTCTCG  
TCCCGGTCGGCAGTGAGGATGAAGCGGTCATCAGGACTCACAGCCACATCTAACAGCATAGA  
CAGGTGCCCCAGCTCTAGACGGCCACACCCGTGTGGCTCCAGCACCGAAAAGGAGTAGACGT  
CTCCAGACTTGTCGGCCACCAAGACCTTCTCCTCCGAGGCTATGAAAGTCAG



SEQ ID NO:120

FUNH2III.7

CNAGATACACAGATAGGANACATGTNCCTGGNCCGTTACACAACACCAAATCTGGCTTCAC  
CCTGNGAATTAGGGGAAAGGAGAGCCACATGGAGTGCAAGGTGGTGAAAACGGTGGAGGGCC  
AGGACTGCTGAAC

SEQ ID NO:121

FUNGIII2.32

ATAAGCGTGGGTTCATACATGCATTGGGTGCTAGGCCCCAGCCTGCCGGGTGGCACCCCTTA  
CAGTTCCTTTGAACAGGGTAGTTAGTTAG

SEQ ID NO:122

FUNDII1.18

CCCGAAAGCGNGTAAGGCCTCCAGACCACCAACACTCAGCTCAAGTCAAACGTCCCTCTGTG  
TCCAAAGAGGGGAGGAAAACATCCATCAAATCTCATNNGTCTGGGTCTCCAGGCCCTGGTGG  
NAGCAACACATTTTNNATCCACACCAGTCATTGGGGGCAGTGATAAG

SEQ ID NO:123

FUNHII1.71

GCCGATGCAACAACCACATTGACTCCAAGGACAATCTAAAATTGAACTCAAGGCAGCACCTA  
ACAAGTCTCTCGTGCTTGACCCCTCCTTCTAGGCCCATCTAAAAGCCTCTCTGCCTCAGGCG  
TTCTCCCAGAAGATCTGCCCACTCTCTTCCCCACACCAGCC

SEQ ID NO:124

FUNHII1.64

CTCTACATTGTGGCCCTCAATAATAGAATAAATTTGTGAAAAAGCTGCATGTTTTAATTTAG  
GAAATGAGTAGAAGTTCACAAGCAACCCAGAATAGGTGCCAGCAGTTTGCTCCAGTGGGCCA  
CACCACAGCAGCAGCTCAGGCTCTGCAGAATCACTGTGTCCAGTGCTTCC

**SEQ ID NO:125**

FUNHII1.59

ACCTGCTTCTGAAGCTCCAACCTCCTCCCTCACCATATTGTAGCCATAGTAGCCTTTCTCAT  
CCAAATTATGCCAACTTTCTATCTCCTCATGAGATATTTGCACCTGCCGTTCCCAGTAACCT  
CAGGGCTCAGTGCATGAGTTGAAGCTGCCTTTCT

**SEQ ID NO:126**

FUNGII1.5

CCATCTAAGGGCCCGTCACAGCTTTGTCTGTTGCCCCAGAATTTGACGCCTTGGTTTGGCT  
GCTAAACTTATGGAGTTNCTAGAGGAGATTTCAGAAAGAAAGGGTGGATTTTTTGTGGATCT

**SEQ ID NO:127**

FUNGIII1.23

GATAAGAGTTGCAGTCAGGCTTCATACGCTATTGTCCTGCCCGTAAGTTCCCGTTTTGTGTG  
TGGTTAGAGCAGCCAGCGGGTACAGAATGGATTTTGAAGAGGGAGTCACCACTGGACCTCC  
AAGGAAGCCACGTGCAGACATCTACACAGGATGAATGCGGGTGTGGTAGTTAGTT

**SEQ ID NO:128**

FUNDII1.5

TGTGAAGAACCTGTATCCNCTTAGAAAGTGTCTTTTGTCTGGGGTGAGAGGGTGACTGCAT  
GTGCCCTCTNGCAGTCTGCTGCTGTGTCCAGAGTCCGACTCCAGCTGGGCTGTAACTGGGCT  
TGGCCCCCGCCTTAGGCCCCGCCAGCAGGCGAAGCAGGGAGATGTCAGACTGCTACACGGAG  
CTGGAGAAGGCAGTCNTTGTCT

**SEQ ID NO:129**

FUNH2III.3

TTTATACCATTTNCCCCTNGGTGAACAGTCCTACAAGCAGCCTGNAGATTCTTCTCCCTACA  
TCTCCTGTAAGGACGAAGGAGTGGTGTAACCTGAGCTCCGGCCCTGTGGAGACCCTCATGAG  
GCCTGAGGCTAAG

SEQ ID NO:130

FUNGII1.37

CCCCTCTTCCTCAACGGCAACAAAACTCCCCAAGTCAGCACTCTNNTTATTTTATACGCCA  
CAACCCTCTTGTAATCCATGGT

SEQ ID NO:131

FUNH5III.8

AGTTGAATATTTATCCAACCTCAGAAGACCCTAAAAAAGCACTTGTTTCGATTCTTTGAGGCTG  
TTGGTGTAACCTACGGGAACGTCCAGACACTTTCTGATAAATCTGCCATGGTCACAAA

4004394-1004

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention. Thus the expressions "means to..." and "means for...", or any method step language, as may be found in the specification above and/or in the claims below, followed by a functional statement, are intended to define and cover whatever structural, physical, chemical or electrical element or structure, or whatever method step, which may now or in the future exist which carries out the recited function, whether or not precisely equivalent to the embodiment or embodiments disclosed in the specification above, i.e., other means or steps for carrying out the same functions can be used; and it is intended that such expressions be given their broadest interpretation.

## REFERENCES

- Abe et al, "Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells", Antivir Chem Chemother 9:253-262 (1998)
- Adams et al, "Complementary DNA sequencing: expressed sequence tags and human genome project", Science 252(5013):1651-1656 (1991)
- Ausubel et al (Eds), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (New York, 1994-2000)
- Bai et al, "Gene transfer to vein graft wall by HVJ-liposome method: time course and localization of gene expression", Ann Thorac Surg 66:814-819 (1998)
- Belecky-Adams et al, "Intragenic sequences are required for cell type-specific and injury-induced expression of the rat peripherin gene", J Neurosci 13:5056-5065 (1993)
- Bochot et al, "Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides", Pharm Res 15:1364-1369 (1998)

Boutin et al, "Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells," Molec Endocrinol 3(9):1455-1461 (1989)

Braun et al, "A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts", EMBO J 8(3):701-709 (1989)

Cantor et al, " Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression", Proc Natl Acad Sci, 90(23):10932 (1993)

Cao et al, "Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity", J Immunol 161:6238-6244 (1998)

Capaccioli et al, "Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum", Biochem Biophys Res Comm 197:818-825 (1993)

Chan et al, " Molecular cloning and localization to chromosome 6 of mouse INT1L1 gene", Somatic Cell Molec Genet 15(6):555-562 (1989)

Chen et al, "Inhibition of HIV-1 replication by novel multitarget ribozymes", Ann NY Acad Sci 660:271-273 (1992)

Croyle et al, "Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery", Pharm Dev Technol 3(3)365-372 (1998)

Daniel et al, "Retroviral transfer of antisense sequences results in reduction of C-Abl and induction of apoptosis in hemopoietic cells", J Biomed Sci 5:383-394 (1998)

Davis et al (eds.), Basic Methods in Molecular Biology, Elsevier Press, NY (1986)

Edinger et al, "Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins", Virology 249:367-378 (1998)

Fang et al, "A packaging system for SV40 vectors without viral coding sequences", Anal Biochem 254:139-143 (1997)

Flanagan, WM, "Antisense comes of age", Cancer Metastasis Rev, 17(2):169-176 (1998)

Galizzi et al, Molecular cloning of a cDNA encoding the human interleukin 4 receptor", Int Immunol 2(7):669-675 (1990)

Gennaro, AR (ed.), Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 1990, pp 1521-1712

Gerster et al, "Quantitative analysis of modified antisense oligonucleotides in biological fluids using cationic nanoparticles for solid-phase extraction", Anal Biochem 262:177-184 (1998)

Gould et al, "Use of the DNA polymerase chain reaction for homology probing: isolation of partial cDNA or genomic clones encoding the iron-sulfur protein of succinate dehydrogenase from several species", Proc Nat Acad Sci USA 86(6):1934-1938 (1989)

Griscelli et al, "Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors", Hum Gene Ther, 9:1919-1928 (1998)

Guang-Lin et al, "Adenovirus-mediated gene transfer of CTLA4IG gene results in prolonged survival of heart allograft", Transplant Proc, 30:2923-2924 (1998)

Guinot et al, "Antisense oligonucleotides: a new therapeutic approach", Pathol Biol, 46:347-354 (1998)

Gutkowska et al, "Circulating forms and radioimmunoassay of atrial natriuretic factor", Endocrinol Metab Clin North Am 16(1):183-198 (1987)



He et al, " Molecular cloning of androgen receptors from divergent species with a polymerase chain reaction technique: complete cDNA sequence of the mouse androgen receptor and isolation of androgen receptor cDNA probes from dog, guinea pig and clawed frog, Biochem Biophys Res Comm 171(2):697-704 (1990)

Hemmi et al, "The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures", Hum Gene Ther 9:2363-2373 (1998)

Higuti et al, "Molecular cloning of cDNA for the import precursor of human subunit B of H(+)-ATP synthase in mitochondria", Biochem Biophys Res Comm 178(3):1014-1020 (1991)

Hofmann et al, "Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette", Proc Natl Acad Sci 93(11):5185-5190 (1996)

Hsieh et al, "Chromosome localization and cDNA sequence of murine and human genes for ras p21 GTPase activating protein (GAP)", Somat Cell Mol Genet 15(6):579-590 (1989)

Imamura et al, " Molecular cloning and primary structure of rat thyroxine-binding globulin", Biochemistry 30(22):5406-5411 (1991)

Iwata et al, " Structure of the mouse tyrosine hydroxylase gene", Biochem Biophys Res Comm 182(1):348-354 (1992)

Jakubiczka et al, " A bovine homologue of the human TSPY gene", Genomics 17(3):732-735 (1993)

James-Pederson et al, "Flanking and intragenic sequences regulating the expression of the rabbit alpha-globin gene", J Bio. Chem 270:3965-3973 (1995)

Jeung et al, " Molecular cloning of the full-length cDNA encoding the human calbindin-D9k", FEBS Lett 307(2):224-228 (1992)

Joseph et al, "Optimization of an anti-HIV hairpin ribozyme by in vitro selection", J Biol Chem 268:24515 (1993)

Kähäri et al, "Deletion analyses of 5'-flanking region of the human elastin gene. Delineation of functional promoter and regulatory cis-elements", J Biol Chem 265(16):9485-9490 (1990)

Kanamaru et al, "Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes", J Drug Target 5:235-246 (1998)

Kim et al, " A new non-viral DNA delivery vector: the terplex system", J Controlled Release 53(1-3):175-82 (1998)

Kita et al, "Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes", Int J Cancer 80:553-558 (1999)

Kondo et al, "Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells", Oncogene 17:2585-2591 (1998)

Kumar et al, "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes", Microbiol Mol Biol Rev, 62:1415-1434 (1998)

Langner et al, "Viral particles with heterologous binding motifs. An approach to specifically alter the tropism of the B-lymphotropic papovavirus", Adv Exp Med Biol 451:415-422 (1998)

Libert et al, "Cloning and functional characterization of a human A1 adenosine receptor", Biochem Biophys Res Comm 187(2):919-926 (1992)

Lockyer et al., "CAPRI regulates Ca<sup>2+</sup>-dependent inactivation of the Ras-MAPK pathway," Current Biology 11:981-986, (2001)

Meinkoth et al, "Hybridization of nucleic acids immobilized on solid supports", Anal Biochem 138:267-284 (1984)

Meiri et al, "Memory and long-term potentiation (LTP) dissociated: normal spatial memory despite CA1 LTP elimination with Kv1.4 antisense", Proc Natl Acad Sci, 95:15037-15042 (1998)

Meyer et al, "Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides," J Biol Chem 273(25):15621-15627 (1998)

Minagawa et al., "Distinct phosphoinositide binding specificity of the GAP1 Family proteins: characterization of the Pleckstrin homology domains of MSARAL and KIAA0538," Biochem. Biophys. Res. Comm. 288:87-90 (2001)

Mizuguchi et al, "Efficient gene transfer into mammalian cells using fusogenic liposome", Biochem Biophys Res Commun 218:402-407 (1996)

Muranishi et al, "Lipophilic peptides: synthesis of lauroyl thyrotropin-releasing hormone and its biological activity", Pharm Research 8:649-652 (1991)

Nahmias et al, "Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes", EMBO J 10(12):3721-3727 (1991)

Nakamura et al, "A comparison of in vivo gene delivery methods for antisense therapy in ligament healing", Gene Ther 5:1455-1461 (1998)

Narumi et al, "Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo", Am J Respir Cell Mol Biol 19:936-941 (1998)

Nishida et al, "Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration", Spine 23:2437-2442, 1998

Noguchi et al, "Membrane fusion plays an important role in gene transfection mediated by cationic liposomes", FEBS Lett 433:169-173 (1998)

Oro et al, " The Drosophila gene knirps-related is a member of the steroid-receptor gene superfamily", Nature 336(6198):493-496 (1988)

Paglia et al, "Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma", Blood 92(9):3172-3176 (1998)

Pederson et al, "Combined cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells", J Gastrointest Surg 2:283-291 (1998)

Peng Ho et al, "Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS", Brain Res Mol Brain Res 62(1):1-11 (1998)

Potier et al, "The human glutamate receptor cDNA GluR1: cloning, sequencing, expression and localization to chromosome 5", DNA Seq 2(4):211-218 (1992)

Quattrone et al, "Enhancing antisense oligonucleotide intracellular levels by means of cationic lipids as vectors", Biochemica 1:25-29 (1995)

Reecy et al, "Multiple regions of the porcine alpha-skeletal actin gene modulate muscle-specific expression in cell culture and directly injected skeletal muscle", Anim Biotechnol 9:101-120 (1998)

Sambrook et al (Eds), Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, (NY, 1989)

Schwarzenberger et al, "IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for *in vivo* evaluation of cytokines", J Immunol 161:6383-6389 (1998)

Shimayama et al, "Cleavage of the highly conserved hairpin-loop region of HIV-1 by synthetic ribozymes", Nucleic Acids Symp Ser 29:177-178 (1993)

Shoji et al, "Enhancement of anti-herpetic activity of antisense phosphorothioate oligonucleotides 5' end modified with geraniol", J Drug Target 5:261-273 (1998)

Shore et al, "Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity", Oncogene 8:3183-3188 (1993)

Soni et al, "Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection", Hepatology 28:1402-1410 (1998)

Soukchareun et al, " Use of Nalpha-Fmoc-cysteine(S-thiobutyl) derivatized oligodeoxynucleotides for the preparation of oligodeoxynucleotide-peptide hybrid molecules", Bioconjug. Chem 9(4):466-475 (1998)

Stix, G, "Shutting down a gene. Antisense drug wins approval", Sci Am 279(5):46, 50 (1998)

Sugawa et al, "An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro", J Neurooncol 39:237-244 (1998)

Sumimoto et al, " Complementary DNA for the mouse homolog of the small subunit of human cytochrome b558", Biochem Biophys Res Comm 165(2):902-906 (1989)

Teoh et al, "Adenovirus vector-based purging of multiple myeloma cells", Blood, 92:4591-4601 (1998)

Waelti et al., "Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes)", Int J Cancer 77:728-733 (1998)

Wang, "Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60 (c-) (src)", J Controlled Release 53:39-48 (1998)

Wang et al, "3-Hydroxy-3-methylglutaryl coenzyme A lyase (HL): cloning and characterization of a mouse liver HL cDNA and subchromosomal mapping of the human and mouse HL gene", Mamm Genome 4(7):382-387 (1993)

Weissig et al, "DQAsomes: a novel potential drug and gene delivery system made from Dequalinium", Pharm Res 15:334-337 (1998)

Yeh et al, "Inhibition of BMP receptor synthesis by antisense oligonucleotides attenuates OP-1 action in primary cultures of fetal rat calvaria cells", J Bone Miner Res 13:1870-1879 (1998)



Yotsuyanagi et al, "Cationic liposomes in gene delivery",  
Nippon Rinsho 56:705-712 (1998)

Zacharia et al, "New reduced peptide bond substance P agonists  
and antagonists: effects on smooth muscle contraction",  
Eur J Pharmacol 203:353-357 (1991)

Zhao et al, "Generating loss-of-function phenotypes of the  
fushi tarazu gene with a targeted ribozyme in  
Drosophila", Nature 365:448-451 (1993)

100430-494